"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtWith_AU_IN_FIRST","meanArtWith_AU_IN_LAST","meanArtWith_AU_IN_CORR","mean_articles_per_internal_author","mean_articles_per_internal_first_author","mean_articles_per_internal_last_author","mean_articles_per_internal_corresponding_author","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","meanCitationTrend","InternCoauthorship","AffCoauthorship","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"IRCCS_TUMORIBARI",2000,7,10.7142857142857,6.57142857142857,0,0.857142857142857,0,1.04545454545455,0,1,0,0,0,1,1,1,4,0.14,0.14,0.14,0.57,77.43,1.70807195195284,NA,0.142857142857143,1,0.234,0,0.229,0,"M. DE LENA;F MARZULLO;MODESTO DʼAPRILE;PALMA AURELIA IACOVAZZI;P CALABRESE;FERDINANDO DE VITA;GIUSEPPE LUCARELLI;M. CORREALE;STEFANIA TOMMASI;ROSANNA ALTIERI;P BAZAN;G. FRASCI;C VELLEJO;VITO LORUSSO;INES ZANNA;GIUSEPPE POLIMENO;A. BARLETTA;VIVIANA BAZAN;MICHELE QUARANTA;G.P. NICOLELLA","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","M. DE LENA;GIUSEPPE TARANTINO;ALESSANDRA LUCARELLI;NICOLA SILVESTRIS;FRANK L. D’ELIA;F MARZULLO;P CALABRESE;A. MAZZEI;AGNESE LATORRE;ANNAMARIA CATINO;ALESSANDRA ALOE;VITO LORUSSO;PALMA AURELIA IACOVAZZI;M. CORREALE;MICHELE QUARANTA;VIVIANA GIANNUZZI;S. LANZILLOTTA;MARTA VALENZA;INES ABBATE;ONOFRIO G. MANGHISI","0.31;0.25;0.25;0.25;0.25;0.16;0.14;0.14;0.14;0.14;0.14;0.14;0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.1","M. DE LENA;F MARZULLO;MODESTO DʼAPRILE;PALMA AURELIA IACOVAZZI;P CALABRESE;FERDINANDO DE VITA;GIUSEPPE LUCARELLI;ROSANNA ALTIERI;P BAZAN;GIUSEPPE POLIMENO;A. BARLETTA;MICHELE QUARANTA;G.P. NICOLELLA;VITO MICHELE LAUTA;A. MAZZEI;GIANNA PALMIERI;GIOVANNA MANTOVANI;FRANCESCO SCHITTULLI;VIVIANA GIANNUZZI;ANNUNZIATO IANNELLI","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","M. DE LENA;GIUSEPPE TARANTINO;ALESSANDRA LUCARELLI;FRANK L. D’ELIA;F MARZULLO;P CALABRESE;A. MAZZEI;ALESSANDRA ALOE;PALMA AURELIA IACOVAZZI;MICHELE QUARANTA;VIVIANA GIANNUZZI;S. LANZILLOTTA;MARTA VALENZA;ONOFRIO G. MANGHISI;S. ELBA;ROSANNA ALTIERI;A. BARLETTA;FRANCESCO SCHITTULLI;A LABRIOLA;MODESTO DʼAPRILE","0.31;0.25;0.25;0.25;0.16;0.14;0.14;0.14;0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.09;0.09;0.09;0.09;0.07","VITO LORUSSO;ANDREA BIANCO;ANNUNZIATO IANNELLI;B. MASSIDDA;DOMENICO BILANCIA;FRANCOVITO PIANTEDOSI;G. FRASCI;G.P. NICOLELLA;GIUSEPPE COMELLA;GIUSEPPE DE CATALDIS;M BELLI;MARIO DE LENA;NICOLA PANZA;PASQUALE COMELLA;ANTONIO RUSSO;CARLA TUBIOLO;FRANCESCA MARIA TUMMINELLO;GABRIELLA DARDANONI;GAETANO LETO;GIUSEPPE COLUCCI","467;457;457;457;457;457;457;457;457;457;457;457;457;457;28;28;28;28;28;28","ANDREA BIANCO;ANNUNZIATO IANNELLI;B. MASSIDDA;DOMENICO BILANCIA;FRANCOVITO PIANTEDOSI;G.P. NICOLELLA;GIUSEPPE COMELLA;GIUSEPPE DE CATALDIS;M BELLI;MARIO DE LENA;NICOLA PANZA;PASQUALE COMELLA;GIUSEPPE COLUCCI;P BAZAN;MARTA VALENZA;MICHELE QUARANTA;ONOFRIO G. MANGHISI;PALMA AURELIA IACOVAZZI;S. ELBA;S. LANZILLOTTA","457;457;457;457;457;457;457;457;457;457;457;457;28;28;24;24;24;24;24;24","F MARZULLO;M. DE LENA;A LABRIOLA;A. BARLETTA;A. MAZZEI;ALESSANDRA ALOE;ALESSANDRA LUCARELLI;ANDREA BIANCO;ANNUNZIATO IANNELLI;ANTONELLA BIANCO;B. MASSIDDA;DOMENICO BILANCIA;FERDINANDO DE VITA;FRANCESCO SCHITTULLI;FRANCO DAMMACCO;FRANCOVITO PIANTEDOSI;FRANK L. D’ELIA;G ABATE;G.P. NICOLELLA;GIANNA PALMIERI","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY","7;4","INTERNAL MEDICINE;GASTROENTEROLOGY;ONCOLOGY;PATHOLOGY;PALEONTOLOGY;MOLECULAR BIOLOGY;SURGERY;BIOCHEMISTRY;CANCER RESEARCH;DERMATOLOGY;GENETICS;GYNECOLOGY;IMMUNOLOGY;NURSING","7;4;4;4;3;2;2;1;1;1;1;1;1;1","CANCER;CARCINOMA;CHEMOTHERAPY;STAGE (STRATIGRAPHY);ANTIBODY;CIRRHOSIS;CONFIDENCE INTERVAL;ENZYME;GENE;GLYCOPROTEIN;HEPATOCELLULAR CARCINOMA;IMMUNOHISTOCHEMISTRY;LUNG CANCER;LYMPHOMA;QUALITY OF LIFE (HEALTHCARE);RANDOMIZED CONTROLLED TRIAL;REGIMEN;RENAL CELL CARCINOMA;TRANSPLANTATION","4;3;3;3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;CATHEPSIN;CATHEPSIN B;CATHEPSIN D;CHROMOSOME;CISPLATIN;DIFFUSE LARGE B-CELL LYMPHOMA;DOXORUBICIN;FOLLICULAR LYMPHOMA;GEMCITABINE;IMMUNOASSAY;INTERIM ANALYSIS;KIDNEY TRANSPLANTATION;LEUKOPENIA;MERKEL CELL CARCINOMA;METASTASIS;MONOCLONAL ANTIBODY;NEUROENDOCRINE CARCINOMA;PACLITAXEL;PHASES OF CLINICAL RESEARCH;RENAL TRANSPLANT;SKIN CANCER","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MAMMARY GLAND;ANEUPLOIDY;CATHEPSIN L;INTERNATIONAL PROGNOSTIC INDEX;MERKEL CELL;PRIMARY TUMOR;VINORELBINE","2;1;1;1;1;1;1","ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;HUMANS;LIVER NEOPLASMS;LUNG NEOPLASMS;DOXORUBICIN;FEMALE;ADENOCARCINOMA;MALE;MIDDLE AGED;STOMACH NEOPLASMS;AGED;BIOMARKERS, TUMOR;BONE NEOPLASMS;CARCINOMA, MERKEL CELL;DEOXYCYTIDINE;PACLITAXEL;PLEURAL NEOPLASMS;SKIN NEOPLASMS;SOFT TISSUE NEOPLASMS","9;9;7;7;7;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4","ADVANCEMENTS IN LUNG CANCER RESEARCH;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHOLANGIOCARCINOMA;LYMPHOID NEOPLASMS;POLYOMAVIRUS-ASSOCIATED CARCINOGENESIS AND CLINICAL MANIFESTATIONS;ROLE OF GALECTINS IN IMMUNITY AND DISEASE;THE P53 SIGNALING NETWORK IN CANCER RESEARCH","1;1;1;1;1;1;1","BIOMARKER ANALYSIS;BREAST CANCER;CANCER PROGRESSION;CANCER THERAPY;CATHEPSIN L;FOLLICULAR LYMPHOMA;INTERIM ANALYSIS;INTERNATIONAL PROGNOSTIC INDEX;LEUKOPENIA;MERKEL CELL;MERKEL CELL CARCINOMA;MICROTUBULE-TARGETING AGENTS;NEUROENDOCRINE CARCINOMA;NON-SMALL CELL LUNG CANCER;P53;PACLITAXEL;PRIMARY TUMOR;REGIMEN;TUMOR MICROENVIRONMENT;VINORELBINE","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;ADVANCED BREAST;ADVANCED NONSMALL-CELL;ASPARTIC CYSTEINE;CANCER PATIENTS;CELL CARCINOMA;DNA PLOIDY;ELDERLY PATIENTS;FIRST-LINE THERAPY;GASTRIC CARCINOMA;GLYCOPROTEIN LEVELS;GRADE NON-HODGKINS;HEPATOCELLULAR CARCINOMA;I-II STUDY;ITALY COOPERATIVE;IV BREAST;KMAC-BP GLYCOPROTEIN;LUNG CANCER;MERKEL CELL;METASTATIC SITE;MULTICENTER STUDY;NON-HODGKINS LYMPHOMA;NONSMALL-CELL LUNG;OPERABLE GASTRIC;PHASE I-II;PLOIDY S-PHASE;PREVIOUSLY UNTREATED;PRIMARY TUMOR;PROGNOSTIC SIGNIFICANCE;RANDOMISED MULTICENTER","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_TUMORIBARI",2001,4,9.25,3.75,0,0.25,0,1.15384615384615,0,0.5,0,0,0,0,1,0,3,0,0.25,0,0.75,5,0.10942731885809,NA,0.25,1,0.169,0,0,0,"A PARADISO;LUCIANO GRAMMATICA;A LABRIOLA;F MARZULLO;G ACHILLE;CHRISTIAN SALVATORE;S. WIESEL;PATRIZIA BECCAGLIA;MASSIMO DE FRENZA;P. PRONZATO;GIROLAMO RANIERI;ROBERTO BIANCO;MARIA ANGELA CAPONIO;PAOLO MARCHETTI;GAETANO FALCO;DI COSTANZO F;CARLO PIETRO CAMPOBASSO;GEROLMINA FLORIO;GIUSEPPE COLUCCI;MASSIMO AGLIETTA","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","A PARADISO;LUCIANO GRAMMATICA;A LABRIOLA;F MARZULLO;G ACHILLE;GIROLAMO RANIERI;GEROLMINA FLORIO;S. WIESEL;MASSIMO DE FRENZA;MARIA ANGELA CAPONIO;GAETANO FALCO;CARLO PIETRO CAMPOBASSO;ALVARO LEONE;STELLA PETRONI;GIANNI SIMONE;CHRISTIAN SALVATORE;S PIEPOLI;ZITO FA;C D'AURIA;PATRIZIA BECCAGLIA","0.25;0.25;0.25;0.25;0.25;0.14;0.14;0.12;0.12;0.12;0.12;0.12;0.12;0.12;0.12;0.11;0.11;0.11;0.11;0.08","A LABRIOLA;F MARZULLO;CHRISTIAN SALVATORE;S. WIESEL;MASSIMO DE FRENZA;GAETANO FALCO;CARLO PIETRO CAMPOBASSO;GEROLMINA FLORIO;GIUSEPPE COLUCCI;S PIEPOLI;ALVARO LEONE;ZITO FA;C D'AURIA","2;2;1;1;1;1;1;1;1;1;1;1;1","A LABRIOLA;F MARZULLO;GEROLMINA FLORIO;S. WIESEL;MASSIMO DE FRENZA;GAETANO FALCO;CARLO PIETRO CAMPOBASSO;ALVARO LEONE;CHRISTIAN SALVATORE;S PIEPOLI;ZITO FA;C D'AURIA;GIUSEPPE COLUCCI","0.25;0.25;0.14;0.12;0.12;0.12;0.12;0.12;0.11;0.11;0.11;0.11;0.08","A LABRIOLA;A PARADISO;F MARZULLO;G ACHILLE;LUCIANO GRAMMATICA;GEROLMINA FLORIO;GIROLAMO RANIERI;ALVARO LEONE;CARLO PIETRO CAMPOBASSO;GAETANO FALCO;GIANNI SIMONE;MARIA ANGELA CAPONIO;MASSIMO DE FRENZA;S. WIESEL;STELLA PETRONI;C D'AURIA;CHRISTIAN SALVATORE;S PIEPOLI;ZITO FA;D. AMADORI","13;13;13;13;13;8;8;6;6;6;6;6;6;6;6;5;5;5;5;1","A LABRIOLA;F MARZULLO;GEROLMINA FLORIO;ALVARO LEONE;CARLO PIETRO CAMPOBASSO;GAETANO FALCO;MASSIMO DE FRENZA;S. WIESEL;C D'AURIA;CHRISTIAN SALVATORE;S PIEPOLI;ZITO FA;GIUSEPPE COLUCCI","13;13;8;6;6;6;6;6;5;5;5;5;1","A LABRIOLA;F MARZULLO;ALVARO LEONE;C D'AURIA;CARLO PIETRO CAMPOBASSO;CHRISTIAN SALVATORE;GAETANO FALCO;GEROLMINA FLORIO;GIUSEPPE COLUCCI;MASSIMO DE FRENZA;S PIEPOLI;S. WIESEL;ZITO FA","2;2;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY","4;3","INTERNAL MEDICINE;GENETICS;PATHOLOGY;ECOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;ONCOLOGY;PEDIATRICS","4;3;3;1;1;1;1;1","IMMUNOHISTOCHEMISTRY;CANCER;CARCINOMA;STEM CELL;ANEMIA;ANGIOGENESIS;ASCITES;BASAL CELL;BLOOD TRANSFUSION;CHEMOTHERAPY;COMPLICATION;DISEASE;GRADING (ENGINEERING);IMMUNOCYTOCHEMISTRY;MAST CELL;PATHOLOGICAL;PROPORTIONAL HAZARDS MODEL;SEROUS FLUID;STATISTICAL SIGNIFICANCE;SURVIVAL ANALYSIS","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CD34;ADENOCARCINOMA;CELL CYCLE;IMMUNOSTAINING;LOG-RANK TEST;NEOVASCULARIZATION;OVARIAN CANCER;P53 EXPRESSION;TRYPTASE","2;1;1;1;1;1;1;1;1","MOLECULAR MEDICINE;ONCOGENE","1;1","CARCINOMA, SQUAMOUS CELL;MOUTH NEOPLASMS;FEMALE;HUMANS;MIDDLE AGED;NEOVASCULARIZATION, PATHOLOGIC;TUMOR SUPPRESSOR PROTEIN P53;ANEMIA;ASCITIC FLUID;CYSTADENOCARCINOMA, SEROUS;MALE;OVARIAN NEOPLASMS;ANTIGENS, CD34;ANTINEOPLASTIC AGENTS;BIOMARKERS, TUMOR;IMMUNOENZYME TECHNIQUES;MONOMERIC GTP-BINDING PROTEINS;NEOPLASM STAGING;NEOPLASMS;TRANSCRIPTION FACTORS","7;7;4;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2","BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM;FIBROBLAST GROWTH FACTOR SIGNALING PATHWAY;MOLECULAR MECHANISMS OF METASTASIS SUPPRESSOR GENES;ROLE OF ERYTHROPOIETIN IN DISEASE TREATMENT AND MANAGEMENT","1;1;1;1","ANEMIA;CELL GROWTH;CELL PROLIFERATION;GRADING (ENGINEERING);IMMUNOSTAINING;LOG-RANK TEST;ODONTOGENIC TUMORS;P53 EXPRESSION;TRYPTASE","1;1;1;1;1;1;1;1;1","ASCITIC EFFUSIONS;BIOLOGICAL-CLINICAL SIGNIFICANCE;CARCINOMA PATIENTS;CELL CARCINOMA;CELL INFILTRATION;CHEMOTHERAPY ITALIAN;ITALIAN SURVEY;MALIGNANT ASCITIC;MAST CELL;NATIONAL LEVEL;NM EXPRESSION;ONCOLOGIC PATIENTS;ORAL CARCINOMA;ORAL CAVITY;OVARIAN ADENOCARCINOMA;PATIENTS TREATED;PRIMARY TUMOURS;SEROUS OVARIAN;SQUAMOUS CELL;TUMOURS NEOANGIOGENESIS","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_TUMORIBARI",2002,4,7.5,2.25,0,0.25,0,1.28571428571429,0,0.5,0,0,0,0,4,0,0,0,1,0,0,35.75,0.648012245805238,NA,0,1,0.216,0,0,0,"M. DE LENA;VITO LORUSSO;GIROLAMO RANIERI;E. CRUCITTA;NICOLA SILVESTRIS;MONICA FORNIER;D. SAMBIASI;A. COSTA;N. LOCOPO;A. MISINO;GEROLMINA FLORIO;J. LACAVA;MICHELE GUIDA;ANGELO LEONE;AGNESE LATORRE;A PARADISO;LUCIANO GRAMMATICA;ANNAMARIA CATINO;ANGELO PARADISO;CARLOS VALLEJO","3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","M. DE LENA;VITO LORUSSO;E. CRUCITTA;NICOLA SILVESTRIS;GIROLAMO RANIERI;MONICA FORNIER;N. LOCOPO;GEROLMINA FLORIO;A PARADISO;LUCIANO GRAMMATICA;ANGELA LABRIOLA;GAETANO ACHILLE;ALFREDO ZITO;D. SAMBIASI;A. MISINO;MICHELE GUIDA;AGNESE LATORRE;ANNAMARIA CATINO;A. COSTA;J. LACAVA","0.4;0.29;0.29;0.28;0.25;0.17;0.17;0.14;0.14;0.14;0.14;0.14;0.14;0.12;0.12;0.12;0.12;0.12;0.11;0.11","M. DE LENA;E. CRUCITTA;MONICA FORNIER;N. LOCOPO;GEROLMINA FLORIO;ANGELA LABRIOLA;ALFREDO ZITO","3;2;1;1;1;1;1","M. DE LENA;E. CRUCITTA;MONICA FORNIER;N. LOCOPO;GEROLMINA FLORIO;ANGELA LABRIOLA;ALFREDO ZITO","0.4;0.29;0.17;0.17;0.14;0.14;0.14","GIROLAMO RANIERI;A PARADISO;ALFREDO ZITO;ANGELA LABRIOLA;GAETANO ACHILLE;GEROLMINA FLORIO;LUCIANO GRAMMATICA;M. DE LENA;E. CRUCITTA;VITO LORUSSO;A. MISINO;AGNESE LATORRE;ANNAMARIA CATINO;D. SAMBIASI;MICHELE GUIDA;NICOLA SILVESTRIS;A. COSTA;ANGELO LEONE;ANGELO PARADISO;CARLOS VALLEJO","102;94;94;94;94;94;94;49;41;41;36;36;36;36;36;13;8;8;8;8","ALFREDO ZITO;ANGELA LABRIOLA;GEROLMINA FLORIO;M. DE LENA;E. CRUCITTA;MONICA FORNIER;N. LOCOPO","94;94;94;49;36;5;5","M. DE LENA;ALFREDO ZITO;ANGELA LABRIOLA;E. CRUCITTA;GEROLMINA FLORIO;MONICA FORNIER;N. LOCOPO","3;1;1;1;1;1;1","MEDICINE;BIOLOGY;MATHEMATICS","4;1;1","INTERNAL MEDICINE;ONCOLOGY;BIOCHEMISTRY;CANCER RESEARCH;GENETICS;GEOMETRY;IMMUNOLOGY;SURGERY","4;3;1;1;1;1;1;1","CANCER;ADJUVANT;BASAL CELL;CELL;CHEMOTHERAPY;CORRELATION;MAST CELL;SOFT TISSUE","4;1;1;1;1;1;1;1","COLORECTAL CANCER;BREAST CANCER;CELL CYCLE;CISPLATIN;DOCETAXEL;FLUOROURACIL;GEMCITABINE;MEGESTROL ACETATE;OVARIAN CANCER;SALVAGE THERAPY;SOFT TISSUE SARCOMA;THYMIDINE PHOSPHORYLASE;TOPOTECAN","2;1;1;1;1;1;1;1;1;1;1;1;1","AROMATASE;DEBULKING;HORMONAL THERAPY;MOLECULAR MEDICINE;NEDAPLATIN;ONCOGENE;OXALIPLATIN;TAMOXIFEN;TRABECTEDIN","1;1;1;1;1;1;1;1;1","ADENOCARCINOMA;ANTINEOPLASTIC AGENTS;CARCINOMA, SQUAMOUS CELL;COLORECTAL NEOPLASMS;FEMALE;HUMANS;MOUTH NEOPLASMS;APOPTOSIS;BREAST NEOPLASMS;NEOVASCULARIZATION, PATHOLOGIC;ANDROSTADIENES;ANTIMETABOLITES, ANTINEOPLASTIC;ENZYME INHIBITORS;FLUOROURACIL;IMMUNOENZYME TECHNIQUES;MALE;MAST CELLS;MIDDLE AGED;OVARIAN NEOPLASMS;PROTO-ONCOGENE PROTEINS","4;4;4;4;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2","GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;MECHANISMS OF ESTROGEN RECEPTOR SIGNALING;ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE;THE P53 SIGNALING NETWORK IN CANCER RESEARCH","1;1;1;1","CANCER THERAPY;DEBULKING;ESTROGEN;EXEMESTANE;HORMONAL THERAPY;NEDAPLATIN;P53;PLATINUM-SENSITIVE OVARIAN CANCER;SALVAGE THERAPY;THYMIDINE PHOSPHORYLASE;TOPOTECAN;TRABECTEDIN;TUMOR MICROENVIRONMENT;TUMOR REGRESSION","2;1;1;1;1;1;1;1;1;1;1;1;1;1","ADVANCED BREAST;ADVANCED COLORECTAL;BREAST CANCER;CANCER REVIEW;CELL DENSITY;CHEMOTHERAPY REVIEW;COLORECTAL CANCER;CURRENT STATUS;DENSITY MAST;EPITHELIAL OVARIAN;FUTURE POTENTIAL;INTERACTION LACK;LINE CHEMOTHERAPY;MAST CELL;MDM-P INTERACTION;MICROVESSEL DENSITY;ORAL SQUAMOUS;OVARIAN CANCER;PHOSPHORYLASE EXPRESSION;POTENTIAL ROLE;SQUAMOUS CARCINOMA;THYMIDINE PHOSPHORYLASE","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,0,0,28.57,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,2,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","2;1;1",NA,NA,"CANCER","1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","1;1","BLADDER CANCER;BRAIN TUMOR","1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_TUMORIBARI",2003,10,7.9,1.9,0,0.4,0,1.1875,0,1,0,0,0,0,2,2,6,0,0.2,0.2,0.6,22.9,0.43266404407902,NA,0.3,1,0.248,0,0.133,0,"P CALABRESE;ANTONIA BELLIZZI;STEPHAN J. RESHKIN;GIUSEPPE COLUCCI;E. CRUCITTA;ANNAMARIA CATINO;ANGELO PARADISO;ROBERTO GENNARI;J MELIA;D. SAMBIASI;VITTORIO GEBBIA;PETER SANTORO;CARSTEN STEPHAN;V. MATTIOLI;JONAS HUGOSSON;EMANUELE NAGLIERI;DOMENICO PISCITELLI;VITO LORUSSO;F. ARMENISE;ANTONELLA CRAPOLICCHIO","2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","P CALABRESE;ANTONIA BELLIZZI;STEPHAN J. RESHKIN;E. CRUCITTA;ANNAMARIA CATINO;ANGELO PARADISO;PETER SANTORO;ANDREA DE CEGLIE;F. SCOTTO;A PELLECCHIA;A MANNARINI;STEFANO OLIVA;FRANCESCO GIOTTA;G. COLUCCI;GIUSEPPE COLUCCI;D. SAMBIASI;V. MATTIOLI;DOMENICO PISCITELLI;VITO LORUSSO;F. ARMENISE","0.37;0.33;0.33;0.33;0.33;0.33;0.25;0.25;0.25;0.25;0.2;0.2;0.2;0.2;0.2;0.17;0.17;0.17;0.17;0.17","P CALABRESE;ANTONIA BELLIZZI;STEPHAN J. RESHKIN;GIUSEPPE COLUCCI;E. CRUCITTA;PETER SANTORO;F. ARMENISE;ANTONELLA CRAPOLICCHIO;MICHELE QUARANTA;FRANCESCO SCHITTULLI;GLORIA M. CÓNSOLE;VITA FEDELE;M. DI BISCEGLIE;G. COLUCCI;M. DE LENA;A PELLECCHIA","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","P CALABRESE;ANTONIA BELLIZZI;STEPHAN J. RESHKIN;E. CRUCITTA;PETER SANTORO;A PELLECCHIA;G. COLUCCI;GIUSEPPE COLUCCI;F. ARMENISE;ANTONELLA CRAPOLICCHIO;GLORIA M. CÓNSOLE;VITA FEDELE;M. DE LENA;M. DI BISCEGLIE;MICHELE QUARANTA;FRANCESCO SCHITTULLI","0.37;0.33;0.33;0.33;0.25;0.25;0.2;0.2;0.17;0.17;0.17;0.17;0.17;0.12;0.06;0.06","ANGELO PARADISO;ANTONIA BELLIZZI;STEPHAN J. RESHKIN;MASSIMO TOMMASINO;ROSA ANGELA CARDONE;VALERIA CASAVOLA;GIUSEPPE COLUCCI;EVARISTO MAIELLO;FRANCESCO DE VITA;FRANCESCO GIULIANI;GIUSEPPE CATALANO;M. DI BISCEGLIE;NICOLO' GEBBIA;VITTORIO GEBBIA;ANTONELLA CRAPOLICCHIO;STEFANIA TOMMASI;VITA FEDELE;ANNAMARIA CATINO;A. CASAMASSIMA;ANTONELLA AMODIO","121;121;121;101;101;101;79;64;64;64;64;64;64;64;20;20;20;18;15;15","ANTONIA BELLIZZI;GIUSEPPE COLUCCI;M. DI BISCEGLIE;ANTONELLA CRAPOLICCHIO;STEPHAN J. RESHKIN;VITA FEDELE;E. CRUCITTA;F. ARMENISE;GLORIA M. CÓNSOLE;P CALABRESE;M. DE LENA;G. COLUCCI;A PELLECCHIA;FRANCESCO SCHITTULLI;MICHELE QUARANTA;PETER SANTORO","121;79;64;20;20;20;15;10;10;8;7;4;0;0;0;0","ANTONIA BELLIZZI;E. CRUCITTA;GIUSEPPE COLUCCI;ANTONELLA CRAPOLICCHIO;F. ARMENISE;G. COLUCCI;GLORIA M. CÓNSOLE;M. DE LENA;M. DI BISCEGLIE;P CALABRESE;STEPHAN J. RESHKIN;VITA FEDELE;A PELLECCHIA;FRANCESCO SCHITTULLI;MICHELE QUARANTA;PETER SANTORO","2;2;2;1;1;1;1;1;1;1;1;1;0;0;0;0","MEDICINE;BIOLOGY;CHEMISTRY;POLITICAL SCIENCE","9;2;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;GASTROENTEROLOGY;CANCER RESEARCH;PHARMACOLOGY;BIOCHEMISTRY;CELL BIOLOGY;GENETICS;IMMUNOLOGY;INTENSIVE CARE MEDICINE;LAW;PATHOLOGY;RADIOLOGY","8;4;4;3;2;2;1;1;1;1;1;1;1;1","CANCER;CHEMOTHERAPY;NAUSEA;TOXICITY;ADMINISTRATION (PROBATE LAW);APOPTOSIS;CATHETER;CELL;CELL CULTURE;CELL GROWTH;CYTOKINE;DISEASE;EMBOLIZATION;GENE;GOLD STANDARD (TEST);HORMONE;IMMUNOSUPPRESSION;INTERFERON;KINASE;LEIOMYOSARCOMA;MALIGNANCY;MITOMYCIN C;MYOCARDIAL INFARCTION;PERFUSION;PREMEDICATION;RENAL CELL CARCINOMA;SARCOMA;SIGNAL TRANSDUCTION;STENT;VOMITING","8;4;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;NEUTROPENIA;ALPHA INTERFERON;AMIFOSTINE;ANGINA;ARTERIAL EMBOLIZATION;BALLOON CATHETER;CAUSES OF CANCER;CELL CYCLE;CLONE (JAVA METHOD);COLORECTAL CANCER;CYCLOPHOSPHAMIDE;DOCETAXEL;DOXORUBICIN;ETOPOSIDE;GEMCITABINE;LEUKOPENIA;MEDROXYPROGESTERONE ACETATE;METASTASIS;MUCOSITIS;PACLITAXEL;PHASES OF CLINICAL RESEARCH;PROGRESSIVE DISEASE;PROTEIN KINASE A;SOFT TISSUE SARCOMA;TRANSFECTION","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTHRACYCLINE;COLONOSCOPY;DEOXYCYTIDINE;EPIRUBICIN;ESTROGEN RECEPTOR;FEBRILE NEUTROPENIA;IFOSFAMIDE;MEDROXYPROGESTERONE;METASTATIC BREAST CANCER;ONCOGENE;P38 MITOGEN-ACTIVATED PROTEIN KINASES","1;1;1;1;1;1;1;1;1;1;1","BREAST NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;HUMANS;ANTINEOPLASTIC AGENTS;FEMALE;MIDDLE AGED;ANTINEOPLASTIC AGENTS, PHYTOGENIC;LUNG NEOPLASMS;MALE;ADULT;AGED;CARCINOMA, RENAL CELL;DEOXYCYTIDINE;KIDNEY NEOPLASMS;ADENOCARCINOMA;ANTIMETABOLITES, ANTINEOPLASTIC;BONE NEOPLASMS;CISPLATIN;EPIRUBICIN;IFOSFAMIDE","9;8;8;6;6;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3","CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CANCER IMMUNOTHERAPY;GASTRIC CANCER RESEARCH AND TREATMENT;GLOBAL TRENDS IN COLORECTAL CANCER RESEARCH;HEPATOCELLULAR CARCINOMA;MOLECULAR MECHANISMS OF METASTASIS SUPPRESSOR GENES;NUTRITIONAL GENOMICS: PERSONALIZED NUTRITION AND HEALTH;ROLE OF NITRIC OXIDE IN HEALTH AND DISEASE;SARCOMA RESEARCH AND TREATMENT","2;1;1;1;1;1;1;1;1","ADENOMATOUS POLYPS;AMIFOSTINE;APOPTOSIS REGULATION;ARTERIAL EMBOLIZATION;BALLOON CATHETER;CARDIOVASCULAR RISK ASSESSMENT;CAUSES OF CANCER;CELL REGULATION;CELL SIGNALING;CLONE (JAVA METHOD);COLONOSCOPY;COLORECTAL CANCER;COLORECTAL CANCER SCREENING;EPIRUBICIN;GOLD STANDARD (TEST);IMMUNOSUPPRESSION;LEUKOPENIA;MACHINE PERFUSION;MEDROXYPROGESTERONE;METASTATIC","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;ADVANCED GASTRIC;ADVANCED PRIMARY;ANTIMETASTATIC NMNDP;ARTERIAL STENT;ARTERIAL WALL;CANCER CELLS;CANCER INVASION;CANCER PATIENTS;CANCER SCREENING;CDDP ADMINISTRATION;CELL CARCINOMA;CIS-DIAMMINODICHLOROPLATINUM CDDP;COLORECTAL CANCER;EXCHANGER NHE;GASTRIC CANCER;GRUPPO ONCOLOGICO;HEPATIC ARTERIAL;HUMAN BREAST;HYPOXIC STOP-FLOW;IATROGENIC LESIONS;II STUDY;INDUCED BREAST;INDUCES APOPTOSIS;INTERLEUKIN- INTERFERON-ALPHA;ITALIA MERIDIONALE;KINASE A-;LIVER METASTASES;LOCALLY ADVANCED;MEDROXYPROGESTERONE ACETATE","3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,5,1166,20,0,0,16,0,0,1,0,2,0,0,0,0,1,0,0,0,0,0,0,0,2,1,0,1,2,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","3;3;1;1;1","BREAST CANCER;CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COLO-RECTAL CANCER;DIGESTIVE DISEASES;LUNG;ORPHAN DRUG;PREVENTION;RARE DISEASES","1;1;1;1;1;1;1;1;1;1","CANCER;RENAL AND UROGENITAL","3;1","6.1 PHARMACEUTICALS","2","BREAST CANCER;COLON AND RECTAL CANCER;KIDNEY CANCER;LUNG CANCER;OVARIAN CANCER;STOMACH CANCER","1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_TUMORIBARI",2004,7,9.28571428571429,3.28571428571429,0.142857142857143,0.285714285714286,0.142857142857143,1.4375,0.5,0.666666666666667,0.5,0.142857142857143,0,2,3,0,1,0.29,0.43,0,0.14,33,0.701327652828692,NA,0.142857142857143,1,0.287,0,0.167,0,"MICHELE QUARANTA;GIROLAMO RANIERI;ANGELO PARADISO;BALDASSARRE STEA;FRANCESCO SCHITTULLI;M. COVIELLO;MARIO DE LENA;SEVERINO MONTEMURRO;ALFREDO ZITO;CARLO SABBÀ;STEFANIA TOMMASI;GIUSEPPE LEONE;I. ZULLO;FRANCESCO RESTA;PIETRO MILELLA;A. DISTANTE;ANNALISA CHIRIATTI;VITO LORUSSO;EDOARDO GUASTAMACCHIA;A NUZZACO","4;4;4;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","ANGELO PARADISO;GIROLAMO RANIERI;MICHELE QUARANTA;BALDASSARRE STEA;MARIO DE LENA;M. COVIELLO;FRANCESCO SCHITTULLI;GIUSEPPE LEONE;I. ZULLO;A NUZZACO;MAURO CARINO;L AMBROSI;GABRIELLA TRANI;SEVERINO MONTEMURRO;ALFREDO ZITO;ANNALISA CHIRIATTI;MASSIMO TOMMASINO;LUCIANO GRAMMATICA;INGEBORG ZEHBE;RUGGERO DITTADI","0.45;0.42;0.41;0.36;0.22;0.21;0.2;0.17;0.17;0.17;0.17;0.17;0.17;0.12;0.12;0.12;0.12;0.12;0.12;0.12","MICHELE QUARANTA;BALDASSARRE STEA;FRANCESCO SCHITTULLI;M. COVIELLO;MARIO DE LENA;ALFREDO ZITO;ANNALISA CHIRIATTI;A NUZZACO;EUGENIO CANNIELLO;GIUSEPPE COLUCCI;MASSIMO TOMMASINO;VITTORIO CATALANO;INGEBORG ZEHBE;ARTUR TIMURIAN;M. BRUNO;A PELLECCHIA","4;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1","MICHELE QUARANTA;BALDASSARRE STEA;MARIO DE LENA;M. COVIELLO;FRANCESCO SCHITTULLI;A NUZZACO;ALFREDO ZITO;ANNALISA CHIRIATTI;MASSIMO TOMMASINO;INGEBORG ZEHBE;M. BRUNO;EUGENIO CANNIELLO;GIUSEPPE COLUCCI;ARTUR TIMURIAN;VITTORIO CATALANO;A PELLECCHIA","0.41;0.36;0.22;0.21;0.2;0.17;0.12;0.12;0.12;0.12;0.11;0.09;0.09;0.09;0.08;0.08","GIROLAMO RANIERI;MARIO DE LENA;ANGELO PARADISO;ANNAMARIA CATINO;ANTONIO CRAMAROSSA;ARTUR TIMURIAN;COSMO DAMIANO GADALETA;EUGENIO CANNIELLO;GIANMARIA FIORENTINI;GIUSEPPE COLUCCI;VITO LORUSSO;VITTORIO MATTIOLI;MICHELE QUARANTA;BALDASSARRE STEA;FRANCESCO SCHITTULLI;M. COVIELLO;A. DISTANTE;A. MASTROPASQUA;ALFREDO ZITO;INGEBORG ZEHBE","180;136;108;105;105;105;105;105;105;105;105;105;94;89;50;44;31;31;31;31","MARIO DE LENA;ARTUR TIMURIAN;EUGENIO CANNIELLO;GIUSEPPE COLUCCI;BALDASSARRE STEA;MICHELE QUARANTA;FRANCESCO SCHITTULLI;M. COVIELLO;ALFREDO ZITO;INGEBORG ZEHBE;M. BRUNO;MASSIMO TOMMASINO;ANNALISA CHIRIATTI;A PELLECCHIA;VITTORIO CATALANO;A NUZZACO","136;105;105;105;89;63;50;44;31;31;31;31;27;17;17;1","BALDASSARRE STEA;MICHELE QUARANTA;FRANCESCO SCHITTULLI;M. COVIELLO;MARIO DE LENA;A NUZZACO;A PELLECCHIA;ALFREDO ZITO;ANNALISA CHIRIATTI;ARTUR TIMURIAN;EUGENIO CANNIELLO;GIUSEPPE COLUCCI;INGEBORG ZEHBE;M. BRUNO;MASSIMO TOMMASINO;VITTORIO CATALANO","3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;ENGINEERING;POLITICAL SCIENCE;PSYCHOLOGY;SOCIOLOGY","7;2;1;1;1;1","INTERNAL MEDICINE;ENDOCRINOLOGY;PATHOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;GENETICS;GYNECOLOGY;IMMUNOLOGY;ONCOLOGY;ANDROLOGY;CANCER RESEARCH;CIVIL ENGINEERING;DEMOGRAPHY;DEVELOPMENTAL PSYCHOLOGY;FAMILY MEDICINE;GERONTOLOGY;LAW;NUCLEAR MEDICINE;PHYSICAL THERAPY;RADIOLOGY","6;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CANCER;ANGIOGENESIS;POPULATION;VEGF RECEPTORS;ABLATION;ASTHMA;BODY MASS INDEX;CELL;CONFIDENCE INTERVAL;DECREE;DIABETES MELLITUS;EPIDEMIOLOGY;FAMILY HISTORY;GENETIC COUNSELING;GENETIC TESTING;GRADING (ENGINEERING);IMMUNOHISTOCHEMISTRY;LOGISTIC REGRESSION;LUNG;MALIGNANT TRANSFORMATION;OBESITY;ODDS RATIO;PLATELET;RATING SCALE;VENOUS BLOOD;WHOLE BLOOD","5;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;VASCULAR ENDOTHELIAL GROWTH FACTOR;CARCINOGENESIS;CELL CYCLE;COLORECTAL CANCER;EPIDERMOID CARCINOMA;HEAD AND NECK CANCER;INSULIN RESISTANCE;MARITAL STATUS;OCCUPATIONAL ASTHMA;RADIOFREQUENCY ABLATION;TYPE 2 DIABETES","2;2;1;1;1;1;1;1;1;1;1;1","HEAD AND NECK SQUAMOUS-CELL CARCINOMA;HYPERINSULINEMIA;MOLECULAR MEDICINE;ONCOGENE;TUMOR SUPPRESSOR GENE","1;1;1;1;1","BREAST NEOPLASMS;HUMANS;AGED;DIABETES MELLITUS, TYPE 2;FEMALE;MIDDLE AGED;COLONIC NEOPLASMS;GASTROINTESTINAL NEOPLASMS;RECTAL NEOPLASMS;STOMACH NEOPLASMS;VASCULAR ENDOTHELIAL GROWTH FACTOR A;ADENOCARCINOMA;ADULT;ASTHMA;BIOMARKERS, TUMOR;CARCINOMA, SIGNET RING CELL;CARCINOMA, SQUAMOUS CELL;COLORECTAL NEOPLASMS;HEAD AND NECK NEOPLASMS;ITALY","9;7;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3","CARDIAC SURGERY AND BYPASS GRAFTING OUTCOMES;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;MOLECULAR BASIS OF RETT SYNDROME AND RELATED DISORDERS;MOLECULAR MECHANISMS OF ANGIOGENESIS AND VASCULAR FUNCTION;OCCUPATIONAL ASTHMA AND HEALTH IMPACTS IN WORK ENVIRONMENTS;PULMONARY CALCIFICATION AND NODULAR TUMORS IN THE LUNG;ROLE OF AMP-ACTIVATED PROTEIN KINASE IN CELLULAR METABOLISM","1;1;1;1;1;1;1","BREAST CANCER;CANCER RISK;BODY MASS INDEX;CANCER;CANCER SUSCEPTIBILITY;DECREE;ENDOTHELIAL CELL BEHAVIOR;EPIDERMOID CARCINOMA;FHIT;GENETIC TESTING;GRADING (ENGINEERING);HYPERINSULINEMIA;LUNG CANCER;LUNG NODULES;LUNG TRANSPLANT;MALIGNANT TRANSFORMATION;MARITAL STATUS;NON-SMALL CELL LUNG CANCER;OCCUPATIONAL ASTHMA;PLATELET-RICH PLASMA","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;CANCER PATIENTS;ENDOTHELIAL GROWTH;GROWTH FACTOR;HEALTHY CONTROLS;VASCULAR ENDOTHELIAL;ADEQUATE COMPENSATION;ALTERED PINKA;BIOLOGICAL DAMAGE;BLOOD FRACTIONS;BODY MASS;CANCER CURRENT;CANCER GENETICS;COLORECTAL CANCER;CURRENT THERAPEUTIC;DAMAGE ADEQUATE;FACTOR ASSESSMENT;FACTOR CONCENTRATIONS;FHIT EXPRESSION;GASTROINTESTINAL CANCER;GENETIC TESTING;HUMAN ORAL;ITALIAN POPULATION;LUNG NEOPLASMS;MASS INDEX;NEOPLASMS PRELIMINARY;OCCUPATIONAL ASTHMA;ORAL CANCER;PLASMA-ACTIVATED PLATELETS;PLATELETS RICH","2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;GENETIC TESTING;CANCER RISK;FAMILY HISTORY;AD HOC;ADVANCE RESEARCH;AGE ODDS;APULIA ITALY;BARI ITALY;CANCER GENETICS;CANCER PREDISPOSING;CANCER RISKA;CHILDRENS RISK;CITED REASONS;CLINICAL BENEFIT;COLLECTED RESPONSES;CONFIDENCE INTERVAL;CONSECUTIVE SERIES;DEVELOP AD;DIRECT CLINICAL;EDUCATIONAL STRATEGIES;FREQUENTLY CITED;GATHER INFORMATION;GENESMOST WOMEN;GENETIC TESTINGSOUTHERN;HEALTHY WOMEN;HOC EDUCATIONAL;INAPPROPRIATE KNOWLEDGE;INDEPENDENTLY NA;INDEPENDENTLY PREDICTED","9;8;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,0,0,20,0,0,1,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,3,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY","3;3;1",NA,NA,"CANCER;RENAL AND UROGENITAL","2;1","6.1 PHARMACEUTICALS","1","COLON AND RECTAL CANCER;EAR CANCER;HEAD AND NECK CANCER;KIDNEY CANCER;LARYNGEAL CANCER;NASAL CAVITY AND PARANASAL SINUS CANCER;NOT SITE-SPECIFIC CANCER;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER","1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_TUMORIBARI",2005,10,11.5,2,0.1,0.4,0.1,1.25,0.5,1.33333333333333,0.5,0.2,0,2,2,2,4,0.2,0.2,0.2,0.4,25.8,0.487309841317141,NA,0.3,0.9,0.347,0,0.1,0,"VITTORIO GEBBIA;VITO LORUSSO;DOMENICO GALETTA;GIUSEPPE COLUCCI;ANGELO PARADISO;PAOLO VERDERIO;GERARDO ROSATI;ETTORE MARUBINI;M. DI BISCEGLIE;NICOLA SILVESTRIS;LUIGI MANZIONE;MARTA CORTESE;A. ZITO;C. GRIDELLI;JUAN ROSAÍ;GRAZIA CASSANO;MASSIMILIANO SPADA;ANNA MARIA CIANCIULLI;ALBERTO SOBRERO;D. SAMBIASI","4;4;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","VITTORIO GEBBIA;VITO LORUSSO;GIUSEPPE COLUCCI;ANGELO PARADISO;DOMENICO GALETTA;M. DI BISCEGLIE;GERARDO ROSATI;LUIGI MANZIONE;PAOLO VERDERIO;ETTORE MARUBINI;MARTA CORTESE;A. ZITO;NICOLA SILVESTRIS;STEFANIA TOMMASI;ANNALISA CHIRIATTI;FRANCESCO SCHITTULLI;AGNESE LATORRE;ANITA MANGIA;L. DE APPOLLONIA;SARA PIZZAMIGLIO","0.4;0.36;0.31;0.3;0.29;0.24;0.2;0.2;0.18;0.18;0.18;0.18;0.15;0.12;0.12;0.12;0.12;0.12;0.12;0.12","VITO LORUSSO;GIUSEPPE COLUCCI;ANGELO PARADISO;M. DI BISCEGLIE;LUIGI MANZIONE;A. ZITO;GRAZIA CASSANO;MASSIMILIANO SPADA;D. SAMBIASI;G. VINCIARELLI;MARIANNA GIAMPAGLIA;E. CRUCITTA;VITO LORUSSO;G. COLUCCI;GIOVANNI IZZI;F MARZULLO","4;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1","VITO LORUSSO;GIUSEPPE COLUCCI;ANGELO PARADISO;M. DI BISCEGLIE;LUIGI MANZIONE;A. ZITO;G. VINCIARELLI;D. SAMBIASI;G. COLUCCI;GRAZIA CASSANO;MASSIMILIANO SPADA;MARIANNA GIAMPAGLIA;GIOVANNI IZZI;E. CRUCITTA;VITO LORUSSO;F MARZULLO","0.36;0.31;0.3;0.24;0.2;0.18;0.11;0.09;0.09;0.08;0.08;0.08;0.08;0.07;0.07;0.05","VITO LORUSSO;ANGELO PARADISO;A. ZITO;AGNESE LATORRE;ANITA MANGIA;ANNALISA CHIRIATTI;FRANCESCO SCHITTULLI;STEFANIA TOMMASI;VITTORIO GEBBIA;GIUSEPPE COLUCCI;M. DI BISCEGLIE;C BATTAGLIA;EVARISTO MAIELLO;FRANCESCO GIULIANI;G. VINCIARELLI;NICOLA GEBBIA;STEFANO MOLICA;GERARDO ROSATI;LUIGI MANZIONE;NICOLA SILVESTRIS","191;148;146;134;134;134;134;134;56;53;50;43;43;43;43;43;43;29;29;25","A. ZITO;GIUSEPPE COLUCCI;M. DI BISCEGLIE;G. VINCIARELLI;VITO LORUSSO;E. CRUCITTA;D. SAMBIASI;F MARZULLO;LUIGI MANZIONE;G. COLUCCI;GIOVANNI IZZI;GRAZIA CASSANO;MARIANNA GIAMPAGLIA;MASSIMILIANO SPADA;ANGELO PARADISO","146;53;50;43;32;22;12;12;7;3;3;3;3;3;2","GIUSEPPE COLUCCI;A. ZITO;M. DI BISCEGLIE;VITO LORUSSO;ANGELO PARADISO;D. SAMBIASI;E. CRUCITTA;F MARZULLO;G. COLUCCI;G. VINCIARELLI;GIOVANNI IZZI;GRAZIA CASSANO;LUIGI MANZIONE;MARIANNA GIAMPAGLIA;MASSIMILIANO SPADA","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PHILOSOPHY","10;2;1","INTERNAL MEDICINE;ONCOLOGY;GASTROENTEROLOGY;PATHOLOGY;SURGERY;BIOCHEMISTRY;ECOLOGY;GYNECOLOGY;MEDICAL PHYSICS;PHARMACOLOGY;THEOLOGY;UROLOGY","10;7;5;4;3;1;1;1;1;1;1;1","CHEMOTHERAPY;CANCER;TOXICITY;IMMUNOHISTOCHEMISTRY;LUNG CANCER;REGIMEN;ADVERSE EFFECT;ANEMIA;BIOMARKER;CHRISTIAN MINISTRY;CLINICAL RESEARCH;CLINICAL TRIAL;EXTERNAL QUALITY ASSESSMENT;GRADING (ENGINEERING);MESOTHELIOMA;MITOMYCIN C;PLEURAL EFFUSION;URINARY BLADDER","7;6;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","NEUTROPENIA;BREAST CANCER;CISPLATIN;GEMCITABINE;PHASES OF CLINICAL RESEARCH;PACLITAXEL;PERFORMANCE STATUS;ANTIMETABOLITE;CHROMOGRANIN A;COLORECTAL CANCER;CYCLOPHOSPHAMIDE;DOXORUBICIN;HEAD AND NECK CANCER;LEUKOPENIA;MUCOSITIS;PREDICTIVE MARKER;PROGRESSIVE DISEASE;TOLERABILITY;TOPOTECAN;UROTHELIUM","4;3;3;3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CARBOPLATIN;ANTHRACYCLINE;EPIRUBICIN;FEBRILE NEUTROPENIA;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;IFOSFAMIDE;IRINOTECAN;METASTATIC BREAST CANCER;PEMETREXED","3;1;1;1;1;1;1;1;1","ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;DEOXYCYTIDINE;LUNG NEOPLASMS;AGED;FEMALE;HUMANS;BREAST NEOPLASMS;CARCINOMA, NON-SMALL-CELL LUNG;MIDDLE AGED;MALE;TREATMENT OUTCOME;ADULT;NEUTROPENIA;PACLITAXEL;CAMPTOTHECIN;CISPLATIN;EPIRUBICIN;ADENOCARCINOMA;CARBOPLATIN;DOXORUBICIN","21;9;9;8;8;8;7;7;7;6;6;5;5;5;4;4;4;3;3;3","CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;DIAGNOSIS AND TREATMENT OF LUNG CANCER;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GASTRIC CANCER RESEARCH AND TREATMENT;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;MOLECULAR RESEARCH ON BREAST CANCER;SMALL CELL LUNG CANCER","3;1;1;1;1;1;1;1","CARBOPLATIN;BREAST CANCER;PERFORMANCE STATUS;REGIMEN;BARTHOLIN GLAND CYST;BREAST CANCER DIAGNOSIS;CANCER IMAGING;CANCER THERAPY;CHRISTIAN MINISTRY;CHROMOGRANIN A;CLINICAL RESEARCH;DIAGNOSTIC CRITERIA;EPIRUBICIN;GASTRIC CANCER;GRADING (ENGINEERING);LEUKOPENIA;LUNG CANCER;MALIGNANT PLEURAL EFFUSION;MALIGNANT PLEURAL MESOTHELIOMA;METASTATIC BREAST CANCER","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PHASE II;BREAST CANCER;CELL CARCINOMA;II STUDY;II TRIAL;LUNG CANCER;QUALITY CONTROL;ADVANCED BREAST;ADVANCED GASTRIC;ADVANCED TRANSITIONAL;ADVANCEDMETASTATIC NON-SMALL;ANTHRACYCLINE PRETREATED;BIOMARKERS PREDICTIVE;CANCER PATIENTS;CELL LUNG;CGA ASSAY;CGA MEASUREMENT;CISPLATIN VERSUS;CLINICAL EFFICACY;CLINICAL RESEARCH;DELLITALIA MERIDIONALE;EXTERNAL QUALITY;FIRST-LINE CHEMOTHERAPY;FIRST-LINE TREATMENT;GASTRIC CANCER;GRUPPO ONCOLOGICO;HISTOLOGICAL GRADING;IRINOTECAN CPT-;ITALIAN CLINICAL;ITALIAN EXPERIENCE","4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BETA-TUBULIN III;ADVANCED BREAST;BREAST CANCER;CLINICAL RESEARCH;LUNG CANCER;ABC TREATED;ADVANCED NSCLC;ANALYSIS ICA;APOPTOTIC FRACTION;BETA-TUBULIN IMMUNOHISTOCHEMICAL;BETA-TUBULIN IV;BIOMARKERS CHARACTERISTICS;BIOMARKERS PREDICTIVE;CANCER ABC;CANCER DEATHS;CANCER NSCLC;CANCER PATIENTS;CANCERS SURGERY;CHEMOTHERAPYIMMUNOHISTOCHEMICAL ANALYSIS;CLASS III;CLINICAL RESPONSE;CLINICAL TRIALS;CONTROLLED CLINICAL;COX MULTIVARIATE;CURATIVE TREATMENT;DENSITY MVD;DEPENDENT VARIABLE;DISAPPOINTING RESULTS;ELDERLY PATIENTS;ENDOTHELIAL GROWTH","4;3;3;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,2,128,15.38,0,0,7,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,2,0,0,1,1,0,0,0,0,0,0,0,0,"United States","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","2;2",NA,NA,NA,NA,NA,NA,"COLON AND RECTAL CANCER","1",NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_TUMORIBARI",2006,10,10,1.6,0,0.2,0,1.23076923076923,0,0.666666666666667,0,0.8,0,6,2,0,1,0.6,0.2,0,0.1,28.3,0.554052335862826,NA,0.8,1,0.454,0,0.278,0,"ANGELO PARADISO;STEFANIA TOMMASI;LETIZIA PORCELLI;AMALIA AZZARITI;GIUSEPPE COLUCCI;G. SIMONE;S. ROMITO;SEVERINO MONTEMURRO;BAUKE YLSTRA;FABIENNE HERMITTE;P.B. BERLOCO;NICOLA DI RENZO;PAOLO VERDERIO;ALFREDO DI LEO;CHRISTOPHER C. BENZ;VITTORIO GEBBIA;L POLLICE;PIETRO NAZZARO;YUE MIN LI;MARIO PAZZAGLI","7;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","ANGELO PARADISO;LETIZIA PORCELLI;AMALIA AZZARITI;G. SIMONE;GIUSEPPE COLUCCI;S. ROMITO;JIAN-MING XU;YUE MIN LI;JIAN XU;YU HAN;CHUAN HUA ZHAO;YAN WANG;STEFANIA TOMMASI;NICOLA ANTONIO COLABUFO;DOMENICO GALETTA;VITO LORUSSO;ROBERTO PERRONE;MAURO NISO;FRANCESCO GIOTTA;NICOLA SILVESTRIS","0.8;0.32;0.32;0.32;0.24;0.24;0.2;0.17;0.17;0.17;0.17;0.17;0.13;0.12;0.12;0.12;0.12;0.12;0.12;0.12","ANGELO PARADISO;STEFANIA TOMMASI;GIUSEPPE COLUCCI;G. SIMONE;ANNALISA CHIRIATTI;MARCO BRUNO;FRANCESCO ALFREDO ZITO;FRANCESCO SCHITTULLI;MATTIA GENTILE;ROSANNA MALLAMACI;A. RUCCI;M. COVIELLO;A L BUONADONNA","7;2;2;2;1;1;1;1;1;1;1;1;1","ANGELO PARADISO;G. SIMONE;GIUSEPPE COLUCCI;STEFANIA TOMMASI;ROSANNA MALLAMACI;MARCO BRUNO;MATTIA GENTILE;A L BUONADONNA;ANNALISA CHIRIATTI;FRANCESCO ALFREDO ZITO;A. RUCCI;M. COVIELLO;FRANCESCO SCHITTULLI","0.8;0.32;0.24;0.13;0.11;0.1;0.1;0.1;0.07;0.07;0.07;0.07;0.06","ANGELO PARADISO;AMALIA AZZARITI;G. SIMONE;LETIZIA PORCELLI;FRANCESCO BERARDI;MAURO NISO;NICOLA ANTONIO COLABUFO;ROBERTO PERRONE;GIUSEPPE COLUCCI;S. ROMITO;CLAUDIO ORLANDO;ETTORE MARUBINI;FABIENNE HERMITTE;GRAEME DUNCAN;MARIO PAZZAGLI;MICHAEL NEUMAIER;PAOLO VERDERIO;SARA PIZZAMIGLIO;SARAH B. DALY;SIMON RAMSDEN","215;132;132;132;112;112;112;112;50;50;42;42;42;42;42;42;42;42;42;42","G. SIMONE;ANGELO PARADISO;ROSANNA MALLAMACI;GIUSEPPE COLUCCI;A L BUONADONNA;MATTIA GENTILE;MARCO BRUNO;A. RUCCI;ANNALISA CHIRIATTI;FRANCESCO ALFREDO ZITO;M. COVIELLO;FRANCESCO SCHITTULLI;STEFANIA TOMMASI","132;56;29;21;18;18;17;10;10;10;10;9;9","ANGELO PARADISO;G. SIMONE;A L BUONADONNA;A. RUCCI;ANNALISA CHIRIATTI;FRANCESCO ALFREDO ZITO;FRANCESCO SCHITTULLI;GIUSEPPE COLUCCI;M. COVIELLO;MARCO BRUNO;MATTIA GENTILE;ROSANNA MALLAMACI;STEFANIA TOMMASI","3;2;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;BUSINESS;COMPUTER SCIENCE;MATERIALS SCIENCE","9;5;2;1;1;1","INTERNAL MEDICINE;BIOCHEMISTRY;SURGERY;CANCER RESEARCH;GASTROENTEROLOGY;ONCOLOGY;PATHOLOGY;GENETICS;MOLECULAR BIOLOGY;PHARMACOLOGY;ANESTHESIA;DATA MINING;ECONOMIC POLICY;IMMUNOLOGY;MEDICAL PHYSICS;METALLURGY","7;4;4;3;3;3;3;2;2;2;1;1;1;1;1;1","CANCER;CHEMOTHERAPY;GENE;REGIMEN;CELL GROWTH;IN VITRO;RANDOMIZED CONTROLLED TRIAL;RECEPTOR;TOXICITY;ADVERSE EFFECT;ALTERNATIVE MEDICINE;ANALGESIC;ANGIOGENESIS;ANTIBODY;APOPTOSIS;ASBESTOS;BOLUS (DIGESTION);CELECOXIB;CELL CULTURE;COMPLICATION;EUROPEAN UNION;EXTERNAL QUALITY ASSESSMENT;FLOW CYTOMETRY;HELICOBACTER PYLORI;LUNG CANCER;MESOTHELIOMA;NAUSEA;PATHOGENESIS;RASH;VEGF RECEPTORS","8;4;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;COLORECTAL CANCER;CYTOTOXIC T CELL;EPIDERMAL GROWTH FACTOR RECEPTOR;AGONIST;ALLELE;ANTAGONIST;CANCER CELL;CANCER PAIN;CHEMOTHERAPY REGIMEN;DOXORUBICIN;EPIDERMAL GROWTH FACTOR;ERBB;FLUOROURACIL;GENOTYPE;GROWTH FACTOR RECEPTOR;GROWTH INHIBITION;METASTASIS;MUCOSITIS;NEUTROPENIA;PERFORMANCE STATUS;PHASES OF CLINICAL RESEARCH;PLACEBO;POLYMERASE CHAIN REACTION;PROGRESSIVE DISEASE;QUALITY ASSURANCE;REAL-TIME POLYMERASE CHAIN REACTION;THYMIDINE PHOSPHORYLASE;TOPOTECAN;TRAMADOL;VASCULAR ENDOTHELIAL GROWTH FACTOR;VIRULENCE","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GEFITINIB;AMPLICON;ANTHRACYCLINE;BRAIN METASTASIS;CAGA;EGFR INHIBITORS;GENOTYPING;IRINOTECAN;SINGLE-NUCLEOTIDE POLYMORPHISM;TAQMAN;TRAMADOL HYDROCHLORIDE","2;1;1;1;1;1;1;1;1;1;1","HUMANS;ANTINEOPLASTIC AGENTS;FEMALE;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;LUNG NEOPLASMS;MALE;ADULT;AGED;MIDDLE AGED;QUINAZOLINES;STOMACH NEOPLASMS;CAMPTOTHECIN;CARCINOMA, NON-SMALL-CELL LUNG;HELICOBACTER INFECTIONS;HELICOBACTER PYLORI;NEOVASCULARIZATION, PATHOLOGIC;ADENOCARCINOMA;ANTHRACYCLINES;ANTIGENS, BACTERIAL","10;9;8;7;7;7;7;6;5;5;5;5;4;4;4;4;4;3;3;3","ADVANCEMENTS IN LUNG CANCER RESEARCH;CYCLOOXYGENASE-2 INHIBITORS IN INFLAMMATION AND CANCER;HELICOBACTER PYLORI INFECTION AND GASTRIC CANCER;HER2 SIGNALING IN BREAST CANCER TREATMENT;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;MECHANISMS AND MANAGEMENT OF NEUROPATHIC PAIN;REAL-TIME POLYMERASE CHAIN REACTION;REGULATION OF CHROMATIN STRUCTURE AND FUNCTION;ROLE OF SIGMA RECEPTORS IN CELLULAR SIGNALING;SMALL CELL LUNG CANCER","1;1;1;1;1;1;1;1;1;1","REGIMEN;AMPLICON;BLOOD-BRAIN BARRIER;BOLUS (DIGESTION);BRAIN METASTASES;CAGA;CAGA PROTEIN;CANCER PAIN;CELECOXIB;CHEMOTHERAPY REGIMEN;COLORECTAL CANCER;DNA MISMATCH REPAIR;EGFR INHIBITORS;ENHANCERS;ERBB;FOLFIRI;GROWTH INHIBITION;MALIGNANT PLEURAL MESOTHELIOMA;MUCOSITIS;PATHOGENESIS","3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PHASE II;DELLITALIA MERIDIONALE;GRUPPO ONCOLOGICO;II STUDY;ONCOLOGICO DELLITALIA;ADVANCED COLORECTAL;ADVANCED NON-SMALL-CELL;AGENT ZD;ALTERED PROMOTER;ANALGESIC COMPOUND;ANGIOGENESIS FACTORS;ANTAGONIST RECEPTOR;ANTIANGIOGENIC AGENT;ASSESSMENT SCHEME;BIOMOLECULAR EFFECTS;BRAIN METASTASES;BREAST CANCER;BREAST CANCERS;CANCER CELLS;CANCER PAIN;CELL GROWTH;CHARACTERIZES MONOALLELIC;CHINESE PATIENTS;CHRONIC MODERATE;COBROTOXIN-CONTAINING ANALGESIC;COLON CANCER;COLORECTAL CANCER;COMPARATIVE GENOMIC;CROSS-OVER STUDY;CYCLOHEXYLPIPERAZINE DERIVATIVE","3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TRAMADOL HYDROCHLORIDE;CANCER PAIN;PAIN RELIEF;CELL LINES;CROSS-OVER STUDY;OPEN-LABEL STUDY;SEVERE CANCER;Σ RECEPTOR;CANCER PATIENTS;CELL GROWTH;CHRONIC MODERATE;MCF ADR;PAIN SCORE;REAL-TIME PCR;RESPONSE RATE;VEGF LEVELS;ADVANCED COLORECTAL;ADVANCED NSCLC;ADVERSE EVENTS;ANGIOGENIC MARKERS;BOLUS INJECTION;CANCER CELL;CHINESE PATIENTS;CIRCULATING VEGF;CKLQ PACKAGE;COLON CANCER;DOUBLE-BLIND CROSS-OVER;DRUG EXPOSURE;EQA SCHEME;FOLFIRI REGIMEN","9;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,5,48,10,0,0,26,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,"Italy","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","1;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;LYMPHOMA;RARE DISEASES","1;1;1;1;1;1","CANCER","1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","1;1","NON-HODGKIN'S LYMPHOMA","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",1,2177810,7805.77,11,279,36,1,38,709.61550993809,14.0921384326456,"HOSPITAL BASE;ADDENBROOKE'S HOSPITAL;ALEXANDER FLEMING BIOMEDICAL SCIENCES RESEARCH CENTER;ALL INDIA INSTITUTE OF MEDICAL SCIENCES;ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY;ANHUI PROVINCIAL HOSPITAL;ANKARA ONKOLOJI EĞITIM VE ARAŞTIRMA HASTANESI;ANTONI VAN LEEUWENHOEK HOSPITAL;ARGERICH HOSPITAL;ASSOCIATION FOR CANCER SURGERY;ASTRAZENECA (UNITED KINGDOM);AUSTRIAN BREAST & COLORECTAL CANCER STUDY GROUP;AUTONOMOUS UNIVERSITY OF BARCELONA;BETH ISRAEL DEACONESS MEDICAL CENTER;BIRMINGHAM CHILDREN'S HOSPITAL;BOX HILL HOSPITAL;BRADFORD ROYAL INFIRMARY;CAIRO UNIVERSITY;CANCER CARE ONTARIO;CANCER INSTITUTE","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICAL RESEARCH COUNCIL","1","COALITION S;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;UKRI - UK RESEARCH AND INNOVATION","1;1;1","INTRAMURAL (PROJECT CATEGORY)","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1;1","BREAST CANCER;CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES","1;1;1;1","CANCER","1","6.1 PHARMACEUTICALS;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","1;1;1","BREAST CANCER","1","5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","1","A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE","1","3 GOOD HEALTH AND WELL BEING","1",0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_TUMORIBARI",2007,14,8.85714285714286,3.14285714285714,0.285714285714286,0.5,0.285714285714286,1.33333333333333,1,1.75,0.8,0.285714285714286,0,4,2,5,3,0.29,0.14,0.36,0.21,46.29,0.877022173555311,NA,0.214285714285714,0.785714285714286,0.383,0.222,0.333,0.188,"ANGELO PARADISO;STEFANIA TOMMASI;FRANCESCO GIULIANI;ANTONIA BELLIZZI;SILVIA DI TARDO;MICHELE QUARANTA;ROSA DIVELLA;FRANCESCO SCHITTULLI;AMALIA AZZARITI;GIUSEPPE COLUCCI;ANITA MANGIA;MARIA TERESA VENNERI;ANTONELLA DANIELE;PIERANGELO GEPPETTI;SEVERINO MONTEMURRO;ANTONELLA ARESTA;L. DE APOLLONIA;MARIANGELA CANTORE;PATRIZIA RUSSO;ROBERTO BORDONARO","5;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","FRANCESCO GIULIANI;GIUSEPPE COLUCCI;GIANLUCA COLUCCI;ANGELO PARADISO;STEFANIA TOMMASI;SILVIA DI TARDO;MICHELE QUARANTA;ROSA DIVELLA;MARIA TERESA VENNERI;ANTONELLA DANIELE;AMALIA AZZARITI;ANTONIA BELLIZZI;ANITA MANGIA;SEVERINO MONTEMURRO;E MASELLI;ZITO AF;F CHIUMARULO;G GARGANO;E RUGGIERI;FRANCESCO SCHITTULLI","1.07;0.57;0.5;0.49;0.27;0.22;0.22;0.22;0.22;0.22;0.18;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.15","ANGELO PARADISO;STEFANIA TOMMASI;FRANCESCO GIULIANI;ANTONIA BELLIZZI;SILVIA DI TARDO;MICHELE QUARANTA;ROSA DIVELLA;FRANCESCO SCHITTULLI;AMALIA AZZARITI;GIUSEPPE COLUCCI;ANITA MANGIA;MARIA TERESA VENNERI;ANTONELLA DANIELE;SEVERINO MONTEMURRO;ALESSANDRO MONACO;ANNALISA CHIRIATTI;VITO LORUSSO;LETIZIA PORCELLI;CLAUDIA CALABRÒ;FRANCESCO ALFREDO ZITO","5;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","FRANCESCO GIULIANI;GIUSEPPE COLUCCI;ANGELO PARADISO;STEFANIA TOMMASI;SILVIA DI TARDO;MICHELE QUARANTA;ROSA DIVELLA;MARIA TERESA VENNERI;ANTONELLA DANIELE;AMALIA AZZARITI;ANTONIA BELLIZZI;ANITA MANGIA;SEVERINO MONTEMURRO;ZITO AF;F CHIUMARULO;G GARGANO;FRANCESCO SCHITTULLI;CLAUDIA CALABRÒ;A. RUCCI;F. DIGIUSEPPE","1.07;0.57;0.49;0.27;0.22;0.22;0.22;0.22;0.22;0.18;0.17;0.17;0.17;0.17;0.17;0.17;0.15;0.14;0.14;0.14","ANGELO PARADISO;ANITA MANGIA;ANTONIA BELLIZZI;STEFANIA TOMMASI;AMALIA AZZARITI;FRANCESCO SCHITTULLI;AGNESE LATORRE;ANNALISA CHIRIATTI;CHRISTOPHER THOMSSEN;FRANCESCO ALFREDO ZITO;MARIA KAVALLARIS;NANCY KENDZIERSKI;ROSANNA LACALAMITA;VITA FEDELE;VITO LORUSSO;EDWARD J. WEINMAN;GIOVANNI BUSCO;MARIA ELENA DELL’AQUILA;ROSA ANGELA CARDONE;STEPHAN J. RESHKIN","471;271;271;237;210;190;140;140;140;140;140;140;140;140;140;131;131;131;131;131","ANGELO PARADISO;ANITA MANGIA;ANTONIA BELLIZZI;AMALIA AZZARITI;FRANCESCO SCHITTULLI;AGNESE LATORRE;ANNALISA CHIRIATTI;FRANCESCO ALFREDO ZITO;ROSANNA LACALAMITA;VITA FEDELE;VITO LORUSSO;STEFANIA TOMMASI;G. SIMONE;LETIZIA PORCELLI;GIUSEPPE COLUCCI;M. GENNARO;ALESSANDRO MONACO;BRUNELLA PILATO;ANTONELLA DANIELE;MARIA TERESA VENNERI","471;271;271;210;190;140;140;140;140;140;140;97;79;79;60;50;46;46;40;40","ANGELO PARADISO;GIUSEPPE COLUCCI;AMALIA AZZARITI;ANITA MANGIA;ANTONIA BELLIZZI;FRANCESCO GIULIANI;FRANCESCO SCHITTULLI;STEFANIA TOMMASI;A. RUCCI;AGNESE LATORRE;ALESSANDRO MONACO;ANNALISA CHIRIATTI;ANTONELLA DANIELE;BRUNELLA PILATO;CLAUDIA CALABRÒ;F CHIUMARULO;F. DIGIUSEPPE;FRANCESCO ALFREDO ZITO;G GARGANO;G. SIMONE","6;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;PHILOSOPHY","11;4;3;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;SURGERY;PATHOLOGY;BIOCHEMISTRY;CHROMATOGRAPHY;GASTROENTEROLOGY;GENETICS;INTENSIVE CARE MEDICINE;ORGANIC CHEMISTRY;CELL BIOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;MOLECULAR BIOLOGY;PALEONTOLOGY;STEREOCHEMISTRY;THEOLOGY","10;6;4;4;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1","CANCER;CHEMOTHERAPY;GENE;CLINICAL TRIAL;ACTIN;ADSORPTION;ANALYTICAL CHEMISTRY (JOURNAL);ANTIBODY;BRAIN TUMOR;CALCIUM;CATHETER;CHOLECYSTECTOMY;CHRISTIAN MINISTRY;CONCOMITANT;DISPERSITY;EFFLUX;ESTROGEN;EXTERNAL QUALITY ASSESSMENT;GLIOMA;IMMUNOHISTOCHEMISTRY;IN VITRO;ION;LAPAROSCOPY;MASS SPECTROMETRY;MATRIX METALLOPROTEINASE;MEDICAL NUTRITION THERAPY;MICROTUBULE;MOIETY;PARAGANGLIOMA;PARENTERAL NUTRITION;PDZ DOMAIN;PHEOCHROMOCYTOMA;POPULATION;RADIOIMMUNOASSAY;RECEPTOR;REGIMEN;REPEATABILITY;SAMPLE PREPARATION;SIGNAL TRANSDUCTION;SMALL MOLECULE;STAGE (STRATIGRAPHY);TETRAHYDROISOQUINOLINE;TOXICITY","8;5;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;EPIDERMAL GROWTH FACTOR RECEPTOR;COLORECTAL CANCER;MUTATION;ADENOCARCINOMA;ARTIFICIAL NUTRITION;ASTROCYTOMA;BIOLOGICAL ACTIVITY;CENTRAL VENOUS CATHETER;CHEMOTHERAPY REGIMEN;CHROMOGRANIN A;DESORPTION;DOXORUBICIN;EC50;EPIDERMAL GROWTH FACTOR;GELATINASE;GEMCITABINE;IMMUNORADIOMETRIC ASSAY;IONIZATION;LAPAROSCOPIC SURGERY;LEAD COMPOUND;METASTASIS;MONOCLONAL ANTIBODY;OVARIAN CANCER;PACLITAXEL;PANCREATIC CANCER;PHENOTYPE;PSEUDOPODIA;RHOA;STRUCTURE–ACTIVITY RELATIONSHIP;TUBULIN;VERAPAMIL","3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CETUXIMAB;IRINOTECAN;OXALIPLATIN;ANAPLASTIC ASTROCYTOMA;ESTROGEN RECEPTOR;GELATINASES;GERMLINE MUTATION;MALE BREAST CANCER;MATRIX-ASSISTED LASER DESORPTION/IONIZATION;MISSENSE MUTATION;PHENOTYPIC SCREENING;TIME-OF-FLIGHT MASS SPECTROMETRY","2;2;2;1;1;1;1;1;1;1;1;1","BREAST NEOPLASMS;HUMANS;FEMALE;MIDDLE AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ASTROCYTOMA;BRAIN NEOPLASMS;GLIOBLASTOMA;GLIOMA;FLUOROURACIL;LEUCOVORIN;ORGANOPLATINUM COMPOUNDS;TUBULIN;ADULT;ANTIBODIES, MONOCLONAL;BIOMARKERS;BIOMARKERS, TUMOR;BLOOD PROTEINS;CYTOSKELETON;ENZYME-LINKED IMMUNOSORBENT ASSAY","14;12;9;7;6;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;HER2 SIGNALING IN BREAST CANCER TREATMENT;MANAGEMENT OF VASCULAR ACCESS IN HEALTHCARE;MASS SPECTROMETRY TECHNIQUES;MECHANISMS OF INTRACELLULAR MEMBRANE TRAFFICKING;PANCREATIC CANCER RESEARCH AND TREATMENT;PHEOCHROMOCYTOMA AND PARAGANGLIOMA;REGULATION AND FUNCTION OF MICROTUBULES IN CELL DIVISION;ROLE OF HIPPO SIGNALING PATHWAY IN MECHANOTRANSDUCTION;ROLE OF MATRIX METALLOPROTEINASES IN CANCER AND PHYSIOLOGY;ROLE OF SIGMA RECEPTORS IN CELLULAR SIGNALING;SARCOPENIA: DEFINITION, DIAGNOSIS, AND IMPLICATIONS","2;1;1;1;1;1;1;1;1;1;1;1;1","CANCER THERAPY;CETUXIMAB;METASTATIC COLORECTAL CANCER;PANITUMUMAB;ANAPLASTIC ASTROCYTOMA;ARTIFICIAL NUTRITION;BIOMARKER ANALYSIS;BRAIN TUMOR;BRAIN TUMOR EPIDEMIOLOGY;BRCA1;BRCA2;CANCER RISK;CANCER SUSCEPTIBILITY;CATHETER-RELATED BLOODSTREAM INFECTIONS;CENTRAL VENOUS CATHETER;CENTRAL VENOUS CATHETERIZATION;CHEK2;CHEMOTHERAPY REGIMEN;CHRISTIAN MINISTRY;CHROMOGRANIN A","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;COLON CANCER;ADVANCED PANCREATIC;ARTIFICIAL NUTRITION;ASSAY PERFORMANCE;BRCABRCA REARRANGEMENTS;BREAST TUMOR;CANCER PATIENTS;CENTRAL VENOUS;CGA ASSAY;CGA DETERMINATION;CHEK COMMON;CLINICAL PRACTICE;COMMON MUTATIONS;DOMAIN REGULATES;ECONOMIC EFFECTS;EPIDERMAL GROWTH;EXTERNAL QUALITY;EXTRA-ADRENAL PHEOCHROMOCYTOMA;FACTOR RECEPTOR;FOLFOX REGIMEN;GROWTH FACTOR;GRUPPO ONCOLOGICO;HUMAN SERUM;ITALIA MERIDIONALE;ITALIAN MALE;ITALIAN PROGRAM;LAPAROSCOPIC SURGERY;MALDI-TOF MASS;MALE BREAST","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;BRCA BRCA;GERM-LINE MUTATIONS;MBC PREDISPOSITION;NHERF OVEREXPRESSION;SERUM DEPRIVATION;CANCER FAMILIES;CHEK DELC;CHEK MUTATIONS;CLINICAL PRACTICE;COLORECTAL CANCER;CONVENTIONAL CHEMOTHERAPY;FIRST-LINE THERAPY;FOLFOX REGIMEN;METASTATIC COLORECTAL;MONTHS RANGE;NAH EXCHANGER;NHERF EXPRESSION;PDZ DOMAIN;PKA-GATED RHOAP;ADJUVANTNEOADJUVANT SETTING;ADVANCED PANCREATIC;ANTIBODY TARGETING;ASSESSING CETUXIMAB;BINDING GROOVE-MUTATED;BIOLOGICAL AGENTS;BRCA GENES;BRCA GERM-LINE;BRCA REARRANGEMENTS;BRCABRCA GERM-LINE","6;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1",4,0.29,3,2,1,0,0,0,1.5,0,0,2,0,0,1,0,0,0,0,1,0,0,0,49.25,49.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,10,125,3.85,0,0,21,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","1;1;1","CANCER;CLINICAL RESEARCH;HEMATOLOGY;LYMPHOMA;ORPHAN DRUG;RARE DISEASES","1;1;1;1;1;1","CANCER","1",NA,NA,"NON-HODGKIN'S LYMPHOMA","1","4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_TUMORIBARI",2008,23,9.21739130434783,3.21739130434783,0.391304347826087,0.478260869565217,0.347826086956522,1.48,0.9,1.22222222222222,0.888888888888889,0.652173913043478,0,5,5,4,2,0.22,0.22,0.17,0.09,28.04,0.511072028514326,NA,0.217391304347826,0.91304347826087,0.357,0.296,0.375,0.312,"ANGELO PARADISO;STEFANIA TOMMASI;GIUSEPPE COLUCCI;VITTORIO GEBBIA;V. MATTIOLI;EVARISTO MAIELLO;FRANCESCO SCHITTULLI;GIUSEPPE COLUCCI;FRANCESCO GIULIANI;SEVERINO MONTEMURRO;ANTONIA BELLIZZI;ALESSANDRO MONACO;LETIZIA PASSANTINO;STEPHAN J. RESHKIN;MICHELE QUARANTA;ROSANNA MONTANARO;GIROLAMO RANIERI;ROSA ANGELA CARDONE;CLAUDIA CORMIO;AMALIA AZZARITI","9;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","ANGELO PARADISO;GIUSEPPE COLUCCI;VITTORIO GEBBIA;EVARISTO MAIELLO;FRANCESCO GIULIANI;GIUSEPPE COLUCCI;STEFANIA TOMMASI;V. MATTIOLI;SEVERINO MONTEMURRO;ROSANNA MONTANARO;CLAUDIA CORMIO;FRANCESCA ROMITO;FILIPPO MENOLASCINA;FRANCESCO SCHITTULLI;LETIZIA PASSANTINO;GIROLAMO RANIERI;ALESSANDRO MONACO;ANTONIO LOGROSCINO;MICHELE QUARANTA;AMALIA AZZARITI","0.93;0.61;0.49;0.49;0.47;0.45;0.45;0.43;0.29;0.29;0.29;0.29;0.28;0.27;0.23;0.23;0.21;0.2;0.19;0.19","ANGELO PARADISO;STEFANIA TOMMASI;GIUSEPPE COLUCCI;V. MATTIOLI;FRANCESCO SCHITTULLI;GIUSEPPE COLUCCI;FRANCESCO GIULIANI;SEVERINO MONTEMURRO;ANTONIA BELLIZZI;ALESSANDRO MONACO;MICHELE QUARANTA;ROSANNA MONTANARO;GIROLAMO RANIERI;CLAUDIA CORMIO;AMALIA AZZARITI;ROSANNA LACALAMITA;FRANCESCA ROMITO;COSMO DAMIANO GADALETA;FILIPPO MENOLASCINA;ALFREDO ZITO","9;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1","ANGELO PARADISO;GIUSEPPE COLUCCI;FRANCESCO GIULIANI;GIUSEPPE COLUCCI;STEFANIA TOMMASI;V. MATTIOLI;SEVERINO MONTEMURRO;ROSANNA MONTANARO;CLAUDIA CORMIO;FRANCESCA ROMITO;FILIPPO MENOLASCINA;FRANCESCO SCHITTULLI;GIROLAMO RANIERI;ALESSANDRO MONACO;ANTONIO LOGROSCINO;MICHELE QUARANTA;AMALIA AZZARITI;ROSANNA LACALAMITA;ANTONIA BELLIZZI;COSMO DAMIANO GADALETA","0.93;0.61;0.47;0.45;0.45;0.43;0.29;0.29;0.29;0.29;0.28;0.27;0.23;0.21;0.2;0.19;0.19;0.19;0.18;0.18","A. KOFOKOTSIOS;ANCA TRIFAN;DANNY DE LOOZE;E. PEREZ-QUADRADO;EMANUELE RONDONOTTI;ERVIN TÓTH;F. SCOTTO;G. COUTO;GIOVANNI DOMENICO DE PALMA;ILJA TACHECÍ;MARCO PENNAZIO;MARIA ELENA RICCIONI;PEDRO MENCHÉN;RENATO CANNIZZARO;ROBERTO DE FRANCHIS;T. PACHOFSKY;TROELS HAVELUND;ANGELO PARADISO;DOMÉNICO RIBATTI;FRANCESCO SCHITTULLI","220;220;220;220;220;220;220;220;220;220;220;220;220;220;220;220;220;217;121;109","F. SCOTTO;ANGELO PARADISO;FRANCESCO SCHITTULLI;AMALIA AZZARITI;GIROLAMO RANIERI;A. MISINO;ANNAMARIA CATINO;ANTONIA BELLIZZI;COSMO DAMIANO GADALETA;MICHELE QUARANTA;G. SIMONE;ANDREA MALFETTONE;ANNALISA CHIRIATTI;STEFANIA TOMMASI;ALESSANDRO MONACO;ATTILIO GUARINI;DOMENICO GALETTA;BRUNELLA PILATO;MARCO CAMPANA;MARIA DIGENNARO","220;136;109;100;91;77;77;77;77;70;56;55;55;50;44;44;44;43;43;43","ANGELO PARADISO;GIUSEPPE COLUCCI;FRANCESCO SCHITTULLI;FRANCESCO GIULIANI;STEFANIA TOMMASI;ALESSANDRO MONACO;AMALIA AZZARITI;ANTONIA BELLIZZI;FILIPPO MENOLASCINA;GIROLAMO RANIERI;MICHELE QUARANTA;SEVERINO MONTEMURRO;V. MATTIOLI;A. MISINO;ALFREDO ZITO;ANDREA MALFETTONE;ANNALISA CHIRIATTI;ANNAMARIA CATINO;ATTILIO GUARINI;BRUNELLA PILATO","6;6;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;BUSINESS;ENGINEERING;MATHEMATICS;PHILOSOPHY;PHYSICS;POLITICAL SCIENCE;PSYCHOLOGY","19;12;4;2;1;1;1;1;1;1;1","INTERNAL MEDICINE;GENETICS;ONCOLOGY;CANCER RESEARCH;BIOCHEMISTRY;PATHOLOGY;COMPUTATIONAL BIOLOGY;FAMILY MEDICINE;GASTROENTEROLOGY;IMMUNOLOGY;CELL BIOLOGY;ORGANIC CHEMISTRY;RADIOLOGY;SURGERY;ANATOMY;ARTIFICIAL INTELLIGENCE;BIOINFORMATICS;BOTANY;COMMUNICATION;CONDENSED MATTER PHYSICS;ECOLOGY;ENGINEERING MANAGEMENT;EPISTEMOLOGY;GYNECOLOGY;LAW;MACHINE LEARNING;MEDICAL EDUCATION;MOLECULAR BIOLOGY;NURSING;OPERATIONS MANAGEMENT;PALEONTOLOGY;PROCESS MANAGEMENT;PROGRAMMING LANGUAGE;STATISTICS;STEREOCHEMISTRY;VIROLOGY","14;7;7;5;4;4;3;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;GENE;CHEMOTHERAPY;HEPATOCELLULAR CARCINOMA;IN VITRO;MAST CELL;REGIMEN;SIGNAL TRANSDUCTION;ABDOMEN;ABDOMINAL PAIN;ACCEPTOR;ACCREDITATION;AFFECT (LINGUISTICS);AMIDE;BILIRUBIN;BIOPSY;BIPHENYL;BOWEL OBSTRUCTION;CAPSULE ENDOSCOPY;CARBOXAMIDE;CATALYSIS;CELL;CLINICAL PRACTICE;DATA COLLECTION;DISEASE;DOCUMENTATION;ENDOSCOPY;EXCELLENCE;FAMILY HISTORY;GASTROINTESTINAL BLEEDING;GENETIC TESTING;GOLD STANDARD (TEST);GRADING (ENGINEERING);GROUP (PERIODIC TABLE);HEMATOLOGY;IDENTIFICATION (BIOLOGY);IMMUNOHISTOCHEMISTRY;INDUCTIVE LOGIC PROGRAMMING;INSULIN;LIPOPHILICITY;LIVER FUNCTION;LUNG CANCER;LYMPH;MALABSORPTION;MANAGEMENT SYSTEM;MEDIASTINUM;MULTIPLE MYELOMA;NOMOGRAM;NURSING CARE;ORCHIECTOMY;PATHOLOGICAL;PHYSICAL EXAMINATION;PLASMINOGEN ACTIVATOR;PLATELET;QUALITY (PHILOSOPHY);RASH;SARCOMA;SCROTUM;SOMATOSTATIN;STEM CELL;STROMAL CELL;TEST (BIOLOGY);THORAX (INSECT ANATOMY);TOXICITY;VEGF RECEPTORS;VIRUS","12;6;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","COLORECTAL CANCER;BREAST CANCER;CELL CYCLE;GENOTYPE;CARCINOGENESIS;EPIDERMAL GROWTH FACTOR RECEPTOR;RHOA;BASAL (MEDICINE);BIOLOGICAL ACTIVITY;BLEOMYCIN;CHEMICAL SYNTHESIS;DNA SEQUENCING;ENDOTHELIAL STEM CELL;ENTEROSCOPY;FLUOROURACIL;GIST;HAEMATOPOIESIS;HEPATITIS B VIRUS;HEPATITIS C VIRUS;IN SILICO;METASTASIS;MUTATION;OCTREOTIDE;OVARIAN CANCER;POLYMERASE CHAIN REACTION;PROGENITOR CELL;PROTEIN EXPRESSION;QUALITY MANAGEMENT;RHABDOMYOSARCOMA;RNA;SELECTIVITY;SORAFENIB;TARGETED THERAPY;TELOMERASE;TRANSFORMATION (GENETICS);TUMOR PROGRESSION","4;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ONCOGENE;SINGLE-NUCLEOTIDE POLYMORPHISM;CETUXIMAB;EGFR INHIBITORS;ELECTROCHEMOTHERAPY;FOLINIC ACID;GEFITINIB;GENOTYPING;GERMLINE MUTATION;IRINOTECAN;MOLECULAR MEDICINE;PROGENITOR;QUALITY MANAGEMENT SYSTEM;RNA SPLICING;SUPRACLAVICULAR LYMPH NODES;TELOMERASE REVERSE TRANSCRIPTASE","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;BREAST NEOPLASMS;FEMALE;;MIDDLE AGED;DOG DISEASES;AGED;MALE;MASTOCYTOMA, SKIN;ADULT;BIPHENYL COMPOUNDS;CELL TRANSFORMATION, NEOPLASTIC;DNA MUTATIONAL ANALYSIS;DNA, NEOPLASM;LUNG;MASTOCYTOSIS;OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;OVARIAN NEOPLASMS;RHOA GTP-BINDING PROTEIN;TETRAHYDROISOQUINOLINES","14;12;8;7;7;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4","GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;HEPATOCELLULAR CARCINOMA;INTEGRATION OF PALLIATIVE CARE IN END-OF-LIFE;TRANSLATION OF CANINE CANCER RESEARCH TO HUMANS;ADVANCEMENTS IN LUNG CANCER RESEARCH;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;BIOMEDICAL ONTOLOGIES AND TEXT MINING;CALCINEURIN-NFAT SIGNALING IN TRANSCRIPTIONAL REGULATION;DEVELOPMENT AND EVALUATION OF CLINICAL GUIDELINES;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;MECHANISMS OF MULTIDRUG RESISTANCE IN CANCER;MOLECULAR MECHANISMS OF ANGIOGENESIS AND VASCULAR FUNCTION;MOLECULAR RESEARCH ON BREAST CANCER;PANCREATIC CANCER RESEARCH AND TREATMENT;SARCOMA RESEARCH AND TREATMENT","3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CANCER SUSCEPTIBILITY;BRCA1;BRCA2;BREAST CANCER;CANCER RISK;CANINE CANCER;CETUXIMAB;REGIMEN;TUMOR MICROENVIRONMENT;ACCEPTOR;ADVANCE CARE PLANNING;AFFECT (LINGUISTICS);AMIDE;ANGIOGENESIS;ATP-DEPENDENT TRANSPORTERS;BASAL (MEDICINE);BIG DATA IN NURSING;BIPHENYL;CANCER;CAPSULE ENDOSCOPY","3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","BRCA VARIANTS;ADVANCED COLORECTAL;CANCER PATIENTS;COLORECTAL CANCER;GRUPPO ONCOLOGICO;MAST CELL;ONCOLOGICO ITALIA;PRELIMINARY RESULTS;PROTEIN EXPRESSION;ACCREDITATION PROJECT;ACTIVATES NHE;ADULT PARATESTICULAR;ADVANCED CANCER;ADVANCED HEPATOCELLULAR;ADVANCED NON-SMALL;AFFECT PSYCHOLOGICAL;ASSESSMENT PRELIMINARY;BASAL BILIRUBIN;BILIRUBIN LEVELS;BREAST CANCER;BREAST CANCERS;CANCER INPATIENTS;CANCER INSTITUTE;CANCER INSTITUTES;CANCER RISK;CANINE CUTANEOUS;CANINE MAST;CAPSULE ENDOSCOPY;CARCINOMA PRELIMINARY;CARCINOMA TREATED","3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;CANCER CENTRES;RHOA PROTEIN;SMALL-BOWEL TUMORS;BILIRUBIN LEVELS;PROTEIN EXPRESSION;BASAL BILIRUBIN;CARE RESEARCH;TUMOR BIOPSIES;ACCREDITATION TOOL;ADVANCED COLORECTAL;CANCER PATIENTS;CANCER RISK;CIRCULATORY LYMPHOCYTES;COLORECTAL CARCINOMA;GROWTH FACTOR;PATIENTS UNDERGOING;PREVENTION CARE;RESEARCH EDUCATION;STATISTICALLY SIGNIFICANT;ACCREDITATION PROJECT;ACTING OCTREOTIDE;ADVANCED HCC;ADVANCED HEPATOCELLULAR;BONE MARROW;BRCA GA;BRCA MUTATION;BRCA QR;CANCER STRUCTURES;CLINICO-PATHOLOGICAL FEATURES","11;7;7;7;6;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2",4,0.17,3,1.75,0,0,0,0,3.25,1,1,3.25,0,0,0,0,0,0,0,0,0,0,0.25,32.75,33,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,"PUBLIC LIBRARY OF SCIENCE","1","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3208 MEDICAL PHYSIOLOGY","2;2;1;1","CANCER","1",NA,NA,"1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING","1","BIOMEDICAL","1","BASIC SCIENCE","1",NA,NA,NA,NA
"IRCCS_TUMORIBARI",2009,20,10.8,2.85,0.55,0.35,0.6,1.29545454545455,1.22222222222222,1,1.2,0.3,0,7,4,3,5,0.35,0.2,0.15,0.25,18.85,0.407503933319722,NA,0.45,1,0.436,0.351,0.3,0.338,"ANGELO PARADISO;GIROLAMO RANIERI;FRANCESCO ALFREDO ZITO;COSMO DAMIANO GADALETA;PAOLO VERDERIO;ROSA PATRUNO;ANITA MANGIA;MAURIZIO BELFIGLIO;VITTORIO GEBBIA;STEFANIA TOMMASI;ROSELLA SILVESTRINI;LUCIO BERTARIO;NICOLA ZIZZO;AMINA VOCATURO;GENNARO CHIAPPETTA;SANTE TROILO;DOMÉNICO RIBATTI;GIUSEPPE COLUCCI;ATTILIO GUARINI;ANNAMARIA CATINO","6;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","ANGELO PARADISO;NICOLA SILVESTRIS;FRANCESCO ALFREDO ZITO;GIROLAMO RANIERI;COSMO DAMIANO GADALETA;GIUSEPPE COLUCCI;DOMENICO GALETTA;GIOVANNI SIMEONE;PASQUALE TAMBORRA;ENZA CARIOGGIA;ROSA PATRUNO;PAOLO VERDERIO;STEFANIA TOMMASI;ANITA MANGIA;NICOLA ZIZZO;SANTE TROILO;ANNAMARIA CATINO;GIOVANNI MISCIAGNA;VITO GUERRA;ANTONELLA DE CEGLIE","0.68;0.5;0.46;0.42;0.42;0.37;0.33;0.33;0.33;0.33;0.32;0.32;0.28;0.26;0.23;0.23;0.23;0.2;0.2;0.2","ANGELO PARADISO;GIROLAMO RANIERI;FRANCESCO ALFREDO ZITO;COSMO DAMIANO GADALETA;ROSA PATRUNO;ANITA MANGIA;STEFANIA TOMMASI;GIUSEPPE COLUCCI;ATTILIO GUARINI;ANNAMARIA CATINO;NICOLA SILVESTRIS;MICHELE RENI;VITO MICHELE GARRISI;CLARA FUGAZZA;ALESSANDRO MONACO;STEFANO CEREDA;MARIO BRANDI;ANNALISA CHIRIATTI;F. ARMENISE;GIOVANNI SIMEONE","6;4;4;4;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1","ANGELO PARADISO;NICOLA SILVESTRIS;FRANCESCO ALFREDO ZITO;GIROLAMO RANIERI;COSMO DAMIANO GADALETA;GIUSEPPE COLUCCI;GIOVANNI SIMEONE;PASQUALE TAMBORRA;ENZA CARIOGGIA;ROSA PATRUNO;STEFANIA TOMMASI;ANITA MANGIA;ANNAMARIA CATINO;A PELLECCHIA;ATTILIO GUARINI;BRUNELLA PILATO;ANNALISA CHIRIATTI;FRANCESCO SCHITTULLI;FILIPPO MENOLASCINA;ALESSANDRO MONACO","0.68;0.5;0.46;0.42;0.42;0.37;0.33;0.33;0.33;0.32;0.28;0.26;0.23;0.2;0.18;0.17;0.11;0.11;0.11;0.1","FRANCESCO ALFREDO ZITO;DOMÉNICO RIBATTI;COSMO DAMIANO GADALETA;GIROLAMO RANIERI;ROSA PATRUNO;ADDOLORATA RELLA;GIOVANNI BATTISTA DE SARRO;GIUSEPPE CELANO;MICHELE AMMENDOLA;SEVERINO MONTEMURRO;VALENTINA DI LECCE;ANGELO PARADISO;ANGELO VACCA;ANTONIO GNONI;ATTILIO GUARINI;FIORELLA D′AURIA;FRANCO DAMMACCO;GIULIA DI PIETRO;GIUSEPPE MANGIALARDI;MARIA ROSARIA RICCIARDI","160;147;144;144;119;88;88;88;88;88;88;78;59;59;59;59;59;59;59;59","FRANCESCO ALFREDO ZITO;GIROLAMO RANIERI;VALENTINA DI LECCE;ATTILIO GUARINI;COSMO DAMIANO GADALETA;MICHELE GUIDA;A. MISINO;EUSTACHIO RUGGIERI;ROSA PATRUNO;V. GOFFREDO;M. COVIELLO;MICHELE QUARANTA;ROSA DIVELLA;V. RUBINI;VITO MICHELE GARRISI;ANNALISA CHIRIATTI;EUGENIO CANNIELLO;F. ARMENISE;FILIPPO MENOLASCINA;FRANCESCO SCHITTULLI","160;119;88;59;56;45;31;31;31;31;28;28;28;28;28;25;25;25;25;25","FRANCESCO ALFREDO ZITO;ANGELO PARADISO;COSMO DAMIANO GADALETA;GIROLAMO RANIERI;GIUSEPPE COLUCCI;ANITA MANGIA;ATTILIO GUARINI;NICOLA SILVESTRIS;A PELLECCHIA;A. MISINO;ALESSANDRO MONACO;ALESSIA ROGNONE;ANNALISA CHIRIATTI;CLARA FUGAZZA;DOMENICA CERAULO;ENZA CARIOGGIA;EUGENIO CANNIELLO;EUGENIO VILLA;EUSTACHIO RUGGIERI;F. ARMENISE","4;3;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;MATHEMATICS;PHILOSOPHY;PHYSICS;POLITICAL SCIENCE;BUSINESS;ENGINEERING;PSYCHOLOGY","20;8;2;2;2;2;2;2;1;1;1","INTERNAL MEDICINE;ONCOLOGY;PATHOLOGY;CANCER RESEARCH;SURGERY;IMMUNOLOGY;GASTROENTEROLOGY;MEDICAL PHYSICS;BIOCHEMISTRY;GENETICS;FAMILY MEDICINE;LAW;STATISTICS;ARTIFICIAL INTELLIGENCE;ASTROBIOLOGY;BIOTECHNOLOGY;CIVIL ENGINEERING;DATA SCIENCE;DEVELOPMENTAL PSYCHOLOGY;ECOLOGY;ENDOCRINOLOGY;EPISTEMOLOGY;GYNECOLOGY;MARKETING;NUCLEAR MEDICINE;NURSING;OPERATING SYSTEM;ORGANIC CHEMISTRY;PALEONTOLOGY;PROGRAMMING LANGUAGE;QUANTUM MECHANICS;RADIOLOGY;THEOLOGY;VIROLOGY","18;8;8;7;6;5;4;4;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CHEMOTHERAPY;ANGIOGENESIS;GENE;IMMUNOHISTOCHEMISTRY;CHRISTIAN MINISTRY;GRADING (ENGINEERING);LYMPHOMA;MALIGNANCY;MAST CELL;ABLATION;ADVERSE EFFECT;ANTIBODY;BIOMARKER;BIOPSY;BONE MARROW;CARCINOMA;CEREBROSPINAL FLUID;CONFIDENCE INTERVAL;CONTEXT (ARCHAEOLOGY);CONTROL (MANAGEMENT);DISEASE;ENDOSCOPY;FRACTION (CHEMISTRY);GENETIC COUNSELING;GENETIC TESTING;HEPATOCELLULAR CARCINOMA;HUMAN IMMUNODEFICIENCY VIRUS (HIV);IMMUNE SYSTEM;IN VITRO;IN VIVO;INTERVIEW;LIKERT SCALE;LIVER FUNCTION;LOGISTIC REGRESSION;LUNG CANCER;MELANOMA;MULTIPLE MYELOMA;PATIENT SATISFACTION;PERCUTANEOUS;PLATELET;POISSON DISTRIBUTION;QUALITY (PHILOSOPHY);RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;REFRACTORY (PLANETARY SCIENCE);REPRODUCIBILITY;SARCOMA;SCALE (RATIO);SCHEDULE;SERVICE (BUSINESS);SOFTWARE;STEM CELL;TOXICITY;VACCINATION;VEGF RECEPTORS;VIRUS;ZOLEDRONIC ACID","10;5;4;4;4;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;CHYMASE;GEMCITABINE;MUTATION;NON-HODGKIN'S LYMPHOMA;PERFORMANCE STATUS;TRYPTASE;BLADDER CANCER;BORTEZOMIB;CD34;CELL CYCLE;CHEMOKINE;CISPLATIN;CLINICAL ENDPOINT;COLORECTAL CANCER;CYCLOPHOSPHAMIDE;DOCETAXEL;EX VIVO;EXON;FOLLICULAR LYMPHOMA;GERMLINE;HAZARD RATIO;LIPIODOL;MENINGEAL CARCINOMATOSIS;MONOCLONAL ANTIBODY;MUCOSITIS;NEUTROPENIA;OVARIAN CANCER;PACLITAXEL;PERIPHERAL BLOOD MONONUCLEAR CELL;PHASES OF CLINICAL RESEARCH;PROGRESSION-FREE SURVIVAL;PROGRESSIVE DISEASE;PROSTATE CANCER;PROTEOMICS;RADIOFREQUENCY ABLATION;RITUXIMAB;TELOMERASE;TOLERABILITY;TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION;VACCINE TRIAL;VASCULAR ENDOTHELIAL GROWTH FACTOR;VIRAL LOAD","8;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","AIDS VACCINES;ANTHRACYCLINE;BIOMARKER DISCOVERY;EPIRUBICIN;ESTROGEN RECEPTOR;FIBROADENOMA;GERMLINE MUTATION;HIV VACCINE;METASTATIC BREAST CANCER;ONCOGENE;PERITONEAL CARCINOMATOSIS;RADIOIMMUNOTHERAPY;TAXANE;TELOMERASE REVERSE TRANSCRIPTASE","1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST NEOPLASMS;HUMANS;FEMALE;NEOVASCULARIZATION, PATHOLOGIC;;MIDDLE AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;MICROVESSELS;ANTHRACYCLINES;BIOMARKERS, TUMOR;CARCINOMA, HEPATOCELLULAR;DOG DISEASES;IMMUNOHISTOCHEMISTRY;ITALY;LIVER NEOPLASMS;MALE;ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR;AGED;AGED, 80 AND OVER;ANGIOGENESIS INHIBITORS","17;13;9;8;6;6;5;5;4;4;4;4;4;4;4;4;3;3;3;3","DIAGNOSIS AND TREATMENT OF LUNG CANCER;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE;;CELLULAR SENESCENCE AND AGING-RELATED DISEASES;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DEEP LEARNING IN MEDICAL IMAGE ANALYSIS;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;FACTORS INFLUENCING PATIENT SATISFACTION WITH HEALTHCARE;HEPATOCELLULAR CARCINOMA;HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME;LYMPHOID NEOPLASMS;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;MANAGEMENT OF BRAIN METASTASES IN CANCER PATIENTS;MOLECULAR MECHANISMS OF ANGIOGENESIS AND VASCULAR FUNCTION;RADIOTHERAPY PHYSICS AND TECHNOLOGY;VIRAL-RELATED CANCERS IN IMMUNOCOMPROMISED PATIENTS","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;BIOMARKER ANALYSIS;CANCER IMAGING;CANCER RISK;CANCER SUSCEPTIBILITY;CELL GROWTH;CHRISTIAN MINISTRY;CHYMASE;GRADING (ENGINEERING);TRYPTASE;BIOMARKER DISCOVERY;BONE MARROW MICROENVIRONMENT;BRCA1;BRCA2;CANCER DIAGNOSTICS;CANCER TREATMENT;CLINICAL PRACTICE GUIDELINES;ENDOTHELIAL CELL BEHAVIOR;EPIRUBICIN;FOLLICULAR LYMPHOMA","3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;INTEGRATED ONCOLOGY;ITALIAN MINISTRY;MAST CELLS;NON-HODGKIN LYMPHOMA;ONCOLOGY PROGRAM;ADJUVANT ANTHRACYCLINES;ADVANCED BREAST;ANTHRACYCLINE-REFRACTORY CLASSICAL;BARI ITALY;BONE MARROW;BRCA EXPRESSION;BRONCHIOLOALVEOLAR CARCINOMA;CANCER HBOC;CANCER PATIENTS;CANCER PRETREATED;CANINE NON-HODGKIN;CELLS CORRELATE;CELLS POSITIVE;CHALLENGES SEPTEMBER;CIRCULATING HTERT;CLASSICAL KAPOSIS;CLINICAL GENETIC;CLINICAL VALIDATION;COOPERATIVE STUDY;DATA ANALYSIS;DIAGNOSIS NETWORK;ENDOSCOPY SERVICE;ENDOTHELIAL GROWTH;FACTOR CONCENTRATIONS","6;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;CLINICAL GENETIC;HIV-INFECTED PATIENTS;KINASE INHIBITOR;MELANOMA FAMILIES;CLINICAL TRIALS;CYCLIN-DEPENDENT KINASE;FIRST-LINE TREATMENT;GENETIC COUNSELING;GENETIC TESTING;HR CI;MCAPT MVD;MCDPT MCAPT;MCS POSITIVE;MEDIAN OS;MGM WEEKLY;MVD EA;SIGU RECOMMENDATIONS;SINGLE-AGENT GEMCITABINE;VIRAL LOAD;ADVANCED ANDOR;AFFECTED MEMBERSA;AFFECTED MEMBERSIN;ALONEMETHODS PATIENTS;ALPHA PTS;AMPLIFICATION ANALYSIS;ANALYSIS METHODS;ANDOR METASTATIC;ANGIOGENESIS DUE;ANTI-ANGIOGENETIC APPROACH","3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1",1,0.05,3,2,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,0,0,49,49,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_TUMORIBARI",2010,22,11.5909090909091,2.95454545454545,0.409090909090909,0.363636363636364,0.409090909090909,1.44444444444444,0.9,1,0.9,0.454545454545455,0,9,7,1,1,0.41,0.32,0.05,0.05,42.23,0.934426156894162,NA,0.409090909090909,0.954545454545455,0.339,0.3,0.308,0.3,"ANGELO PARADISO;STEFANIA TOMMASI;FRANCESCO ALFREDO ZITO;NICOLA SILVESTRIS;GIUSEPPE COLUCCI;ANITA MANGIA;MICHELE QUARANTA;ROSA DIVELLA;ANDREA MALFETTONE;PAOLO VERDERIO;ANTONIA BELLIZZI;DOMENICO GALETTA;DANIELA PETRIELLA;ANTONIO MAZZOCCA;ROSA ANGELA CARDONE;EVARISTO MAIELLO;ROSANNA LACALAMITA;BRUNELLA PILATO;GIANLUIGI GIANNELLI;ANTONELLA DANIELE","7;5;5;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2","ANGELO PARADISO;ANITA MANGIA;FRANCESCO ALFREDO ZITO;STEFANIA TOMMASI;NICOLA SILVESTRIS;ANDREA MALFETTONE;GIUSEPPE COLUCCI;MICHELE QUARANTA;ROSA DIVELLA;ANTONIA BELLIZZI;ROSA ANGELA CARDONE;ROSANNA MONTANARO;FRANCESCA ROMITO;VITTORIO MATTIOLI;ANTONIO MAZZOCCA;MÁSSIMO CONIO;DEBORAH A. FISHER;GIANLUIGI GIANNELLI;ANTONELLA DANIELE;ANTONELLA DE CEGLIE","0.66;0.56;0.51;0.51;0.49;0.49;0.39;0.35;0.35;0.34;0.34;0.33;0.33;0.33;0.25;0.25;0.25;0.25;0.25;0.25","ANGELO PARADISO;STEFANIA TOMMASI;FRANCESCO ALFREDO ZITO;NICOLA SILVESTRIS;GIUSEPPE COLUCCI;ANITA MANGIA;MICHELE QUARANTA;ROSA DIVELLA;ANDREA MALFETTONE;ANTONIA BELLIZZI;DOMENICO GALETTA;DANIELA PETRIELLA;ROSANNA LACALAMITA;BRUNELLA PILATO;ANTONELLA DANIELE;GIOVANNI DE SIMONE;ALFREDO FRANCESCO ZITO;ROSAMARIA PINTO;COSIMO D’AMICO;MICHELE BRUNO","7;5;5;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2","ANGELO PARADISO;ANITA MANGIA;FRANCESCO ALFREDO ZITO;STEFANIA TOMMASI;NICOLA SILVESTRIS;ANDREA MALFETTONE;GIUSEPPE COLUCCI;MICHELE QUARANTA;ROSA DIVELLA;ANTONIA BELLIZZI;ROSANNA MONTANARO;VITTORIO MATTIOLI;ANTONELLA DANIELE;ANTONELLA DE CEGLIE;ALFREDO FRANCESCO ZITO;COSIMO D’AMICO;MICHELE BRUNO;DANIELA PETRIELLA;ROSANNA LACALAMITA;BRUNELLA PILATO","0.66;0.56;0.51;0.51;0.49;0.49;0.39;0.35;0.35;0.34;0.33;0.33;0.25;0.25;0.25;0.22;0.22;0.19;0.19;0.19","ALBERT DE LA CHAPELLE;ALESSANDRA DRUSCO;ANDREA VECCHIONE;ANGELO VERONESE;ANNE DEJEAN;ANNE ROSENBERG;ARIANNA BOTTONI;CARLO M. CROCE;CAROLINE DESPONTS;CHANG‐GONG LIU;CRISTIAN TACCIOLI;CURTIS C. HARRIS;DIDO LENZE;FLAVIA PICHIORRI;GEORGE A. CALIN;GIACOMO GAMBERONI;GIANPIERO DI LEVA;JEFF PALATINI;JLENIA MARCHESINI;KAY HUEBNER","350;350;350;350;350;350;350;350;350;350;350;350;350;350;350;350;350;350;350;350","MARILENA V. IORIO;ANGELO PARADISO;ANTONIA BELLIZZI;GIUSEPPE COLUCCI;DOMENICO GALETTA;ALFREDO FRANCESCO ZITO;MICHELE QUARANTA;MARIA CONSILIA ASSELTI;ANDREA MALFETTONE;NICOLA SILVESTRIS;FRANCESCO ALFREDO ZITO;AMALIA AZZARITI;ETTORE FISTOLA;KATIA LUBELLO;MARIANGELA PORCELLI;MICHELE GUIDA;STEFANIA TOMMASI;COSIMO D’AMICO;MICHELE BRUNO;BRUNELLA PILATO","350;243;211;91;72;64;64;62;55;45;33;31;31;31;31;31;30;28;28;23","GIUSEPPE COLUCCI;ANGELO PARADISO;NICOLA SILVESTRIS;ANDREA MALFETTONE;FRANCESCO ALFREDO ZITO;ALFREDO FRANCESCO ZITO;ANITA MANGIA;COSIMO D’AMICO;DOMENICO GALETTA;MICHELE BRUNO;MICHELE QUARANTA;STEFANIA TOMMASI;A. MISINO;AMALIA AZZARITI;ANTONELLA DANIELE;ANTONELLA DE CEGLIE;ANTONIA BELLIZZI;ATTILIO GUARINI;BRUNELLA PILATO;CARLA LASALANDRA","5;4;4;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;PHILOSOPHY;COMPUTER SCIENCE;MATHEMATICS;PSYCHOLOGY","20;13;2;2;1;1;1","INTERNAL MEDICINE;ONCOLOGY;PATHOLOGY;CANCER RESEARCH;GENETICS;BIOCHEMISTRY;RADIOLOGY;CELL BIOLOGY;GASTROENTEROLOGY;MEDICAL PHYSICS;NURSING;SURGERY;BIOINFORMATICS;BIOPHYSICS;COMPUTATIONAL BIOLOGY;ECOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;EPISTEMOLOGY;GENERAL SURGERY;GERONTOLOGY;IMMUNOLOGY;LINGUISTICS;MACHINE LEARNING;MOLECULAR BIOLOGY;ORGANIC CHEMISTRY;PALEONTOLOGY;PSYCHIATRY;PSYCHOTHERAPIST;STATISTICS;THEOLOGY","18;12;10;6;6;5;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;GENE;IMMUNOHISTOCHEMISTRY;CHEMOTHERAPY;LUNG CANCER;LYMPH NODE;ANGIOGENESIS;BIOPSY;DNA;ENZYME;EXTERNAL QUALITY ASSESSMENT;LYMPH;MATRIX METALLOPROTEINASE;RECEPTOR;ADIPOSE TISSUE;ASYMPTOMATIC;BINDING SITE;BIOMARKER;CELL;CHRISTIAN MINISTRY;COHEN'S KAPPA;CONFIDENCE INTERVAL;CYTOPLASM;DIMER;DISEASE;DOCKING (ANIMAL);ESOPHAGUS;EXTRACELLULAR;EXTRACELLULAR MATRIX;GLIOBLASTOMA;GRADING (ENGINEERING);IN VITRO;INSULIN;KAPPA;LEUKEMIA;LYMPHOMA;MAST CELL;MELANOMA;MYOCARDIAL INFARCTION;NATURAL HISTORY;NURSING RESEARCH;OBESITY;PDZ DOMAIN;POPULATION;PRESENTATION (OBSTETRICS);PROPORTIONAL HAZARDS MODEL;PSYCHOSOCIAL;PUBLIC HEALTH;QUALITY (PHILOSOPHY);RADIATION THERAPY;REGIMEN;REPRODUCIBILITY;RETROSPECTIVE COHORT STUDY;SOCIAL SUPPORT;SPLEEN;STAGE (STRATIGRAPHY);VASCULAR PERMEABILITY;VEGF RECEPTORS","18;5;4;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;METASTASIS;COLORECTAL CANCER;CARCINOGENESIS;CISPLATIN;GENE EXPRESSION;MUTATION;PHASES OF CLINICAL RESEARCH;ADENOCARCINOMA;CANCER CELL;CANCER SURVIVOR;CDKN2A;CELL CYCLE;CHEMOTHERAPY REGIMEN;CHROMATIN;CHROMOSOME;CHRONIC LYMPHOCYTIC LEUKEMIA;CHYMASE;CONVENTIONAL PCI;CYTOSKELETON;DACARBAZINE;DNA REPAIR;ENZYME-LINKED RECEPTOR;EPIDERMAL GROWTH FACTOR RECEPTOR;EPIGENETICS;ESOPHAGEAL CANCER;ESOPHAGEAL DILATATION;ETOPOSIDE;GELATINASE;HAZARD RATIO;HELA;HISTONE;INSULIN RESISTANCE;LEPTIN;LIGAND (BIOCHEMISTRY);MALIGNANT DISEASE;MESENTERIC LYMPH NODES;METASTATIC MELANOMA;METHYLATION;MICRORNA;PROGRESSION-FREE SURVIVAL;PROGRESSIVE DISEASE;PROTEASE;PROTEOLYSIS;QUALITY ASSURANCE;SUBCELLULAR LOCALIZATION;SURVIVORSHIP CURVE;TEMOZOLOMIDE;TOPOTECAN;TRYPTASE;TUMOR PROGRESSION;VASCULAR ENDOTHELIAL GROWTH FACTOR","8;5;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","SENTINEL LYMPH NODE;ADIPOKINE;ADIPONECTIN;ANTHRACYCLINE;AXILLARY LYMPH NODES;CANCER SURVIVORSHIP;CARBOPLATIN;CETUXIMAB;CORE BIOPSY;DNA METHYLATION;FLUORESCENCE IN SITU HYBRIDIZATION;GELATINASES;GERMLINE MUTATION;IN SITU HYBRIDIZATION;INVADOPODIA;KRAS;LYMPHOVASCULAR INVASION;MAMMARY GLAND;METASTATIC BREAST CANCER;NUCLEOSOME;ONCOGENE;OXALIPLATIN;PODOSOME;PRIMARY TUMOR;PROPHYLACTIC CRANIAL IRRADIATION;PROTEASE-ACTIVATED RECEPTOR 2;SERINE PROTEASE","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","LUNG NEOPLASMS;HUMANS;BREAST NEOPLASMS;NEOPLASMS;FEMALE;ADENOCARCINOMA;ADULT;LIVER NEOPLASMS;MIDDLE AGED;AGED;CARCINOMA, NON-SMALL-CELL LUNG;COLORECTAL NEOPLASMS;MALE;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;COLONIC NEOPLASMS;BIOMARKERS, TUMOR;;AGED, 80 AND OVER;ERBB RECEPTORS;ITALY","18;17;12;12;11;9;9;9;9;8;8;8;8;7;7;6;5;5;5;5","EPIGENETIC MODIFICATIONS AND THEIR FUNCTIONAL IMPLICATIONS;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;ROLE OF MATRIX METALLOPROTEINASES IN CANCER AND PHYSIOLOGY;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;CANCER OF UNKNOWN PRIMARY SITE;CANCER SURVIVORSHIP AND QUALITY OF LIFE;CELL MECHANICS AND EXTRACELLULAR MATRIX INTERACTIONS;DEEP LEARNING IN MEDICAL IMAGE ANALYSIS;ESOPHAGEAL INTERVENTION TECHNIQUES;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;INFLAMMATION AND OBESITY-RELATED METABOLIC DISORDERS;MANAGEMENT OF BRAIN METASTASES IN CANCER PATIENTS;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE;ROLE OF SIGMA RECEPTORS IN CELLULAR SIGNALING;SMALL CELL LUNG CANCER;STRUCTURE AND FUNCTION OF G PROTEIN-COUPLED RECEPTORS","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;ARGININE METHYLATION;AXILLARY LYMPH NODES;B-CELL RECEPTOR SIGNALING;BONE METASTASIS;BRAIN METASTASES;BRCA1;BRCA2 PROTEIN;CANCER BIOMARKERS;CANCER RISK;CANCER SURVIVOR;CANCER SURVIVORSHIP;CANCER SUSCEPTIBILITY;CARBOPLATIN;CELL MIGRATION;CELL SIGNALING;CETUXIMAB;CHEMOTHERAPY REGIMEN;CHRISTIAN MINISTRY;CHYMASE","3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;CANCER PATIENTS;BREAST LESIONS;CELL LUNG;COLORECTAL CANCER;GRUPPO ONCOLOGICO;II STUDY;LUNG CANCER;LYMPH NODE;METALLOPROTEINASES MMP-;MULTICENTER PHASE;PHASE II;SENTINEL LYMPH;ADIPONECTIN LEVELS;ADVANCED COLORECTAL;ASYMPTOMATIC BRAIN;B-CELL CHRONIC;BIOMARKER DETECTION;BONE DISEASE;BONE METASTASES;BRAIN METASTASES;BRCA VARIANTS;CANCER BIOMARKER;CANCER CLINICAL;CANCER FAMILIAL;CANCER FINAL;CANCER SURVIVORSHIP;CELL BLOCKS;CELLS POSITIVE;CHEMO-MODULATING TEMOZOLOMIDE","6;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;ECM DEGRADATION;BREAST LESIONS;EGFR GCN;EXTRACELLULAR ACIDIFICATION;GROWTH FACTOR;KRAS MUTATIONS;MUTATION RISK;NORMAL TISSUES;CANCER NETWORKS;CELL BLOCKS;COLORECTAL CANCER;COX MULTIVARIATE;DNA COPY;EGFR GENE;EPIDERMAL GROWTH;FACTOR RECEPTOR;GENETIC NETWORKS;HR CI;INTEROBSERVER REPRODUCIBILITY;LUNG METASTASES;LUNG NODULES;MEDIAN Κ;METASTATIC COLORECTAL;MULTIVARIATE REGRESSION;NAH EXCHANGER;NHE EXPRESSION;NONPALPABLE BREAST;OBJECTIVE RESPONSE;PERITUMORAL INVASION","6;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",4,0.18,3,1.25,0,0,0,0,0,0,1,2,0,0,1,0,1.75,0,0,1,0,0,0,30.5,30.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,2.5,84,4.76,0,0,20.5,0,0,1,0,1,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES","2;2;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;AGING;CARDIOVASCULAR;HEMATOLOGY;LUNG;LUNG CANCER;LYMPHOMA;RARE DISEASES","2;2;2;1;1;1;1;1;1;1","CANCER","1",NA,NA,"HODGKIN'S DISEASE;LUNG CANCER;NON-HODGKIN'S LYMPHOMA","1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_TUMORIBARI",2011,26,10.2307692307692,3.38461538461539,0.538461538461538,0.538461538461538,0.538461538461538,1.3134328358209,1.07692307692308,1.27272727272727,1.07692307692308,0.423076923076923,0,13,4,1,7,0.5,0.15,0.04,0.27,44.15,1.0380765563638,NA,0.346153846153846,0.807692307692308,0.478,0.381,0.364,0.381,"ANGELO PARADISO;VITTORIO GEBBIA;GIROLAMO RANIERI;FRANCESCA ROMITO;VITTORIO MATTIOLI;ANGELO VACCA;ROBERTO RIA;STEFANIA TOMMASI;DOMENICO GALETTA;STEFANIA GORI;PAOLO DITONNO;ARIANNA FERRUCCI;MARIA GRAZIA DAIDONE;LETIZIA PORCELLI;FRANCO M. MUGGIA;ANTONELLA CAIVANO;MICHELE QUARANTA;ANNUNZIATA DE LUISI;ROSANNA MONTANARO;SIMONA DE SUMMA","9;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANGELO PARADISO;FRANCO M. MUGGIA;MARIA GRAZIA DAIDONE;PETER RIEGMAN;FRANCESCA ROMITO;VITTORIO MATTIOLI;ROSANNA MONTANARO;SIMONA DE SUMMA;CHIARA CORVASCE;STEFANIA TOMMASI;MARCELLA MOTTOLESE;DANIELA PISTILLO;GIUSEPPE PELAGIO;V. SMALDONE;GIROLAMO RANIERI;S. TOMMAS;LAURA CALECA;BRUNELLA PILATO;KATIA DANZA;PAOLO RADICE","2;0.83;0.67;0.67;0.62;0.62;0.5;0.5;0.5;0.34;0.33;0.33;0.33;0.33;0.29;0.25;0.25;0.25;0.25;0.25","ANGELO PARADISO;GIROLAMO RANIERI;FRANCESCA ROMITO;VITTORIO MATTIOLI;ANGELO VACCA;ROBERTO RIA;STEFANIA TOMMASI;DOMENICO GALETTA;PAOLO DITONNO;ARIANNA FERRUCCI;LETIZIA PORCELLI;ANTONELLA CAIVANO;MICHELE QUARANTA;ANNUNZIATA DE LUISI;ROSANNA MONTANARO;SIMONA DE SUMMA;CHIARA CORVASCE;SIMONA BERARDI;AMALIA AZZARITI;DOMÉNICO RIBATTI","9;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","ANGELO PARADISO;FRANCESCA ROMITO;VITTORIO MATTIOLI;ROSANNA MONTANARO;SIMONA DE SUMMA;CHIARA CORVASCE;STEFANIA TOMMASI;GIUSEPPE PELAGIO;GIROLAMO RANIERI;S. TOMMAS;BRUNELLA PILATO;KATIA DANZA;ANITA MANGIA;MICHELE QUARANTA;GIUSEPPE COLUCCI;FRANCO BALACCO;ROBERTO MARIA BERNARDI;PASQUALE TAMBORRA;ENZA CARIOGGIA;NICOLA PERNA","2;0.62;0.62;0.5;0.5;0.5;0.34;0.33;0.29;0.25;0.25;0.25;0.23;0.22;0.18;0.17;0.17;0.17;0.17;0.17","MICHELE GUIDA;AVIRAM NISSAN;DAVID M. BERMAN;DAVID M. HYAMS;HENRIK SCHMIDT;HENRY GÓMEZ;JOHAN HANSSON;LARS BASTHOLT;LAURA RIDOLFI;OMID HAMID;SCOTT D. CHASALOW;STEINAR AAMDAL;ANGELO PARADISO;GIROLAMO RANIERI;STEFANIA GORI;ANGELO VACCA;ANNUNZIATA DE LUISI;ANTONELLA CAIVANO;ANTONIO BASILE;ARIANNA FERRUCCI","533;518;518;518;518;518;518;518;518;518;518;518;174;159;116;113;113;113;113;113","MICHELE GUIDA;ATTILIO GUARINI;FRANCESCO ALFREDO ZITO;VINCENZO VENTRELLA;STEFANO OLIVA;GIOVANNI DE SIMONE;ADDOLORATA MARIA LUCE COLUCCIA;ANDREA URBANI;ANGELO VACCA;ANNUNZIATA DE LUISI;ANTONELLA CAIVANO;ANTONIO BASILE;ARIANNA FERRUCCI;DOMÉNICO RIBATTI;EMANUELA DE LUCA;FRANCO DAMMACCO;GIOVANNI QUARTA;GIROLAMO RANIERI;GIULIA DI PIETRO;LUISA PIERONI","533;113;103;103;101;83;76;76;76;76;76;76;76;76;76;76;76;76;76;76","ANGELO PARADISO;FRANCESCA ROMITO;GIUSEPPE COLUCCI;AMALIA AZZARITI;ATTILIO GUARINI;CHIARA CORVASCE;DOMENICO GALETTA;GIROLAMO RANIERI;LETIZIA PORCELLI;MICHELE GUIDA;MICHELE QUARANTA;ROSANNA MONTANARO;SIMONA DE SUMMA;STEFANIA TOMMASI;VITTORIO MATTIOLI;ADDOLORATA MARIA LUCE COLUCCIA;ANDREA URBANI;ANGELO VACCA;ANITA MANGIA;ANNA ELISA QUATRALE","7;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","MEDICINE;BIOLOGY;COMPUTER SCIENCE;CHEMISTRY;ECONOMICS;SOCIOLOGY;GEOGRAPHY;MATHEMATICS;ART;ENGINEERING;HISTORY;PHILOSOPHY;PHYSICS;PSYCHOLOGY","23;17;8;4;3;3;2;2;1;1;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;PATHOLOGY;CANCER RESEARCH;BIOINFORMATICS;IMMUNOLOGY;BIOCHEMISTRY;FAMILY MEDICINE;GENETICS;PHARMACOLOGY;CELL BIOLOGY;GERONTOLOGY;PALEONTOLOGY;SOCIAL SCIENCE;BIOTECHNOLOGY;COMPUTATIONAL BIOLOGY;ECONOMIC GROWTH;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;LIBRARY SCIENCE;PROGRAMMING LANGUAGE;PSYCHIATRY;STATISTICS;SURGERY;WORLD WIDE WEB","17;8;7;6;5;5;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","CANCER;CHEMOTHERAPY;GENE;ANGIOGENESIS;BIOBANK;RECEPTOR;ADJUVANT;ANTIBODY;ATTENDANCE;CROSS-SECTIONAL STUDY;HEALTH CARE;IMMUNOHISTOCHEMISTRY;IN VIVO;INFORMATION NEEDS;MAST CELL;MULTIPLE MYELOMA;NEEDS ASSESSMENT;OBSERVATIONAL STUDY;POPULATION;RADIATION THERAPY;STEM CELL;TEST (BIOLOGY)","13;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;CANCER CELL;CD34;CHYMASE;COLORECTAL CANCER;EPIDERMAL GROWTH FACTOR RECEPTOR;TRYPTASE;ADENOCARCINOMA;ADIPOGENESIS;ADJUVANT THERAPY;ALLELE;ANTIDEPRESSANT;BEVACIZUMAB;BIOLOGICAL ACTIVITY;BIOREPOSITORY;CARDIOTOXICITY;CATHODE RAY;CELL CYCLE;CISPLATIN;CLINICAL ENDPOINT;DESORPTION;DNA SEQUENCING;DOCETAXEL;DOXORUBICIN;ERASMUS+;FIBROBLAST GROWTH FACTOR;FIRST-DEGREE RELATIVES;FOXP3;GEMCITABINE;GENOME;GENOTYPE;HEPATOCYTE GROWTH FACTOR;IMMUNOTHERAPY;IN SILICO;IONIZATION;LENALIDOMIDE;LINEAR PARTICLE ACCELERATOR;MAINTENANCE THERAPY;MAJOR DEPRESSIVE DISORDER;MONOCLONAL ANTIBODY;MTT ASSAY;MYOFIBROBLAST;NEOVASCULARIZATION;NEUTROPENIA;PACLITAXEL;PEROXISOME;PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR;PHASES OF CLINICAL RESEARCH;POTENCY;QUALITY ASSURANCE;RADIATION TREATMENT PLANNING;SORAFENIB;SUMMARY OF PRODUCT CHARACTERISTICS;SUNITINIB;TRANSCRIPTION FACTOR;TUMOR MICROENVIRONMENT;VASCULAR ENDOTHELIAL GROWTH FACTOR","5;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ADJUVANT CHEMOTHERAPY;BARRETT'S ESOPHAGUS;CANCER-ASSOCIATED FIBROBLASTS;CAPECITABINE;CARBOPLATIN;CETUXIMAB;CORE BIOPSY;ERLOTINIB;GEFITINIB;GENOMICS;HORMONAL THERAPY;HUMAN GENOME;IPILIMUMAB;MAMMOGRAPHY;MATRIX-ASSISTED LASER DESORPTION/IONIZATION;METASTATIC BREAST CANCER;MONOCLONAL;NUCLEAR RECEPTOR;PEMETREXED;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;SANGER SEQUENCING;SEROTONIN TRANSPORTER;TAXANE;TIME-OF-FLIGHT MASS SPECTROMETRY;TRASTUZUMAB;TRIPLE-NEGATIVE BREAST CANCER;TUMOR-INFILTRATING LYMPHOCYTES;WHOLE GENOME SEQUENCING","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST NEOPLASMS;HUMANS;FEMALE;ANTINEOPLASTIC AGENTS;MIDDLE AGED;AGED;CARCINOMA, NON-SMALL-CELL LUNG;FIBROBLASTS;LUNG NEOPLASMS;OVARIAN NEOPLASMS;ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;MALE;MULTIPLE MYELOMA;;GENETIC TESTING;BONE MARROW CELLS;CELL MOVEMENT;ENDOTHELIAL CELLS;ITALY","27;20;16;13;11;10;8;8;8;8;7;7;7;7;6;6;5;5;5;5","ADVANCEMENTS IN LUNG CANCER RESEARCH;ECONOMIC BURDEN OF CANCER TREATMENT;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE;SHARED DECISION MAKING IN HEALTHCARE;14-3-3 PROTEINS: STRUCTURE, FUNCTION, AND REGULATION;BREAST PATHOLOGY AND IMAGING TECHNIQUES;CANCER IMMUNOTHERAPY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;ETHICAL CONSIDERATIONS IN MEDICAL RESEARCH PARTICIPATION;HER2 SIGNALING IN BREAST CANCER TREATMENT;MECHANISMS OF MULTIDRUG RESISTANCE IN CANCER;MOLECULAR MECHANISMS OF DEPRESSION TREATMENT STRATEGIES;MOLECULAR RESEARCH ON BREAST CANCER;PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;PREOPERATIVE CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER;RADIOTHERAPY PHYSICS AND TECHNOLOGY","2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;ATTENDANCE;BARRETT'S ESOPHAGUS;BONE MARROW MICROENVIRONMENT;CANCER COMMUNICATION;CANCER GENOMICS;CHYMASE;CROSS-SECTIONAL STUDY;GENETIC TESTING;INFORMATION NEEDS;NEEDS ASSESSMENT;PATIENT PARTICIPATION;TREATMENT RESPONSE;TRYPTASE;ADJUVANT CHEMOTHERAPY;ADJUVANT THERAPY;ANTICANCER DRUGS;ANTIDEPRESSANT TREATMENT;BIOBANKING;BIOMARKER ANALYSIS","4;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","BREAST CANCER;CANCER PATIENTS;ELDERLY CANCER;MULTIPLE MYELOMA;PATIENTS TREATED;PHASE II;ACTIVE MULTIPLE;ADJUVANT CHEMOTHERAPY;ADVANCED BREAST;ADVANCED MELANOMA;ADVANCED NON-SQUAMOUS;ANALYSIS CONDUCTED;ANTI-ANGIOGENETIC MOLECULAR;ANTI-CANCER DRUGS;BARI ITALY;BARRETTS ESOPHAGUS;BIOBANKING REQUIREMENTS;BIOLOGICAL EVALUATION;BIOPSY VANCB;BONE MARROW;BRCA GENES;BREAST LESIONS;CALCULATION ALGORITHM;CANCER BIOBANKING;CANCER CENTER;CANCER ERACLE;CANCER HUMAN;CANCER RESEARCH;CANCER RISK;CANCER TRYPTASE","6;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;MARIA GRAZIA;CANCER RESEARCH;GRAZIA DAIDONE;NATIONAL CANCER;PUBMED SCOPUS;CANCER RISK;FAMILIAL BREAST;VOLUME ISSUE;BREAST LESIONS;CANCER BIOBANKING;CANCER CENTRE;CD FIBROBLASTS;CORE BIOPSY;CROSSREF PUBMED;ENDOTHELIAL CELLS;GROWTH FACTOR;NOVEMBER BARI;OVARIAN CANCER;PARADISO MARIA;POLYADP-RIBOSE POLYMERASE;REMARKS BIOBANKING;RESEARCH RULES;ROLES NOVEMBER;-ΖΔ PROTEIN;ACCELERATED PACE;ANIMAL MODELS;ANN LIEBERT;ANTIANGIOGENIC EFFECT;ASSEMBLED DOCUMENT","10;7;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2",6,0.23,2.56,2.75,1,0,0,1,15.5,0,1,2.75,0,1,2,0,0,0,0,1,2,0,0,93,93,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,5,3219,1.59,0,0,322,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY","1;1;1;1","CANCER","1",NA,NA,"MELANOMA","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",1,11998454,461479,6,26,12,1,76,77622.7821766048,0.334953209237536,"ANTONI VAN LEEUWENHOEK HOSPITAL;CHRISTIE HOSPITAL NHS FOUNDATION TRUST;DANISH CANCER SOCIETY;ECANCER;ERASMUS MC;EUROPEAN CANCER ORGANISATION;EUROPEAN INSTITUTE OF ONCOLOGY;EUROPEAN MOLECULAR BIOLOGY LABORATORY;EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER;FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI;FUNDACIÓN INSTITUTO VALENCIANO DE ONCOLOGÍA;GERMAN CANCER RESEARCH CENTER;INSTITUT GUSTAVE ROUSSY;INSTITUT JULES BORDET;INSTITUTE CURIE;INTERNATIONAL AGENCY FOR RESEARCH ON CANCER;ISTITUTO TUMORI BARI;KAROLINSKA INSTITUTET;LEIDEN UNIVERSITY MEDICAL CENTER;NATIONAL INSTITUTE OF ONCOLOGY","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","FP7-HEALTH - SPECIFIC PROGRAMME ""COOPERATION"": HEALTH (PROGRAMME);FP7-HEALTH-2010-SINGLE-STAGE (CALL FOR PROPOSAL);NOE - NETWORK OF EXCELLENCE (FUNDING SCHEME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1;1","CANCER;DIGESTIVE DISEASES;PANCREATIC CANCER;PREVENTION;RARE DISEASES","1;1;1;1;1","CANCER","1","2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);6.9 RESOURCES AND INFRASTRUCTURE (TREATMENT EVALUATION)","1;1;1;1","LUNG CANCER;MELANOMA;NOT SITE-SPECIFIC CANCER;PANCREATIC CANCER","1;1;1;1","3.6 RESOURCES AND INFRASTRUCTURE RELATED TO PREVENTION;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","1;1;1","A01 CLINICAL MEDICINE","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_TUMORIBARI",2012,50,9.78,2.98,0.46,0.36,0.56,1.71264367816092,1.15,1.5,1.21739130434783,0.46,1,25,9,8,3,0.5,0.18,0.16,0.06,20,0.478831633653656,4.57425742574257,0.18,0.78,0.441,0.485,0.438,0.47,"ANGELO PARADISO;NICOLA SILVESTRIS;SEVERINO MONTEMURRO;STEFANIA TOMMASI;MICHELE QUARANTA;GIROLAMO RANIERI;COSMO DAMIANO GADALETA;GIOVANNI DE SIMONE;MICHELE AMMENDOLA;RAFFAELE DE LUCA;ROSA PATRUNO;AMALIA AZZARITI;ATTILIO GUARINI;EUSTACHIO RUGGIERI;EMILIO IANNITTO;FORTUNATO MORABITO;COSIMO CALIANDRO;ROSA DIVELLA;BRUNELLA PILATO;SANDRO BARNI","15;10;7;7;6;6;6;6;4;4;4;4;4;4;3;3;3;3;3;3","ANGELO PARADISO;NICOLA SILVESTRIS;STEFANIA TOMMASI;GIOVANNI DE SIMONE;SEVERINO MONTEMURRO;COSMO DAMIANO GADALETA;MICHELE QUARANTA;GIROLAMO RANIERI;EUSTACHIO RUGGIERI;ANTÔNIO ROSSI;GALETTA;ANNA ELISABETTA BRUNETTI;RAFFAELE DE LUCA;GIUSEPPE COLUCCI;BRUNELLA PILATO;AMALIA AZZARITI;MICHELE AMMENDOLA;ROSA PATRUNO;ANTONIO TUFARO;ROSA DIVELLA","2.75;1.3;0.95;0.78;0.76;0.65;0.62;0.61;0.52;0.5;0.5;0.48;0.48;0.45;0.43;0.41;0.37;0.37;0.34;0.34","ANGELO PARADISO;NICOLA SILVESTRIS;SEVERINO MONTEMURRO;STEFANIA TOMMASI;MICHELE QUARANTA;GIROLAMO RANIERI;COSMO DAMIANO GADALETA;GIOVANNI DE SIMONE;MICHELE AMMENDOLA;RAFFAELE DE LUCA;ROSA PATRUNO;AMALIA AZZARITI;ATTILIO GUARINI;EUSTACHIO RUGGIERI;COSIMO CALIANDRO;ROSA DIVELLA;BRUNELLA PILATO;GIUSEPPE COLUCCI;V. GOFFREDO;ANTONIO TUFARO","15;10;7;7;6;6;6;6;4;4;4;4;4;4;3;3;3;3;3;3","ANGELO PARADISO;NICOLA SILVESTRIS;STEFANIA TOMMASI;GIOVANNI DE SIMONE;SEVERINO MONTEMURRO;COSMO DAMIANO GADALETA;MICHELE QUARANTA;GIROLAMO RANIERI;EUSTACHIO RUGGIERI;GALETTA;ANNA ELISABETTA BRUNETTI;RAFFAELE DE LUCA;GIUSEPPE COLUCCI;BRUNELLA PILATO;AMALIA AZZARITI;MICHELE AMMENDOLA;ROSA PATRUNO;ANTONIO TUFARO;ROSA DIVELLA;ILARIA MARECH","2.75;1.3;0.95;0.78;0.76;0.65;0.62;0.61;0.52;0.5;0.48;0.48;0.45;0.43;0.41;0.37;0.37;0.34;0.34;0.34","ANGELO PARADISO;STEFANIA TOMMASI;NICOLA SILVESTRIS;GIOVANNI DE SIMONE;MICHELE QUARANTA;SEVERINO MONTEMURRO;AMALIA AZZARITI;BRUNELLA PILATO;FRANCESCO GIOTTA;RAFFAELE DE LUCA;ROSA DIVELLA;COSIMO CALIANDRO;COSMO DAMIANO GADALETA;ANASTASIA CHILLÀ;ANNA LAURENZANA;ESPERANZA FEIJOÓ;FRANCESCA MARGHERI;GABRIELLA FIBBI;JAVIER DOTOR;LUCIA MAGNELLI","439;216;215;194;131;122;117;109;97;89;89;87;84;79;79;79;79;79;79;79","ANGELO PARADISO;STEFANIA TOMMASI;GIOVANNI DE SIMONE;NICOLA SILVESTRIS;SEVERINO MONTEMURRO;COSIMO CALIANDRO;RAFFAELE DE LUCA;FRANCESCO GIOTTA;MICHELE QUARANTA;SIMONA SERRATÌ;ROSSANA LAMBO;BRUNELLA PILATO;JEAN‐FRANÇOIS ROLLAND;LETIZIA PORCELLI;PAOLA MANTUANO;ATTILIO GUARINI;AMALIA AZZARITI;ANNA ELISA QUATRALE;E CARIOGGIA;M.G. LEO","294;178;163;159;120;87;87;83;82;79;73;71;67;67;67;62;58;57;57;57","ANGELO PARADISO;NICOLA SILVESTRIS;SEVERINO MONTEMURRO;STEFANIA TOMMASI;MICHELE QUARANTA;GIOVANNI DE SIMONE;ATTILIO GUARINI;EUSTACHIO RUGGIERI;GIUSEPPE COLUCCI;ANTONIO TUFARO;COSIMO CALIANDRO;RAFFAELE DE LUCA;GIROLAMO RANIERI;A. RUCCI;AMALIA AZZARITI;BRUNELLA PILATO;COSMO DAMIANO GADALETA;DOMENICO GALETTA;FRANCESCO GIOTTA;ILARIA MARECH","10;8;6;6;5;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;ART;MATERIALS SCIENCE;MATHEMATICS;SOCIOLOGY","45;23;3;3;3;1;1;1;1","INTERNAL MEDICINE;CANCER RESEARCH;ONCOLOGY;PATHOLOGY;GENETICS;IMMUNOLOGY;CELL BIOLOGY;SURGERY;BIOCHEMISTRY;GASTROENTEROLOGY;PHARMACOLOGY;RADIOLOGY;ENVIRONMENTAL HEALTH;MOLECULAR BIOLOGY;OPTICS;PALEONTOLOGY;PEDIATRICS;ANATOMY;BIOINFORMATICS;BIOTECHNOLOGY;CARDIOLOGY;COMPUTATIONAL BIOLOGY;ENDOCRINOLOGY","38;18;18;14;12;10;8;8;7;6;5;4;3;3;3;3;3;2;2;2;2;2;2","CANCER;GENE;ANGIOGENESIS;HEPATOCELLULAR CARCINOMA;IMMUNOHISTOCHEMISTRY;MAST CELL;RECEPTOR;STEM CELL;BONE MARROW;CHEMOTHERAPY;EPIDEMIOLOGY;INCIDENCE (GEOMETRY);LUNG CANCER;POPULATION;SIGNAL TRANSDUCTION;TRANSFORMING GROWTH FACTOR;VIRUS;ADVERSE EFFECT;ANASTOMOSIS;BODY MASS INDEX;CLINICAL TRIAL;CONTEXT (ARCHAEOLOGY);CYST;DISEASE;ENZYME;HEART FAILURE;IN VITRO;IN VIVO;LESION;LUNG;OBESITY;PLASMINOGEN ACTIVATOR;PROSPECTIVE COHORT STUDY;RECTUM;RETROSPECTIVE COHORT STUDY;STOMA (MEDICINE);TRANSPLANTATION","31;12;7;4;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;COLORECTAL CANCER;METASTASIS;EPIDERMAL GROWTH FACTOR RECEPTOR;GENE EXPRESSION;TRYPTASE;CHROMOSOME;TARGETED THERAPY;ADENOCARCINOMA;CANCER CELL;CARCINOGENESIS;CYTOPENIA;EJECTION FRACTION;EPIGENETICS;GEMCITABINE;HEPATITIS B VIRUS;HEPATITIS C VIRUS;METHYLATION;MYELODYSPLASTIC SYNDROMES;PANCREATIC CANCER;PHENOTYPE;PI3K/AKT/MTOR PATHWAY;PROTEIN KINASE B;TYROSINE-KINASE INHIBITOR","11;11;6;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","FLUORESCENCE IN SITU HYBRIDIZATION;TRASTUZUMAB;CETUXIMAB;CYTOGENETICS;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;DNA METHYLATION;ERLOTINIB;GEFITINIB;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;ALLELE FREQUENCY;ANAPLASTIC LYMPHOMA KINASE;BENDAMUSTINE;BONE METASTASIS;CAPECITABINE;CHROMOSOME 17 (HUMAN);COPY-NUMBER VARIATION;CRIZOTINIB;DNA MICROARRAY;EGFR INHIBITORS;ENDOTHELIAL PROGENITOR CELL;FOLINIC ACID;GENE EXPRESSION PROFILING;GENE POLYMORPHISM;HOX GENE;IMPAIRED GLUCOSE TOLERANCE;INVADOPODIA;IRINOTECAN;KAPOSI'S SARCOMA;KRAS;METASTATIC BREAST CANCER;MICROARRAY ANALYSIS TECHNIQUES;OXALIPLATIN;POLY ADP RIBOSE POLYMERASE;PRIMARY TUMOR;RIBAVIRIN;SERINE PROTEASE;SINGLE-NUCLEOTIDE POLYMORPHISM;TGF ALPHA;UROTHELIAL CANCER;VASCULOGENIC MIMICRY","3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;BREAST NEOPLASMS;MIDDLE AGED;MALE;;AGED;ADULT;CARCINOMA, HEPATOCELLULAR;LIVER NEOPLASMS;BIOMARKERS, TUMOR;ENDOTHELIAL CELLS;RECEPTOR, ERBB-2;AGED, 80 AND OVER;ANTINEOPLASTIC AGENTS;TRANSFORMING GROWTH FACTOR BETA;BRCA1 PROTEIN;DEOXYCYTIDINE;LUNG NEOPLASMS;NEOPLASM METASTASIS","34;26;24;21;18;16;15;14;12;12;9;9;9;8;8;8;7;7;7;7","CANCER OF UNKNOWN PRIMARY SITE;ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN LUNG CANCER RESEARCH;CARDIOTOXICITY OF CANCER TREATMENTS;COLORECTAL CANCER RESEARCH AND TREATMENT;MOLECULAR MECHANISMS OF ANGIOGENESIS AND VASCULAR FUNCTION;PANCREATIC CANCER RESEARCH AND TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;BIOLOGICAL, EPIDEMIOLOGICAL, AND CLINICAL ASPECTS OF ECHINOCOCCOSIS;CANCER STEM CELLS AND TUMOR METASTASIS;CHALLENGES IN PAIN MANAGEMENT AND TREATMENT;GASTRIC CANCER RESEARCH AND TREATMENT;GENOMIC REARRANGEMENTS AND COPY NUMBER VARIATIONS;HEMATOPOIETIC STEM CELL BIOLOGY;HEPATITIS C INFECTION AND TREATMENT;HER2 SIGNALING IN BREAST CANCER TREATMENT;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS;INTUSSUSCEPTION AND MECKEL'S DIVERTICULUM;LIPID METABOLISM IN CANCER PATHOGENESIS","3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","BREAST CANCER;CANCER;MICROTUBULE-TARGETING AGENTS;TRYPTASE;BONE METASTASIS;METASTATIC BONE DISEASE;TARGETED THERAPY;ANASTOMOTIC LEAKAGE;ANTI-ANGIOGENIC THERAPY;BIOMARKER ANALYSIS;BONE MARROW BIOPSY;CYTOPENIA;KAPOSI'S SARCOMA;METASTASIS;METASTATIC PANCREATIC CANCER;PANCREATIC CANCER;RADIOTHERAPY;SOFT TISSUE METASTASES;STOMA (MEDICINE);TRASTUZUMAB","4;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;COLORECTAL CANCER;CANCER PATIENTS;FAMILIAL BREAST;GROWTH FACTOR;ADJUVANT TRASTUZUMAB;ANGIOTENSIN-CONVERTING ENZYME;ANTIANGIOGENIC EFFECTS;BODY MASS;CANCER CENTRE;CANCER PROCTECTOMY;CENTRE EXPERIENCE;CYTOGENETIC ANALYSIS;DIAGNOSED MYELODYSPLASTIC;DUAL INHIBITOR;ENDOTHELIAL CELLS;ENZYME INHIBITORS;II CANCER;LUNG CANCER;MASS INDEX;MTOR INHIBITORS;MYELODYSPLASTIC SYNDROMES;NATURAL HISTORY;NEWLY DIAGNOSED;PANCREATIC CANCER;PAOLO II;PROSPECTIVE STUDY;PROTEOMIC PROFILE;REAL WORLD;RECTAL CANCER","10;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;CANCER PATIENTS;GROWTH FACTOR;CANCER CELLS;ACUTE GRAFT-VERSUS-HOST;ADJUVANT TRASTUZUMAB;ENDOTHELIAL CELLS;EPIDERMAL GROWTH;FACTOR RECEPTOR;GASTRIC CANCER;TRASTUZUMAB THERAPY;ANALGESIC THERAPY;ANG- ANG-;BONE METASTASES;FIBROBLAST ACTIVATION;GRAFT-VERSUS-HOST DISEASE;STEM CELL;TYROSINE KINASE;ABSTRACT INTRODUCTION;ANTI-TGFß PEPTIDES;AU AU;BONE METASTASIS;BREAST CANCERS;CROSSREF PUBMED;HOX GENES;LUNG CANCER;MEDIAN AGE;PANCREATIC CANCER;PERIPHERAL BLOOD;PROSPECTIVE STUDIES","31;9;8;6;5;5;5;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3",15,0.3,3,3,1.75,0,0,0,2,0,1,3,0,0,2.5,0,1.75,0,1,1,1,0,0,44.5,44.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,9.33,365,3.7,2,0.67,118,0,0,1,0,1,0,0,1,0,3,0,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES","3;3;2;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;LYMPHOMA;RARE DISEASES;BIOMEDICAL IMAGING;PATIENT SAFETY","3;3;3;2;2;2;1;1","CANCER","2","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","3;1","NON-HODGKIN'S LYMPHOMA;MELANOMA","2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_TUMORIBARI",2013,74,11.8243243243243,3.31081081081081,0.378378378378378,0.405405405405405,0.45945945945946,2.04166666666667,1.12,1.5,1.25925925925926,0.445945945945946,0,38,12,14,2,0.51,0.16,0.19,0.03,29.57,0.847388772647158,4.17567567567567,0.175675675675676,0.864864864864865,0.404,0.347,0.413,0.332,"ANGELO PARADISO;VITO LORUSSO;SAVERIO CINIERI;GIOVANNI DE SIMONE;FRANCESCO GIOTTA;VITO LORUSSO;EVARISTO MAIELLO;COSMO DAMIANO GADALETA;NICOLA SILVESTRIS;GIROLAMO RANIERI;AMALIA AZZARITI;MICHELE GUIDA;ANITA MANGIA;SALVATORE PISCONTI;IDA GALISE;ANTONIO MOSCHETTA;FRANCESCA ROMITO;GIUSEPPE TONINI;SANDRO BARNI;ANTONIO RUSSO","11;11;9;8;7;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4","VITO LORUSSO;ANGELO PARADISO;GIOVANNI DE SIMONE;FRANCESCO GIOTTA;VITTORIO MATTIOLI;FRANCESCA ROMITO;ANTONIA BELLIZZI;COSMO DAMIANO GADALETA;VITO LORUSSO;GIROLAMO RANIERI;ANGELO VACCA;MICHELE GUIDA;AMALIA AZZARITI;SAVERIO CINIERI;CLAUDIA CORMIO;NICOLA SILVESTRIS;KEVIN STEIN;ANTONIO GNONI;STEFANIA TOMMASI;ANITA MANGIA","1.25;1.16;0.83;0.79;0.78;0.72;0.67;0.65;0.63;0.6;0.6;0.57;0.56;0.53;0.52;0.51;0.5;0.5;0.5;0.5","ANGELO PARADISO;VITO LORUSSO;GIOVANNI DE SIMONE;FRANCESCO GIOTTA;VITO LORUSSO;COSMO DAMIANO GADALETA;NICOLA SILVESTRIS;GIROLAMO RANIERI;AMALIA AZZARITI;MICHELE GUIDA;ANITA MANGIA;IDA GALISE;ANTONIO MOSCHETTA;FRANCESCA ROMITO;SEVERINO MONTEMURRO;ANTONIA BELLIZZI;STEFANIA TOMMASI;MICHELE QUARANTA;ROSA DIVELLA;ROSA PATRUNO","11;11;8;7;6;6;6;5;5;5;5;4;4;4;3;3;3;3;3;3","VITO LORUSSO;ANGELO PARADISO;GIOVANNI DE SIMONE;FRANCESCO GIOTTA;VITTORIO MATTIOLI;FRANCESCA ROMITO;ANTONIA BELLIZZI;COSMO DAMIANO GADALETA;VITO LORUSSO;GIROLAMO RANIERI;MICHELE GUIDA;AMALIA AZZARITI;CLAUDIA CORMIO;NICOLA SILVESTRIS;STEFANIA TOMMASI;ANITA MANGIA;IVAN RASHID;ANTONIO MOSCHETTA;FRANCESCO GIOTTA;ANDREA MALFETTONE","1.25;1.16;0.83;0.79;0.78;0.72;0.67;0.65;0.63;0.6;0.57;0.56;0.52;0.51;0.5;0.5;0.42;0.41;0.38;0.37","VITO LORUSSO;DANIEL WATERKAMP;DAVID CUNNINGHAM;DEREK J. JONKER;EUGENIO MARCUELLO;ISTVÁN LÁNG;JANJA OCVIRK;MARK SAUNDERS;STUART OSBORNE;DONG BOK SHIN;NIKO ANDRE;ANGELO PARADISO;NICOLA SILVESTRIS;ANITA MANGIA;GIOVANNI DE SIMONE;ANTONIO RUSSO;SAVERIO CINIERI;GIROLAMO RANIERI;ANDREA MALFETTONE;ANTONIO MOSCHETTA","780;594;594;594;594;594;594;594;594;593;593;402;332;311;258;232;229;221;197;187","VITO LORUSSO;ANGELO PARADISO;NICOLA SILVESTRIS;ANITA MANGIA;GIOVANNI DE SIMONE;GIROLAMO RANIERI;ANDREA MALFETTONE;ANTONIO MOSCHETTA;CONCETTA SAPONARO;AMALIA AZZARITI;ANNA ELISABETTA BRUNETTI;FRANCESCO GIOTTA;DOMÉNICO RIBATTI;FRANCESCA ROMITO;ONDINA POPESCU;MICHELE QUARANTA;VITO MICHELE GARRISI;KATIA DANZA;CLAUDIA CORMIO;MICHELE GUIDA","775;387;332;311;258;221;197;187;160;156;155;155;137;102;87;82;81;77;73;73","VITO LORUSSO;ANGELO PARADISO;FRANCESCO GIOTTA;GIOVANNI DE SIMONE;NICOLA SILVESTRIS;AMALIA AZZARITI;ANITA MANGIA;MICHELE GUIDA;COSMO DAMIANO GADALETA;ANTONIO MOSCHETTA;FRANCESCA ROMITO;GIROLAMO RANIERI;IDA GALISE;CLAUDIA CORMIO;SIMONA SERRATÌ;STEFANIA TOMMASI;ANNA ELISABETTA BRUNETTI;ANTONIA BELLIZZI;IVAN RASHID;MICHELE QUARANTA","15;10;9;8;6;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;ECONOMICS;PSYCHOLOGY;COMPUTER SCIENCE;ENGINEERING;SOCIOLOGY;GEOGRAPHY;MATERIALS SCIENCE;MATHEMATICS;POLITICAL SCIENCE","72;20;10;5;3;3;2;2;2;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;PATHOLOGY;SURGERY;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;CELL BIOLOGY;PHARMACOLOGY;NURSING;PSYCHIATRY;CLINICAL PSYCHOLOGY;ENDOCRINOLOGY;GYNECOLOGY;MOLECULAR BIOLOGY;ORGANIC CHEMISTRY;BIOPHYSICS;DEMOGRAPHY;FAMILY MEDICINE;MACROECONOMICS;OPTICS;QUANTUM MECHANICS;RADIOLOGY;STEREOCHEMISTRY;UROLOGY","68;41;22;21;17;12;12;11;9;8;5;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2","CANCER;CHEMOTHERAPY;RECEPTOR;ANGIOGENESIS;GENE;POPULATION;IMMUNOHISTOCHEMISTRY;CLINICAL TRIAL;DISEASE;ADVERSE EFFECT;COHORT;HEPATOCELLULAR CARCINOMA;IN VITRO;MAST CELL;RANDOMIZED CONTROLLED TRIAL;CELL CULTURE;QUALITY OF LIFE (HEALTHCARE);RETROSPECTIVE COHORT STUDY;VEGF RECEPTORS;ANXIETY;BIOPSY;CONFIDENCE INTERVAL;LUNG CANCER;LYMPHOMA;MALIGNANCY;MELANOMA;NAUSEA;OBSERVATIONAL STUDY;RENAL CELL CARCINOMA;ZOLEDRONIC ACID","48;19;11;9;9;8;7;6;6;5;5;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","BREAST CANCER;COLORECTAL CANCER;CLINICAL ENDPOINT;METASTASIS;TRYPTASE;TRANSCRIPTION FACTOR;VASCULAR ENDOTHELIAL GROWTH FACTOR;BEVACIZUMAB;CELL CYCLE;CISPLATIN;CYCLOPHOSPHAMIDE;IMMUNOTHERAPY;NEUTROPENIA;PROGRESSION-FREE SURVIVAL;PROSTATE CANCER;SOFT TISSUE SARCOMA;ANTIEMETIC;BLADDER CANCER;CANCER CELL;CANCER REGISTRY;CARCINOGENESIS;CERVIX;COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS;HAZARD RATIO;HIF1A;HYPOXIA (ENVIRONMENTAL);MUTATION;PACLITAXEL;PHASES OF CLINICAL RESEARCH;SORAFENIB;TARGETED THERAPY;TRANSPORTER;TUMOR PROGRESSION;TYROSINE-KINASE INHIBITOR","20;14;8;6;5;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CAPECITABINE;METASTATIC BREAST CANCER;BONE METASTASIS;IPILIMUMAB;NUCLEAR RECEPTOR;TRABECTEDIN;TRASTUZUMAB;BRCA MUTATION;CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING;EPIRUBICIN;ESTROGEN RECEPTOR;FEBRILE NEUTROPENIA;IRINOTECAN;KRAS;ONCOGENE;OXALIPLATIN;RELATIVE SURVIVAL;ABCA1;ADENOCARCINOMA OF THE LUNG;ANDROGEN RECEPTOR;APREPITANT;AZOXYMETHANE;BENDAMUSTINE;BREAST DISEASE;CA15-3;CANCER CELL LINES;CANCER SURVIVORSHIP;CARBOPLATIN;CETUXIMAB;CIRCULATING TUMOR CELL;COACTIVATOR;CORE BIOPSY;CXCL1;CYCLIN D1;DUCTAL CARCINOMA;EZRIN;GASTROINTESTINAL CANCER;GEFITINIB;HORMONE RECEPTOR;HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2;KRABBE DISEASE;LYMPHOVASCULAR INVASION;MOLECULAR MEDICINE;NON-SMALL CELL LUNG CANCER (NSCLC);P-GLYCOPROTEIN;PALONOSETRON;PEMETREXED;PEROXISOME PROLIFERATOR;PITTSBURGH SLEEP QUALITY INDEX;PLATELET-DERIVED GROWTH FACTOR RECEPTOR;PROBAND;PROTEASE-ACTIVATED RECEPTOR 2;SMALL HAIRPIN RNA;SPECKLE TRACKING ECHOCARDIOGRAPHY;STEATOHEPATITIS;TAMOXIFEN;UROTHELIAL CANCER;UROTHELIAL CARCINOMA;VEMURAFENIB;VINORELBINE","4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;BREAST NEOPLASMS;FEMALE;MIDDLE AGED;;MALE;ANTINEOPLASTIC AGENTS;NEOPLASMS;ADULT;AGED;LUNG NEOPLASMS;COLORECTAL NEOPLASMS;ITALY;LIVER NEOPLASMS;AGED, 80 AND OVER;BONE NEOPLASMS;NEOVASCULARIZATION, PATHOLOGIC;CARCINOMA, HEPATOCELLULAR;SURVIVAL RATE;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS","45;41;35;30;28;27;26;25;23;22;22;17;15;15;13;12;12;11;11;9","ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE;HER2 SIGNALING IN BREAST CANCER TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CANCER STEM CELLS AND TUMOR METASTASIS;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;ADVANCEMENTS IN LUNG CANCER RESEARCH;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;CANCER SURVIVORSHIP AND QUALITY OF LIFE;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;HEPATOCELLULAR CARCINOMA;NURR1/COREST PATHWAY IN NEUROPROTECTION AND INFLAMMATION;PREVENTION AND MANAGEMENT OF POSTOPERATIVE NAUSEA AND VOMITING;RENAL CELL CARCINOMA;ACUTE MYELOID LEUKEMIA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;BREAST PATHOLOGY AND IMAGING TECHNIQUES;CALCINEURIN-NFAT SIGNALING IN TRANSCRIPTIONAL REGULATION;CANCER IMMUNOTHERAPY","5;4;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1","BREAST CANCER;CLINICAL ENDPOINT;TRYPTASE;TRASTUZUMAB;BONE METASTASIS;CANCER;CANCER INCIDENCE;CANCER RISK;CANCER SURVIVORSHIP;CANCER SUSCEPTIBILITY;METASTATIC BONE DISEASE;PROGRESSION-FREE SURVIVAL;RECEPTOR TYROSINE KINASE;TRABECTEDIN;TREATMENT;TUMOR MODELS;ZOLEDRONIC ACID;ANGIOGENIC SIGNALING;BEVACIZUMAB;BRCA MUTATION","9;8;5;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2","BREAST CANCER;CANCER PATIENTS;COLORECTAL CANCER;FINAL RESULTS;ACCESS PROGRAMME;BONE DISEASE;BONE METASTASIS;CANCER BURDEN;CANCER FINAL;EXPANDED ACCESS;GASTRIC CANCER;GRUPPO ONCOLOGICO;HEPATOCELLULAR CARCINOMA;IPILIMUMAB EXPANDED;ITALIAN COHORT;MALIGNANT BONE;METASTASIS SURVEY;NATURAL HISTORY;PHASE II;PHASE III;PROGRAMME EAP;ACTIN ASSEMBLY;BETA- INTERACTION;CANCER CELLS;CANCER SURVIVORS;CELL CARCINOMA;CELLS DEREGULATION;CLINICAL OUTCOME;CLINICAL OUTCOMES;COLO-RECTAL CANCER","14;8;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","BONE METASTASIS;BREAST CANCER;COLORECTAL CANCER;NHERF EXPRESSION;CANCER PATIENTS;MEDIAN SURVIVAL;METABOLIC SYNDROME;CAPILLARY MORPHOGENESIS;CELL LINE;HCC PATIENTS;HUMAN COLORECTAL;MEDIAN TIME;PERIPHERAL BLOOD;SLEEP DISTURBANCES;XENOGRAFT TUMORS;BLOOD MONONUCLEAR;BRCA MUTATIONS;BRCA- CARRIERS;CANCER CELLS;CELL LEUKODYSTROPHY;COLON CANCER;ENDOTHELIAL CELLS;GASTRIC CANCER;GLOBOID CELL;GROWTH FACTOR;MAST CELLS;MONONUCLEAR CELLS;SERUM LEVELS;TRYPTASE LEVELS;AD VPHLXRΑ","18;13;10;8;7;7;7;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;5;5;4",17,0.23,3.5,3,1,1,0,2,1,1,2.5,3,0,1,3,0,1,1,3.25,1,3.5,0,0,47,47,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,7.17,303.67,5.26,2,0.33,54.33,0,1,2,0,3,0,0,0,0,6,0,0,0,0,0,0,0,5,1,0,6,0,0,0,0,0,0,0,0,0,"Japan","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","6;4;4","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;PATIENT SAFETY;AGING;BREAST CANCER;DIGESTIVE DISEASES;ESTROGEN;HEALTH SERVICES;LUNG;LUNG CANCER","6;4;4;4;2;1;1;1;1;1;1;1","CANCER","4","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","6;1","LUNG CANCER;BREAST CANCER;LEUKEMIA / LEUKAEMIA;MELANOMA;STOMACH CANCER","2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","5;1",1,473231,157743.67,4,3,2,1,12,117058.698843271,0.632161477371945,"ISTITUTO TUMORI BARI;UK BIOBANK;UNIVERSITY OF EDINBURGH","1;1;1","MEDICAL RESEARCH COUNCIL","1","COALITION S;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;UKRI - UK RESEARCH AND INNOVATION","1;1;1","RESEARCH GRANT (PROJECT CATEGORY)","1","31 BIOLOGICAL SCIENCES;3105 GENETICS","1;1","BIOTECHNOLOGY;CANCER;GENETICS;HUMAN GENOME","1;1;1;1","CANCER","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.5 RESEARCH DESIGN AND METHODOLOGIES (AETIOLOGY);8.4 RESEARCH DESIGN AND METHODOLOGIES (HEALTH SERVICES)","1;1;1","NOT SITE-SPECIFIC CANCER","1",NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,23,"PUBLIC LIBRARY OF SCIENCE","23","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;49 MATHEMATICAL SCIENCES;44 HUMAN SOCIETY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3103 ECOLOGY;43 HISTORY, HERITAGE AND ARCHAEOLOGY;4301 ARCHAEOLOGY;4401 ANTHROPOLOGY","25;9;9;5;5;4;4;3;1;1;1;1;1;1","GENETICS;RARE DISEASES","2;1","CANCER;MUSCULOSKELETAL;CARDIOVASCULAR","9;3;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","4;3;1","CLINICAL;BIOMEDICAL","2;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","8;6;1","BREAST CANCER;NOT SITE-SPECIFIC CANCER","8;1",NA,NA
"IRCCS_TUMORIBARI",2014,92,13.4565217391304,3.22826086956522,0.33695652173913,0.41304347826087,0.728260869565217,2.49579831932773,1.24,2,1.42553191489362,0.608695652173913,1,44,21,10,4,0.48,0.23,0.11,0.04,31.4,0.830927770411183,4.30516431924883,0.315217391304348,0.902173913043478,0.444,0.395,0.334,0.355,"NICOLA SILVESTRIS;ANGELO PARADISO;VITO LORUSSO;SAVERIO CINIERI;ATTILIO GUARINI;STEFANIA TOMMASI;DOMÉNICO RIBATTI;COSMO DAMIANO GADALETA;SALVATORE PISCONTI;STEFANO CASCINU;EVARISTO MAIELLO;MICHELE GUIDA;DANIELE SANTINI;GIOVANNI DE SIMONE;SEVERINO MONTEMURRO;GIACOMA DE TULLIO;PAOLO MARCHETTI;GIROLAMO RANIERI;AMALIA AZZARITI;CARLA MINOIA","13;12;12;10;10;8;8;8;7;7;7;7;7;7;6;6;6;6;6;6","DOMÉNICO RIBATTI;ANGELO PARADISO;NICOLA SILVESTRIS;ATTILIO GUARINI;VITO LORUSSO;STEFANIA TOMMASI;GIOVANNI DE SIMONE;BRUNELLA PILATO;GIACOMA DE TULLIO;AMALIA AZZARITI;SEVERINO MONTEMURRO;COSMO DAMIANO GADALETA;ANTONIO MOSCHETTA;SAVERIO CINIERI;ONDINA POPESCU;GIROLAMO RANIERI;SIMONA DE SUMMA;MICHELE GUIDA;PASQUALE IACOPINO;SALVATORE PISCONTI","1.55;1.2;1.02;0.99;0.95;0.88;0.77;0.72;0.72;0.67;0.66;0.61;0.59;0.57;0.56;0.53;0.53;0.5;0.48;0.44","NICOLA SILVESTRIS;ANGELO PARADISO;VITO LORUSSO;ATTILIO GUARINI;STEFANIA TOMMASI;DOMÉNICO RIBATTI;COSMO DAMIANO GADALETA;MICHELE GUIDA;GIOVANNI DE SIMONE;SEVERINO MONTEMURRO;GIACOMA DE TULLIO;GIROLAMO RANIERI;AMALIA AZZARITI;CARLA MINOIA;BRUNELLA PILATO;FRANCESCO GIOTTA;MICHELE AMMENDOLA;SIMONA DE SUMMA;ANTONIO MOSCHETTA;ROSA PATRUNO","13;12;12;10;8;8;8;7;7;6;6;6;6;6;6;6;5;5;5;5","DOMÉNICO RIBATTI;ANGELO PARADISO;NICOLA SILVESTRIS;ATTILIO GUARINI;VITO LORUSSO;STEFANIA TOMMASI;GIOVANNI DE SIMONE;BRUNELLA PILATO;GIACOMA DE TULLIO;AMALIA AZZARITI;SEVERINO MONTEMURRO;COSMO DAMIANO GADALETA;ANTONIO MOSCHETTA;ONDINA POPESCU;GIROLAMO RANIERI;SIMONA DE SUMMA;MICHELE GUIDA;PASQUALE IACOPINO;MICHELE AMMENDOLA;ROSA PATRUNO","1.55;1.2;1.02;0.99;0.95;0.88;0.77;0.72;0.72;0.67;0.66;0.61;0.59;0.56;0.53;0.53;0.5;0.48;0.43;0.43","ANTONIO MOSCHETTA;VITO LORUSSO;PAOLO MARCHETTI;CHIARA DEGIROLAMO;MICHELE GUIDA;STEFANIA MURZILLI;JACOPO PIGOZZO;LORENZA DI GUARDO;MICHELE MAIO;PAOLA QUEIROLO;PAOLO A. ASCIERTO;VANNA CHIARION‐SILENI;DOMÉNICO RIBATTI;COSMO DAMIANO GADALETA;MASSIMO AGLIETTA;FABIOLA BOVENGA;STEFANIA RAINALDI;ESTER SIMEONE;FRANCESCO COGNETTI;MICHELE DEL VECCHIO","489;475;460;415;409;379;365;365;365;365;365;365;356;331;328;313;305;268;268;268","ANTONIO MOSCHETTA;VITO LORUSSO;CHIARA DEGIROLAMO;MICHELE GUIDA;COSMO DAMIANO GADALETA;FABIOLA BOVENGA;VITTORIO MATTIOLI;GIROLAMO RANIERI;DOMÉNICO RIBATTI;NICOLA SILVESTRIS;ILARIA MARECH;ANGELO PARADISO;ANNA ELISABETTA BRUNETTI;SEVERINO MONTEMURRO;STEFANIA TOMMASI;GIOVANNI DE SIMONE;MICHELE AMMENDOLA;EUFEMIA SAVINO;ONDINA POPESCU;AMALIA AZZARITI","489;473;415;409;331;313;263;249;246;238;211;206;187;137;122;109;101;99;98;97","VITO LORUSSO;NICOLA SILVESTRIS;ANGELO PARADISO;ATTILIO GUARINI;COSMO DAMIANO GADALETA;MICHELE GUIDA;GIOVANNI DE SIMONE;DOMÉNICO RIBATTI;FRANCESCO GIOTTA;GIROLAMO RANIERI;SEVERINO MONTEMURRO;STEFANIA TOMMASI;AMALIA AZZARITI;ANNA ELISABETTA BRUNETTI;ANTONIO MOSCHETTA;GIACOMA DE TULLIO;ILARIA MARECH;ONDINA POPESCU;BRUNELLA PILATO;DOMENICO GALETTA","13;13;11;10;8;7;7;6;6;6;6;6;6;5;5;5;5;5;5;4","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;PSYCHOLOGY;BUSINESS;MATHEMATICS;PHILOSOPHY;POLITICAL SCIENCE;ECONOMICS;ENGINEERING;HISTORY;SOCIOLOGY","85;42;5;4;3;3;2;2;2;2;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;GENETICS;PATHOLOGY;IMMUNOLOGY;BIOCHEMISTRY;GASTROENTEROLOGY;CELL BIOLOGY;SURGERY;ENVIRONMENTAL HEALTH;ENDOCRINOLOGY;BIOINFORMATICS;PHARMACOLOGY;FAMILY MEDICINE;INTENSIVE CARE MEDICINE;MOLECULAR BIOLOGY;ORGANIC CHEMISTRY;PALEONTOLOGY;RADIOLOGY","74;45;43;22;20;16;15;12;11;10;7;6;4;4;3;3;3;3;3;3","CANCER;GENE;CHEMOTHERAPY;ANGIOGENESIS;IMMUNOHISTOCHEMISTRY;RECEPTOR;POPULATION;BONE MARROW;CLINICAL TRIAL;IN VITRO;LYMPHOMA;VEGF RECEPTORS;LUNG CANCER;MAST CELL;MELANOMA;RETROSPECTIVE COHORT STUDY;ADVERSE EFFECT;DISEASE;HEPATOCELLULAR CARCINOMA;IMMUNE SYSTEM;STROMAL CELL","58;27;21;16;10;8;7;6;6;6;6;6;5;5;5;5;4;4;4;4;4","BREAST CANCER;COLORECTAL CANCER;METASTASIS;CISPLATIN;VASCULAR ENDOTHELIAL GROWTH FACTOR;MICRORNA;PANCREATIC CANCER;TRANSCRIPTION FACTOR;BEVACIZUMAB;GENE EXPRESSION;GENOTYPE;IMMUNOTHERAPY;MUTATION;TRYPTASE;CARCINOGENESIS;CELL CYCLE;DOWNREGULATION AND UPREGULATION;EPIGENETICS;PHASES OF CLINICAL RESEARCH;SORAFENIB;TUMOR MICROENVIRONMENT","17;17;10;6;6;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3","METASTATIC BREAST CANCER;TRASTUZUMAB;VINORELBINE;IPILIMUMAB;IRINOTECAN;KRAS;NUCLEAR RECEPTOR;ONCOGENE;SINGLE-NUCLEOTIDE POLYMORPHISM;BENDAMUSTINE;CAPECITABINE;CARBOPLATIN;CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING;CIRCULATING TUMOR CELL;CXCL1;ESTROGEN RECEPTOR;GEFITINIB;GENE EXPRESSION PROFILING;GENE MUTATION;MONOCLONAL;PEMETREXED;TRANSCRIPTOME;TRIPLE-NEGATIVE BREAST CANCER","5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;BREAST NEOPLASMS;FEMALE;;MALE;MIDDLE AGED;COLORECTAL NEOPLASMS;AGED;ADULT;BIOMARKERS, TUMOR;AGED, 80 AND OVER;LIVER NEOPLASMS;ANIMALS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;MICRORNAS;ANTINEOPLASTIC AGENTS;MELANOMA;TRIPLE NEGATIVE BREAST NEOPLASMS;CARCINOMA, HEPATOCELLULAR;ANTIBODIES, MONOCLONAL, HUMANIZED","54;49;41;33;32;30;29;28;24;24;16;15;14;14;12;11;11;11;9;8","ADVANCEMENTS IN LUNG CANCER RESEARCH;HER2 SIGNALING IN BREAST CANCER TREATMENT;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;CANCER STEM CELLS AND TUMOR METASTASIS;CANCER SURVIVORSHIP AND QUALITY OF LIFE;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;COLORECTAL CANCER RESEARCH AND TREATMENT;NATURAL KILLER CELLS IN IMMUNITY;PANCREATIC CANCER RESEARCH AND TREATMENT;CANCER IMMUNOTHERAPY;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EFFICACY AND RESISTANCE IN CML TREATMENT;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;MECHANISMS OF MULTIDRUG RESISTANCE IN CANCER;METABOLIC REPROGRAMMING IN CANCER BIOLOGY;MOLECULAR MECHANISMS OF ANGIOGENESIS AND VASCULAR FUNCTION;PREVENTION AND MANAGEMENT OF POSTOPERATIVE NAUSEA AND VOMITING","5;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","BREAST CANCER;METASTATIC BREAST CANCER;TRYPTASE;VINORELBINE;ANGIOGENIC SIGNALING;CANCER;CANCER BIOMARKERS;CANCER TREATMENT;EXPANDED ACCESS;HER2;MELANOMA;METASTATIC COLORECTAL CANCER;METASTATIC PANCREATIC CANCER;NON-SMALL CELL LUNG CANCER;PANCREATIC CANCER;TRASTUZUMAB;TUMOR ANGIOGENESIS;TUMOR MICROENVIRONMENT;ANTI-ANGIOGENIC THERAPY;BENDAMUSTINE","7;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2","BREAST CANCER;CANCER PATIENTS;COLORECTAL CANCER;CLINICAL OUTCOME;METASTATIC COLORECTAL;PHASE II;LUNG CANCER;MAST CELLS;METASTATIC BREAST;PATIENTS RECEIVING;CANCER RESEARCH;FAMILIAL BREAST;II STUDY;LOCALLY ADVANCED;MICROVASCULAR DENSITY;MULTIPLE MYELOMA;PANCREATIC CANCER;PHASE III;PROGNOSTIC FACTORS;RECTAL CANCER;STUDY EVALUATING;TUMOR GROWTH;ACCESS PROGRAMME;ADENOCARCINOMA PATIENTS;ADVANCED BREAST;ADVANCED HCC;ADVANCED MELANOMA;AGGRESSIVE PHENOTYPE;ANGIOGENESIS POLYMORPHISMS;ASSAYS PREDICT","16;14;7;6;6;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","BREAST CANCER;CANCER PATIENTS;PATIENTS TREATED;PROGRESSION-FREE SURVIVAL;BONE MARROW;BONE METASTASES;CELL LINES;KRAS MUTATIONS;MEDIAN AGE;SURVIVAL OS;CLINICAL TRIALS;GROWTH FACTOR;MEDIAN OS;METASTATIC MELANOMA;MULTIVARIATE ANALYSIS;BONE METASTASIS;DIFFERENTIALLY EXPRESSED;ELDERLY PATIENTS;FAMILIAL BREAST;KRAS STATUS;MEDIAN PROGRESSION-FREE;MMLMATH XMLNSMMLHTTPWWWWORGMATHMATHML;PERFORMANCE STATUS;PERIPHERAL BLOOD;SURVIVAL PFS;TISSUEPLASMA KRAS;ABSTRACT AIM;ADJUVANT CHEMOTHERAPY;ADVERSE EVENTS;BRCA -RELATED","23;15;10;9;8;8;8;8;8;8;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6;5;5;5;5",35,0.38,3.5,3.5,1,8,1,4,2,1,1.75,4.5,0,1,3,0,1.5,1,2,2,4,0,0,61,61,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,4,367.67,2.78,2,0.67,80,0,0,0,0,2,0,0,1,0,2,1,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,0,0,0,0,"United States","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY","3;3;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;LYMPHOMA;RARE DISEASES;COMPARATIVE EFFECTIVENESS RESEARCH","3;3;2;2;2;2;1","CANCER","2","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","2;1","LEUKEMIA / LEUKAEMIA;MELANOMA;NON-HODGKIN'S LYMPHOMA","2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","3;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,23,"PUBLIC LIBRARY OF SCIENCE","23","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;44 HUMAN SOCIETY;3105 GENETICS;34 CHEMICAL SCIENCES;3401 ANALYTICAL CHEMISTRY;4203 HEALTH SERVICES AND SYSTEMS;4404 DEVELOPMENT STUDIES;4408 POLITICAL SCIENCE;46 INFORMATION AND COMPUTING SCIENCES;50 PHILOSOPHY AND RELIGIOUS STUDIES","21;7;6;2;2;2;2;1;1;1;1;1;1;1;1","CANCER;CHRONIC LIVER DISEASE AND CIRRHOSIS;CLINICAL RESEARCH;DIGESTIVE DISEASES;LIVER CANCER;LIVER DISEASE;RARE DISEASES","2;1;1;1;1;1;1","CANCER;INFECTION;ORAL AND GASTROINTESTINAL","2;1;1","1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","2;2;1","BIOMEDICAL;CLINICAL;HEALTH SERVICES & SYSTEMS","2;2;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","8;2","LIVER CANCER;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;COLON AND RECTAL CANCER;MELANOMA","3;1;1;1","3 GOOD HEALTH AND WELL BEING","1"
"IRCCS_TUMORIBARI",2015,92,14,3.72826086956522,0.391304347826087,0.445652173913043,0.456521739130435,2.52205882352941,1.28571428571429,1.86363636363636,1.5,0.597826086956522,1,45,18,14,6,0.49,0.2,0.15,0.07,26.39,0.708145249060626,4.43253968253968,0.184782608695652,0.934782608695652,0.529,0.381,0.346,0.373,"NICOLA SILVESTRIS;STEFANIA TOMMASI;DOMÉNICO RIBATTI;MICHELE GUIDA;GIOVANNI DE SIMONE;DOMENICO GALETTA;AMALIA AZZARITI;SIMONA DE SUMMA;STEFANO CASCINU;GABRIELLA GUIDA;ATTILIO GUARINI;ANITA MANGIA;SABINO STRIPPOLI;ANGELO PARADISO;EMANUELA SCARPI;COSMO DAMIANO GADALETA;CHRISTIAN MARINACCIO;DANIELE SANTINI;MICHELE AMMENDOLA;MARIO SCARTOZZI","15;12;11;11;11;9;9;8;8;8;8;8;8;8;7;7;7;7;6;6","DOMÉNICO RIBATTI;ANGELO PARADISO;GIOVANNI DE SIMONE;CHRISTIAN MARINACCIO;DOMENICO GALETTA;NICOLA SILVESTRIS;FRANCESCA ROMITO;MICHELE GUIDA;STEFANIA TOMMASI;AMALIA AZZARITI;ANITA MANGIA;SIMONA DE SUMMA;GABRIELLA GUIDA;SABINO STRIPPOLI;FILIPPO BELARDELLI;ATTILIO GUARINI;EMANUELA SCARPI;MARIO SCARTOZZI;ANNAMARIA CATINO;COSMO DAMIANO GADALETA","1.72;1.28;1.27;1.25;1.23;1.2;1.15;1.15;1.1;0.99;0.95;0.87;0.83;0.81;0.75;0.68;0.64;0.61;0.57;0.54","NICOLA SILVESTRIS;STEFANIA TOMMASI;DOMÉNICO RIBATTI;MICHELE GUIDA;GIOVANNI DE SIMONE;DOMENICO GALETTA;AMALIA AZZARITI;SIMONA DE SUMMA;ATTILIO GUARINI;ANITA MANGIA;SABINO STRIPPOLI;ANGELO PARADISO;COSMO DAMIANO GADALETA;MICHELE AMMENDOLA;GIROLAMO RANIERI;ORONZO BRUNETTI;ILARIA MARECH;NICOLA SGHERZA;ANNAMARIA CATINO;ANTONELLA DANIELE","15;12;11;11;11;9;9;8;8;8;8;8;7;6;6;6;6;5;5;5","DOMÉNICO RIBATTI;ANGELO PARADISO;GIOVANNI DE SIMONE;DOMENICO GALETTA;NICOLA SILVESTRIS;FRANCESCA ROMITO;MICHELE GUIDA;STEFANIA TOMMASI;AMALIA AZZARITI;ANITA MANGIA;SIMONA DE SUMMA;SABINO STRIPPOLI;ATTILIO GUARINI;ANNAMARIA CATINO;COSMO DAMIANO GADALETA;VITO LORUSSO;ORONZO BRUNETTI;ONDINA POPESCU;NICOLA SGHERZA;MICHELE AMMENDOLA","1.72;1.28;1.27;1.23;1.2;1.15;1.15;1.1;0.99;0.95;0.87;0.81;0.68;0.57;0.54;0.53;0.53;0.52;0.49;0.49","DOMÉNICO RIBATTI;NICOLA SILVESTRIS;DANIELE SANTINI;STEFANIA TOMMASI;EUGENIO MAIORANO;PASQUALE IACOPINO;PANTALEO BUFO;SIMONA CAGIANO;ANTONIO RUSSO;A. BARILLARO;ALBERT SAIZ;ALESSANDRA LUGARESI;ALESSANDRO RAMBALDI;AMEDEA DONELLI;ANNA REPICE;ANTONIO UCCELLI;ARMANDO TARTARO;AURORA CUOGHI;CARLO RUSSO;D. FARINA","390;348;264;248;242;242;232;232;226;223;223;223;223;223;223;223;223;223;223;223","DOMÉNICO RIBATTI;NICOLA SILVESTRIS;STEFANIA TOMMASI;PASQUALE IACOPINO;VITO LORUSSO;MICHELE GUIDA;CRISTIANO SIMONE;DOMENICO GALETTA;GIOVANNI DE SIMONE;ALESSIA PESERICO;ANTONIO MOSCHETTA;COSMO DAMIANO GADALETA;GIUSI GRAZIANO;AMALIA AZZARITI;ANITA MANGIA;SIMONA DE SUMMA;GIROLAMO RANIERI;ILARIA MARECH;SABINO STRIPPOLI;SIMONA D’AMORE","390;348;248;223;202;191;180;160;152;142;138;128;127;116;108;108;99;99;97;96","NICOLA SILVESTRIS;STEFANIA TOMMASI;GIOVANNI DE SIMONE;MICHELE GUIDA;DOMÉNICO RIBATTI;AMALIA AZZARITI;DOMENICO GALETTA;ANGELO PARADISO;ANITA MANGIA;ATTILIO GUARINI;SIMONA DE SUMMA;SABINO STRIPPOLI;COSMO DAMIANO GADALETA;VITO LORUSSO;GIROLAMO RANIERI;ILARIA MARECH;ORONZO BRUNETTI;NICOLA SGHERZA;ANNAMARIA CATINO;ANTONELLA DANIELE","15;12;11;11;11;9;9;8;8;8;8;8;7;7;6;6;6;5;5;5","MEDICINE;BIOLOGY;CHEMISTRY;POLITICAL SCIENCE;COMPUTER SCIENCE;ECONOMICS;PHYSICS;ART;BUSINESS;ENGINEERING;GEOGRAPHY;MATERIALS SCIENCE;PHILOSOPHY;SOCIOLOGY","86;41;10;8;5;5;5;1;1;1;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;GENETICS;PATHOLOGY;BIOCHEMISTRY;GASTROENTEROLOGY;IMMUNOLOGY;SURGERY;CELL BIOLOGY;LAW;FAMILY MEDICINE;NURSING;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;MEDICAL EDUCATION;OPTICS;PHARMACOLOGY;BIOINFORMATICS;ECONOMIC GROWTH;GYNECOLOGY;PALEONTOLOGY;PHYSICAL THERAPY;PSYCHIATRY;RADIOLOGY","75;41;33;30;23;14;14;14;14;9;7;6;6;5;5;4;4;4;3;3;3;3;3;3;3","CANCER;CHEMOTHERAPY;GENE;ANGIOGENESIS;IMMUNOHISTOCHEMISTRY;MELANOMA;LUNG CANCER;CELL GROWTH;HEPATOCELLULAR CARCINOMA;POPULATION;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;CLINICAL TRIAL;CONCOMITANT;HEALTH CARE;MAST CELL;REGIMEN;ACCREDITATION;APOPTOSIS;CONFIDENCE INTERVAL;HEMATOLOGY;INCIDENCE (GEOMETRY);LYMPHOMA;MULTIVARIATE ANALYSIS;QUALITY OF LIFE (HEALTHCARE);RETROSPECTIVE COHORT STUDY;SIGNAL TRANSDUCTION","54;22;22;13;12;10;7;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4","BREAST CANCER;COLORECTAL CANCER;METASTATIC MELANOMA;METASTASIS;MUTATION;GENOTYPE;MICRORNA;ADENOCARCINOMA;CLINICAL ENDPOINT;GEMCITABINE;GENE EXPRESSION;NEOVASCULARIZATION;NEUTROPENIA;SORAFENIB;TRYPTASE;BEVACIZUMAB;CD31;CD34;CHEMOTHERAPY REGIMEN;HAZARD RATIO;MULTIPLE DRUG RESISTANCE;PROGRESSION-FREE SURVIVAL;UNIVARIATE ANALYSIS","15;12;7;6;6;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3","VEMURAFENIB;IRINOTECAN;CAPECITABINE;EPIRUBICIN;OXALIPLATIN;ANTHRACYCLINE;BILIARY TRACT CANCER;BONE METASTASIS;CETUXIMAB;CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING;DNA METHYLATION;KRAS;MELANOCORTIN 1 RECEPTOR;MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR;MISSENSE MUTATION;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;SINGLE-NUCLEOTIDE POLYMORPHISM;VINORELBINE;ADENOCARCINOMA OF THE LUNG;ADENOMATOUS POLYPOSIS COLI;AURORA INHIBITOR;BENCE JONES PROTEIN;BREAST RECONSTRUCTION;CANCER SURVIVORSHIP;CARMUSTINE;CD117;CD3;CHEMOKINE RECEPTOR;DASATINIB;DIGITAL IMAGE;DNA MICROARRAY;DOUBLE NEGATIVE;ELECTROCHEMOTHERAPY;EOTAXIN;EPITHELIAL–MESENCHYMAL TRANSITION;ESTROGEN RECEPTOR;FAMILIAL ADENOMATOUS POLYPOSIS;FEBRILE NEUTROPENIA;FILGRASTIM;GENE EXPRESSION PROFILING;GENOTYPING;GERMINAL CENTER;GLUCOSE-6-PHOSPHATE DEHYDROGENASE;IPILIMUMAB;MASTECTOMY;MECHANISTIC TARGET OF RAPAMYCIN;MEMBER STATE;METASTATIC BREAST CANCER;METHYLTRANSFERASE;MICROMETASTASIS;MOLECULAR MEDICINE;MONOCLONAL;MTORC1;NILOTINIB;NUCLEAR RECEPTOR;ONCOGENE;P-GLYCOPROTEIN;P38 MITOGEN-ACTIVATED PROTEIN KINASES;PALONOSETRON;PENTOSE PHOSPHATE PATHWAY;POLY ADP RIBOSE POLYMERASE;RPTOR;SANGER SEQUENCING;SCAVENGER RECEPTOR;SENTINEL LYMPH NODE;TAXANE;TRANSLOCATOR PROTEIN;TRASTUZUMAB;VASCULAR ENDOTHELIAL GROWTH FACTOR A;VERY LOW-DENSITY LIPOPROTEIN;WILD TYPE","5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MIDDLE AGED;AGED;BREAST NEOPLASMS;MALE;ADULT;AGED, 80 AND OVER;ANTINEOPLASTIC AGENTS;NEOPLASMS;BIOMARKERS, TUMOR;ITALY;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;LIVER NEOPLASMS;STOMACH NEOPLASMS;NEOVASCULARIZATION, PATHOLOGIC;CANCER CARE FACILITIES;CARCINOMA, HEPATOCELLULAR;CELL PROLIFERATION","52;38;36;35;33;30;29;26;20;20;20;19;19;14;12;12;11;10;10;10","MAMMALIAN MAP KINASE SIGNALING PATHWAYS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;METABOLIC REPROGRAMMING IN CANCER BIOLOGY;ADVANCEMENTS IN LUNG CANCER RESEARCH;CHOLANGIOCARCINOMA;GASTRIC CANCER RESEARCH AND TREATMENT;INTEGRATION OF PALLIATIVE CARE IN END-OF-LIFE;NATURAL KILLER CELLS IN IMMUNITY;ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE;ACUTE MYELOID LEUKEMIA;CANCER SURVIVORSHIP AND QUALITY OF LIFE;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;MOLECULAR MECHANISMS OF ANGIOGENESIS AND VASCULAR FUNCTION;MOLECULAR RESEARCH ON BREAST CANCER;POLY(ADP-RIBOSE) POLYMERASE INHIBITION IN CANCER THERAPY;PREVENTION AND MANAGEMENT OF POSTOPERATIVE NAUSEA AND VOMITING;ROLE OF AMP-ACTIVATED PROTEIN KINASE IN CELLULAR METABOLISM;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH","6;5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1","MELANOMA;BREAST CANCER;CONCOMITANT;METASTATIC COLORECTAL CANCER;REGIMEN;BRAF GENE;CANCER;CLINICAL ENDPOINT;HEMATOLOGY;TRYPTASE;BILIARY TRACT CANCER;CANCER RISK;CANCER SUSCEPTIBILITY;CANCER THERAPY;CD31;CHEMOTHERAPY REGIMEN;CHRISTIAN MINISTRY;EPIRUBICIN;FOLFIRI;METASTATIC GASTRIC CANCER","8;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","CANCER PATIENTS;BREAST CANCER;METASTATIC MELANOMA;COLORECTAL CANCER;GASTRIC CANCER;CLINICAL OUTCOME;LINE CHEMOTHERAPY;LUNG CANCER;METASTATIC COLORECTAL;MICROVASCULAR DENSITY;PATIENTS TREATED;ADVANCED BILIARY;ADVANCED GASTRIC;ADVANCED HCC;ALLEANZA CONTRO;BONE METASTASES;CANCER SURVIVORS;CONTRO IL;HCC PATIENTS;IL CANCRO;ITALIAN CANCER;MAST CELLS;MULTIPLE MYELOMA;NHERF EXPRESSION;RECEIVING SORAFENIB;SERUM LEVELS;BILIARY TRACT;BRAF GA;BRAF INHIBITORS;CANCER CENTRES","13;11;9;6;6;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2","CROSSREF MEDLINE;MEDIAN PFS;GASTRIC CANCER;CAS GOOGLE;MEDLINE CAS;PATIENTS TREATED;ADVANCED GASTRIC;BREAST CANCER;ONCOL CROSSREF;BONE METASTASES;CI LOG-RANK;HR CI;LOG-RANK TEST;CANCER PATIENTS;COLORECTAL CANCER;GC PATIENTS;PHASE III;RESPONSE RATE;ADVERSE EVENTS;AL ANNALS;CELL LINES;KRAS NRAS;LUNG CANCER;MEDIAN OS;METASTATIC MELANOMA;NRAS BRAF;PIKCA GENES;PROGRESSIVE DISEASE;SURVIVAL OS;CELL PROLIFERATION","19;19;18;16;16;15;13;11;11;10;10;10;10;9;9;9;9;9;8;8;8;8;8;8;8;8;8;8;8;7",40,0.43,3.56,3,1,4.5,0,8,3.5,0,1,3.25,1,0,3,0,0,2,2,2,1,0,0,58.25,58.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,8,545,0.75,1,1,110,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,"United States","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","1;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;LUNG;LUNG CANCER","1;1;1;1;1","CANCER","1","6.1 PHARMACEUTICALS","1","LUNG CANCER","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",2,6276557.5,1080774.01,5.5,6.5,4.5,1,17.5,529975.249676605,0.173593012232438,"ISTITUTO TUMORI BARI;ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE;CENTRE FOR PROCESS INNOVATION;CENTRO DI RIFERIMENTO ONCOLOGICO;EUROPEAN RESEARCH SERVICES;ISTITUTO NEUROLOGICO CARLO BESTA;LIONIX (NETHERLANDS);MIDATECH PHARMA (UNITED KINGDOM);UNIVERSITY COLLEGE DUBLIN;UNIVERSITY COLLEGE LONDON;UNIVERSITY OF MÜNSTER","2;2;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME);H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - LEADERSHIP IN ENABLING AND INDUSTRIAL TECHNOLOGIES – NANOTECHNOLOGIES (PROGRAMME);H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-NMP-PILOTS-2014 (CALL FOR PROPOSAL);H2020-PHC-2014-TWO-STAGE (CALL FOR PROPOSAL)","2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;34 CHEMICAL SCIENCES;3401 ANALYTICAL CHEMISTRY;40 ENGINEERING;4014 MANUFACTURING ENGINEERING","2;1;1;1;1;1","BIOENGINEERING;NANOTECHNOLOGY;BIOTECHNOLOGY;ORPHAN DRUG;RARE DISEASES","2;2;1;1;1","GENERIC HEALTH RELEVANCE","1","5.1 PHARMACEUTICALS","1","NOT SITE-SPECIFIC CANCER","2","4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","1;1;1","A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;B12 ENGINEERING","1;1",NA,NA,1,"PUBLIC LIBRARY OF SCIENCE","1","31 BIOLOGICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY","2;1",NA,NA,NA,NA,NA,NA,NA,NA,"BASIC SCIENCE","1",NA,NA,NA,NA
"IRCCS_TUMORIBARI",2016,115,15.304347826087,2.86086956521739,0.330434782608696,0.321739130434783,0.339130434782609,2.43703703703704,1.31034482758621,1.60869565217391,1.44444444444444,0.626086956521739,1,73,31,2,5,0.63,0.27,0.02,0.04,39.16,1.20544621905767,4.56666666666667,0.252173913043478,0.947826086956522,0.493,0.407,0.39,0.419,"STEFANIA TOMMASI;MICHELE GUIDA;NICOLA SILVESTRIS;DOMENICO GALETTA;DOMÉNICO RIBATTI;MICHELE AMMENDOLA;ROSA MARIA IACOBAZZI;MARIO SCARTOZZI;AMALIA AZZARITI;GIROLAMO RANIERI;SABINO STRIPPOLI;RAFFAELE DE LUCA;LETIZIA PORCELLI;STEFANO CASCINU;GIUSI GRAZIANO;COSMO DAMIANO GADALETA;ORONZO BRUNETTI;NUNZIO DENORA;DANIELE SANTINI;ILARIA MARECH","12;12;12;11;11;9;9;9;9;8;8;7;7;7;7;7;7;7;7;7","DOMÉNICO RIBATTI;STEFANIA TOMMASI;MICHELE GUIDA;DOMENICO GALETTA;AMALIA AZZARITI;ROSA MARIA IACOBAZZI;MICHELE AMMENDOLA;RAFFAELE DE LUCA;NICOLA SILVESTRIS;LETIZIA PORCELLI;SABINO STRIPPOLI;NUNZIO DENORA;SIMONA DE SUMMA;GIUSI GRAZIANO;GIROLAMO RANIERI;ROSAMARIA PINTO;ILARIA MARECH;GIOVANNI DE SIMONE;MARIO SCARTOZZI;ANITA MANGIA","1.97;1.08;1.03;1;0.99;0.94;0.85;0.84;0.78;0.78;0.76;0.69;0.68;0.68;0.67;0.6;0.59;0.57;0.56;0.54","STEFANIA TOMMASI;MICHELE GUIDA;NICOLA SILVESTRIS;DOMENICO GALETTA;DOMÉNICO RIBATTI;MICHELE AMMENDOLA;ROSA MARIA IACOBAZZI;AMALIA AZZARITI;GIROLAMO RANIERI;SABINO STRIPPOLI;RAFFAELE DE LUCA;LETIZIA PORCELLI;GIUSI GRAZIANO;COSMO DAMIANO GADALETA;ORONZO BRUNETTI;ILARIA MARECH;SIMONA DE SUMMA;ATTILIO GUARINI;VITO LORUSSO;ROSA PATRUNO","12;12;12;11;11;9;9;9;8;8;7;7;7;7;7;7;6;6;6;5","DOMÉNICO RIBATTI;STEFANIA TOMMASI;MICHELE GUIDA;DOMENICO GALETTA;AMALIA AZZARITI;ROSA MARIA IACOBAZZI;MICHELE AMMENDOLA;RAFFAELE DE LUCA;NICOLA SILVESTRIS;LETIZIA PORCELLI;SABINO STRIPPOLI;SIMONA DE SUMMA;GIUSI GRAZIANO;GIROLAMO RANIERI;ROSAMARIA PINTO;ILARIA MARECH;GIOVANNI DE SIMONE;ANITA MANGIA;COSMO DAMIANO GADALETA;ANNAMARIA CATINO","1.97;1.08;1.03;1;0.99;0.94;0.85;0.84;0.78;0.78;0.76;0.68;0.68;0.67;0.6;0.59;0.57;0.54;0.54;0.53","STEFANIA TOMMASI;ADAM P. BUTLER;ALAIN VIARI;ALASTAIR M. THOMPSON;ANDREA L. RICHARDSON;ANIETA M. SIEUWERTS;ANITA LANGERØD;ANNE VINCENT‐SALOMON;ANNEGIEN BROEKS;ANNE‐LISE BØRRESEN‐DALE;ANTHONY J. GILL;AQUILA FATIMA;ARIE B. BRINKMAN;CARLOS CALDAS;CHRISTINE DESMEDT;COLIN A. PURDIE;EWAN BIRNEY;F. GERMÁN RODRÍGUEZ-GONZÁLEZ;HELEN DAVIES;HENDRIK G. STUNNENBERG","2253;2065;2065;2065;2065;2065;2065;2065;2065;2065;2065;2065;2065;2065;2065;2065;2065;2065;2065;2065","STEFANIA TOMMASI;DOMÉNICO RIBATTI;MICHELE GUIDA;NICOLA SILVESTRIS;ROSA MARIA IACOBAZZI;GIUSI GRAZIANO;GENNARO CORMIO;ANITA MANGIA;AMALIA AZZARITI;GIOVANNI DE SIMONE;LETIZIA PORCELLI;SIMONA DE SUMMA;COSMO DAMIANO GADALETA;GIROLAMO RANIERI;KATIA DANZA;SIMONA D’AMORE;SILKE KROL;ORONZO BRUNETTI;ROSA CINZIA SASSO;ANNA ELISA QUATRALE","2216;445;380;268;196;182;163;155;131;130;125;120;119;119;108;106;102;100;100;94","MICHELE GUIDA;NICOLA SILVESTRIS;DOMENICO GALETTA;DOMÉNICO RIBATTI;STEFANIA TOMMASI;GIROLAMO RANIERI;ROSA MARIA IACOBAZZI;AMALIA AZZARITI;SABINO STRIPPOLI;COSMO DAMIANO GADALETA;FRANCESCO GIOTTA;RAFFAELE DE LUCA;GIUSI GRAZIANO;ILARIA MARECH;ORONZO BRUNETTI;SIMONA DE SUMMA;LETIZIA PORCELLI;ROSAMARIA PINTO;ANITA MANGIA;ATTILIO GUARINI","12;12;11;11;10;8;8;7;7;7;7;7;7;7;6;6;5;5;5;5","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;PSYCHOLOGY;MATHEMATICS;COMPUTER SCIENCE;ECONOMICS;ENGINEERING;GEOGRAPHY;MATERIALS SCIENCE;SOCIOLOGY;ART","105;47;17;7;6;5;4;4;3;3;3;3;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;PATHOLOGY;BIOCHEMISTRY;SURGERY;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;ENVIRONMENTAL HEALTH;PALEONTOLOGY;PHARMACOLOGY;RADIOLOGY;CELL BIOLOGY;BIOTECHNOLOGY;COMPUTATIONAL BIOLOGY;ENDOCRINOLOGY;ORGANIC CHEMISTRY;STEREOCHEMISTRY;DERMATOLOGY;GENERAL SURGERY;GYNECOLOGY;MEDICAL PHYSICS;NANOTECHNOLOGY;NUCLEAR MEDICINE;NURSING;PSYCHIATRY;UROLOGY","85;50;36;27;23;23;22;22;20;9;8;8;8;6;4;4;4;4;4;3;3;3;3;3;3;3;3;3","CANCER;CHEMOTHERAPY;GENE;ANGIOGENESIS;LUNG CANCER;RETROSPECTIVE COHORT STUDY;IMMUNOHISTOCHEMISTRY;ADVERSE EFFECT;CLINICAL TRIAL;MAST CELL;MELANOMA;POPULATION;IN VITRO;MULTIVARIATE ANALYSIS;APOPTOSIS;DISEASE;HEPATOCELLULAR CARCINOMA;INFLAMMATION;RECEPTOR;ANGIOSARCOMA;STAGE (STRATIGRAPHY)","63;28;22;19;11;11;10;9;9;8;8;8;7;7;6;6;6;6;6;5;5","COLORECTAL CANCER;BREAST CANCER;PROGRESSION-FREE SURVIVAL;PROGRESSIVE DISEASE;METASTASIS;TRYPTASE;ADENOCARCINOMA;MUTATION;COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS;GENOTYPE;PHENOTYPE;SORAFENIB;BLEOMYCIN;GENE EXPRESSION;GENOME;LYMPHADENECTOMY;MICRORNA;PHASES OF CLINICAL RESEARCH;VASCULAR ENDOTHELIAL GROWTH FACTOR;CISPLATIN;EPIDERMAL GROWTH FACTOR RECEPTOR;GASTRECTOMY;GEMCITABINE;IMMUNOTHERAPY;METASTATIC MELANOMA;NEUTROPENIA;PERFORMANCE STATUS;PI3K/AKT/MTOR PATHWAY;SOFT TISSUE SARCOMA;SUNITINIB","21;14;8;8;7;7;6;6;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;KRAS;OXALIPLATIN;IRINOTECAN;ELECTROCHEMOTHERAPY;TRASTUZUMAB;CETUXIMAB;GERMLINE MUTATION;METASTATIC BREAST CANCER;NIVOLUMAB;SINGLE-NUCLEOTIDE POLYMORPHISM;TRANSCRIPTOME;ADIPONECTIN;COPY-NUMBER VARIATION;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;GEFITINIB;MELANOCORTIN 1 RECEPTOR;MONOCLONAL;MUCOADHESION;PAZOPANIB;PRIMARY TUMOR;ROS1;TRANSLOCATOR PROTEIN","8;6;6;5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;FEMALE;MALE;ANTINEOPLASTIC AGENTS;BREAST NEOPLASMS;MIDDLE AGED;ADULT;AGED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;NEOVASCULARIZATION, PATHOLOGIC;MELANOMA;BIOMARKERS, TUMOR;LIVER NEOPLASMS;STOMACH NEOPLASMS;RETROSPECTIVE STUDIES;ANIMALS;COLORECTAL NEOPLASMS;AGED, 80 AND OVER;ANGIOGENESIS INHIBITORS","56;52;43;34;33;32;32;27;26;23;23;22;18;18;17;16;15;15;14;13","ADVANCEMENTS IN LUNG CANCER RESEARCH;ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE;GASTRIC CANCER RESEARCH AND TREATMENT;VASCULAR TUMORS AND ANGIOSARCOMA;HER2 SIGNALING IN BREAST CANCER TREATMENT;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CANCER IMMUNOTHERAPY;COLORECTAL CANCER RESEARCH AND TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;MOLECULAR MECHANISMS OF ANGIOGENESIS AND VASCULAR FUNCTION;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;HEPATOCELLULAR CARCINOMA;LIPID METABOLISM IN CANCER PATHOGENESIS;MANAGEMENT OF BRAIN METASTASES IN CANCER PATIENTS;MELANIN PIGMENTATION IN MAMMALIAN SKIN;MOLECULAR RESEARCH ON BREAST CANCER;MUCOSAL DRUG DELIVERY SYSTEMS;APPLICATIONS OF ELECTROPORATION IN BIOTECHNOLOGY AND FOOD PROCESSING","8;7;6;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;1","BREAST CANCER;PROGRESSION-FREE SURVIVAL;MELANOMA;TRYPTASE;GASTRIC CANCER;TREATMENT;TUMOR MICROENVIRONMENT;BRAF GENE;CANCER;EGFR MUTATIONS;ELECTROCHEMOTHERAPY;LYMPHADENECTOMY;TRASTUZUMAB;TUMOR ANGIOGENESIS;ANGIOSARCOMA;BRCA1;CANCER SUSCEPTIBILITY;EXPANDED ACCESS;FOLFIRI;FOLFOX","10;8;7;7;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3","CANCER PATIENTS;BREAST CANCER;GASTRIC CANCER;COLORECTAL CANCER;RETROSPECTIVE ANALYSIS;LUNG CANCER;PATIENTS PTS;PATIENTS TREATED;MAST CELLS;ADVANCED GASTRIC;CELL LUNG;ELDERLY PATIENTS;GROWTH FACTOR;MICROVASCULAR DENSITY;MULTICENTER RETROSPECTIVE;RETROSPECTIVE STUDY;ACCESS PROGRAMME;ANGIOSARCOMAS EFFICACY;CELLS POSITIVE;CLINICAL ACTIVITY;EPIDERMAL GROWTH;EXPANDED ACCESS;FACTOR RECEPTOR;HCC PATIENTS;HEPATOCELLULAR CARCINOMA;HER-POSITIVE METASTATIC;LOCAL TREATMENT;MAST CELL;METASTATIC BREAST;METASTATIC COLORECTAL","14;11;9;8;8;7;6;6;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","BREAST CANCER;RESPONSE RATE;PROGRESSION-FREE SURVIVAL;HR CI;SURVIVAL PFS;MONTHS NA;ADVERSE EVENTS;MEDIAN PFS;BARI ITALY;GASTRIC CANCER;MONTHS CI;PATIENTS TREATED;SURVIVAL OS;CANCER PATIENTS;COLORECTAL CANCER;PALLIATIVE SURGERY;CARCINOMA PTS;COX REGRESSION;ELDERLY POPULATION;FREE SURVIVAL;GIOVANNI PAOLO;MEDICAL ONCOLOGY;PAOLO II;PROGRESSION FREE;ROME ITALY;DISEASE CONTROL;GROWTH FACTOR;MEDIAN AGE;MEDIAN OS;PARTIAL RESPONSE","25;23;17;16;16;15;14;14;13;13;13;13;13;11;11;11;10;10;10;10;10;10;10;10;10;9;9;9;9;9",49,0.43,8.55,5,1,3.25,4.25,1.5,6.25,0,1,5,1,1,4,0,4.5,1,2.75,3.5,2.25,0,0,64,64,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,8,251,0.76,1,1,32,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","1;1;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES","1;1;1","CANCER","1","5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS","1;1","MELANOMA","1","5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1;1",1,6e+06,214285.71,7,28,9,1,47,560587.494574564,0.205141928981621,"ABBVIE (UNITED KINGDOM);ACTELION (SWITZERLAND);AMGEN (UNITED KINGDOM);ASTELLAS PHARMA (NETHERLANDS);ASTRAZENECA (SWEDEN);BAYER (GERMANY);BELGIAN HEALTH CARE KNOWLEDGE CENTRE;CSL (GERMANY);ELI LILLY (UNITED KINGDOM);ERASMUS MC;ERASMUS UNIVERSITY ROTTERDAM;EUROPEAN INSTITUTE OF ONCOLOGY;ISTITUTO TUMORI BARI;JANSSEN (BELGIUM);KU LEUVEN;MERCK (GERMANY);MSD (UNITED STATES);NEWCASTLE UNIVERSITY;NOVARTIS (SWITZERLAND);PFIZER (UNITED KINGDOM)","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);H2020-JTI-IMI2-2015-05-TWO-STAGE (CALL FOR PROPOSAL);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1;1","38 ECONOMICS;3801 APPLIED ECONOMICS;52 PSYCHOLOGY","1;1;1","CLINICAL RESEARCH","1","GENERIC HEALTH RELEVANCE","1","8.4 RESEARCH DESIGN AND METHODOLOGIES (HEALTH SERVICES)","1",NA,NA,NA,NA,"A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1",NA,NA,6,"PUBLIC LIBRARY OF SCIENCE","6","32 BIOMEDICAL AND CLINICAL SCIENCES;49 MATHEMATICAL SCIENCES;3202 CLINICAL SCIENCES;4905 STATISTICS","4;4;2;2",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_TUMORIBARI",2017,123,14.4878048780488,2.69918699186992,0.235772357723577,0.308943089430894,0.268292682926829,2.69918699186992,1.16,1.65217391304348,1.43478260869565,0.682926829268293,0,65,34,13,2,0.53,0.28,0.11,0.02,25.41,0.86196711472341,4.84718498659517,0.235772357723577,0.943089430894309,0.471,0.407,0.315,0.412,"NICOLA SILVESTRIS;DOMENICO GALETTA;MARIO SCARTOZZI;ORONZO BRUNETTI;LUCA FALOPPI;ROSA MARIA IACOBAZZI;DOMÉNICO RIBATTI;ANDREA CASADEI‐GARDINI;NUNZIO DENORA;DANIELE SANTINI;SIMONA DE SUMMA;HÉCTOR SOTO PARRÀ;ATTILIO GUARINI;ANGELO DELMONTE;GIUSEPPE APRILE;FILIPPO DE MARINIS;SALVATORE PISCONTI;D. TURCI;FRANCESCO GROSSI;STEFANO CASCINU","18;17;13;12;10;10;10;10;9;9;8;8;8;8;8;7;7;7;7;7","NICOLA SILVESTRIS;DOMÉNICO RIBATTI;DOMENICO GALETTA;ROSA MARIA IACOBAZZI;NUNZIO DENORA;MARIO SCARTOZZI;SIMONA DE SUMMA;LUCA FALOPPI;ANDREA CASADEI‐GARDINI;GIOVANNI DE SIMONE;ORONZO BRUNETTI;AMALIA AZZARITI;ANITA MANGIA;STEFANIA TOMMASI;INES ABBATE;ANNARITA FANIZZI;ANGELO PARADISO;SIMONA RUGGIERI;ANNAMARIA CATINO;BRUNELLA PILATO","1.38;1.24;1.11;1.11;0.96;0.95;0.86;0.82;0.82;0.78;0.76;0.74;0.7;0.67;0.67;0.66;0.62;0.59;0.57;0.54","NICOLA SILVESTRIS;DOMENICO GALETTA;ORONZO BRUNETTI;ROSA MARIA IACOBAZZI;DOMÉNICO RIBATTI;SIMONA DE SUMMA;ATTILIO GUARINI;AMALIA AZZARITI;ANNAMARIA CATINO;GIOVANNI DE SIMONE;GIROLAMO RANIERI;COSMO DAMIANO GADALETA;ANITA MANGIA;INES ABBATE;FRANCESCO GIOTTA;STEFANIA TOMMASI;RAFFAELE DE LUCA;LETIZIA PORCELLI;ROBERTO TAMMA;BRUNELLA PILATO","18;17;12;10;10;8;8;7;7;7;6;6;6;6;6;5;5;5;5;5","NICOLA SILVESTRIS;DOMÉNICO RIBATTI;DOMENICO GALETTA;ROSA MARIA IACOBAZZI;SIMONA DE SUMMA;GIOVANNI DE SIMONE;ORONZO BRUNETTI;AMALIA AZZARITI;ANITA MANGIA;STEFANIA TOMMASI;INES ABBATE;ANNARITA FANIZZI;ANGELO PARADISO;ANNAMARIA CATINO;BRUNELLA PILATO;ATTILIO GUARINI;ANTONELLA DANIELE;GIROLAMO RANIERI;COSMO DAMIANO GADALETA;ROBERTO TAMMA","1.38;1.24;1.11;1.11;0.86;0.78;0.76;0.74;0.7;0.67;0.67;0.66;0.62;0.57;0.54;0.54;0.52;0.52;0.52;0.51","SILKE KROL;AHMET BEKDEMIR;BARBARA SANAVIO;CAROLINE TAPPAREL;CHIARA MARTINELLI;DAVID LEMBO;EMMA‐ROSE JANEČEK;FRANCESCO STELLACCI;JAN HODEK;JAN WEBER;JEAN‐FRANÇOIS ELÉOUËT;LAURENT KAISER;LELA VUKOVIĆ;MANUELA DONALISIO;MARCO D’ALICARNASSO;MARIE GALLOUX;MARIE MUELLER;MARIE‐ANNE RAMEIX‐WELTI;MARTA VALLINO;PATRIZIA ANDREOZZI","375;357;357;357;357;357;357;357;357;357;357;357;357;357;357;357;357;357;357;357","SILKE KROL;VITO LORUSSO;ATTILIO GUARINI;ALESSANDRA CASTEGNA;ALESSIO MENGA;GIUSEPPE COLUCCI;V. SARACINO;ANNAMARIA QUINTO;GIACOMA DE TULLIO;ROSA MARIA IACOBAZZI;NICOLA SILVESTRIS;ORONZO BRUNETTI;STEFANIA TOMMASI;ANTONIO MOSCHETTA;DOMÉNICO RIBATTI;AMALIA AZZARITI;ANNARITA FANIZZI;SIMONA DE SUMMA;LETIZIA PORCELLI;DOMENICO GALETTA","375;348;347;315;315;310;310;279;279;276;264;229;206;187;187;175;143;134;132;117","DOMENICO GALETTA;NICOLA SILVESTRIS;ORONZO BRUNETTI;DOMÉNICO RIBATTI;ROSA MARIA IACOBAZZI;STEFANIA TOMMASI;ATTILIO GUARINI;AMALIA AZZARITI;ANNAMARIA CATINO;GIOVANNI DE SIMONE;ANITA MANGIA;FRANCESCO GIOTTA;INES ABBATE;COSMO DAMIANO GADALETA;GIROLAMO RANIERI;SIMONA DE SUMMA;ANGELO PARADISO;ELISABETTA MONTAGNA;RAFFAELE DE LUCA;ANTONELLA DANIELE","17;16;12;10;9;9;8;7;7;7;6;6;6;6;6;6;5;5;5;5","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;MATERIALS SCIENCE;ECONOMICS;PSYCHOLOGY;BUSINESS;ENGINEERING;MATHEMATICS;POLITICAL SCIENCE;GEOGRAPHY;SOCIOLOGY","110;63;20;12;7;7;4;3;2;2;2;2;1;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;BIOCHEMISTRY;PATHOLOGY;GASTROENTEROLOGY;SURGERY;GENETICS;PALEONTOLOGY;CELL BIOLOGY;ENDOCRINOLOGY;IMMUNOLOGY;BIOTECHNOLOGY;ENVIRONMENTAL HEALTH;PHARMACOLOGY;ARTIFICIAL INTELLIGENCE;NURSING;PSYCHIATRY;BIOPHYSICS;OPTICS;RADIOLOGY","95;60;33;28;25;20;19;18;16;13;12;11;8;8;7;6;6;6;5;5;5","CANCER;GENE;ADVERSE EFFECT;CHEMOTHERAPY;LUNG CANCER;DISEASE;STAGE (STRATIGRAPHY);COHORT;ANGIOGENESIS;HEPATOCELLULAR CARCINOMA;IMMUNOHISTOCHEMISTRY;CLINICAL TRIAL;EXPANDED ACCESS;IN VITRO;IN VIVO;POPULATION;RECEPTOR;BIOMARKER;LYMPHOMA;VEGF RECEPTORS","69;25;22;20;20;14;14;13;12;12;11;8;8;8;8;8;8;6;6;6","BREAST CANCER;COLORECTAL CANCER;COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS;IMMUNOTHERAPY;SORAFENIB;CLINICAL ENDPOINT;METASTASIS;PROGRESSIVE DISEASE;DOCETAXEL;TOLERABILITY;OVARIAN CANCER;VASCULAR ENDOTHELIAL GROWTH FACTOR;ADENOCARCINOMA;CYTOTOXICITY;GENOTYPE;HAZARD RATIO;PHASES OF CLINICAL RESEARCH;TRYPTASE;ANTIEMETIC;DOWNREGULATION AND UPREGULATION;EPIDERMAL GROWTH FACTOR RECEPTOR;GENE EXPRESSION;METFORMIN;MICRORNA;NEUTROPENIA;PHENOTYPE;PROGRESSION-FREE SURVIVAL;TRANSCRIPTION FACTOR","18;15;11;11;11;7;7;7;6;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","NIVOLUMAB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;KRAS;IRINOTECAN;METASTATIC BREAST CANCER;CETUXIMAB;CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING;NUCLEAR RECEPTOR;OXALIPLATIN;ADIPOKINE;ANAPLASTIC LYMPHOMA KINASE;ANGIOPOIETIN;ANGIOPOIETIN 2;CRIZOTINIB;CYTOREDUCTIVE SURGERY;DASATINIB;DNA METHYLATION;ERLOTINIB;NON-SMALL CELL LUNG CANCER (NSCLC);TAXANE;TRASTUZUMAB","10;8;7;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2",";HUMANS;FEMALE;LIVER NEOPLASMS;MALE;AGED;MIDDLE AGED;ADULT;ANTINEOPLASTIC AGENTS;BREAST NEOPLASMS;CARCINOMA, HEPATOCELLULAR;LUNG NEOPLASMS;AGED, 80 AND OVER;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;COLORECTAL NEOPLASMS;ITALY;NIACINAMIDE;CARCINOMA, NON-SMALL-CELL LUNG;NEOVASCULARIZATION, PATHOLOGIC;ANIMALS","72;44;31;26;26;25;25;23;20;20;20;19;16;16;13;13;12;10;10;9","CANCER IMMUNOTHERAPY;ADVANCEMENTS IN LUNG CANCER RESEARCH;GASTRIC CANCER RESEARCH AND TREATMENT;MOLECULAR MECHANISMS OF ANGIOGENESIS AND VASCULAR FUNCTION;ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;EFFICACY AND RESISTANCE IN CML TREATMENT;HEPATOCELLULAR CARCINOMA;LYMPHOID NEOPLASMS;PREVENTION AND MANAGEMENT OF POSTOPERATIVE NAUSEA AND VOMITING;ROLE OF AMP-ACTIVATED PROTEIN KINASE IN CELLULAR METABOLISM;CHOLANGIOCARCINOMA;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;EPIGENETIC MODIFICATIONS AND THEIR FUNCTIONAL IMPLICATIONS;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS","8;6;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","EXPANDED ACCESS;BREAST CANCER;CLINICAL ENDPOINT;TOLERABILITY;CONCORDANCE;DISCONTINUATION;FOLFIRI;GASTRIC CANCER;TRYPTASE;ANGIOGENIC SIGNALING;BIOMARKERS FOR IMMUNOTHERAPY;CANCER RISK;CHEMOTHERAPY-INDUCED NAUSEA;DRUG DELIVERY;EGFR MUTATIONS;METASTATIC COLORECTAL CANCER;METASTATIC GASTRIC CANCER;METFORMIN;MICRORNAS;PROGRESSION-FREE SURVIVAL","8;7;7;6;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","CANCER PATIENTS;LUNG CANCER;BREAST CANCER;EXPANDED ACCESS;ACCESS PROGRAMME;CELL LUNG;HEPATOCELLULAR CARCINOMA;NON-SMALL CELL;PATIENTS PTS;COLORECTAL CANCER;METASTATIC COLORECTAL;PATIENTS RECEIVING;RECEIVING SORAFENIB;ADVANCED HCC;ADVANCED SQUAMOUS;GASTRIC CANCER;HCC PATIENTS;ITALIAN EXPANDED;ITALIAN NIVOLUMAB;PROGRAMME EAP;SQUAMOUS NSCLC;ACCESS PROGRAM;CANCER NSCLC;CHEMOTHERAPY-INDUCED NAUSEA;CLINICAL OUTCOME;MAST CELLS;MCRC PATIENTS;NIVOLUMAB EXPANDED;OVARIAN CANCER;PATIENTS TREATED","16;14;12;10;7;7;7;7;6;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3","BREAST CANCER;ADVERSE EVENTS;LUNG CANCER;CANCER PATIENTS;BARI ITALY;GIOVANNI PAOLO;PAOLO II;MEDIAN OS;PROGRESSION-FREE SURVIVAL;MEDIAN FOLLOW-UP;ISTITUTO TUMORI;TUMORI GIOVANNI;II BARI;IRCCS ISTITUTO;PATIENTS RECEIVING;RESPONSE RATE;SURVIVAL OS;COMMON TERMINOLOGY;PATIENTS PTS;TERMINOLOGY CRITERIA;ADMINISTERED INTRAVENOUSLY;DISEASE CONTROL;IIIBSTAGE IV;MEDICAL ONCOLOGY;PATIENTS TREATED;PRIOR SYSTEMIC;STAGE IIIBSTAGE;SYSTEMIC TREATMENT;ADVISORY ROLE;BRISTOL-MYERS SQUIBB","28;26;22;21;20;16;16;15;15;14;13;13;12;12;12;12;12;11;11;11;10;10;10;10;10;10;10;10;9;9",49,0.4,3.6,3,1,3.5,1.75,3.5,3.5,1,1,3,2,1,3,0,0,1,4.25,3,4.5,0,0,54,54,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,4,60,0.85,1,1,70,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","1;1;1","CANCER;CLINICAL RESEARCH;HEMATOLOGY;LYMPHOMA;RARE DISEASES","1;1;1;1;1","CANCER","1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","1;1","NON-HODGKIN'S LYMPHOMA","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,"TAYLOR & FRANCIS GROUP","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES","2;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES","1;1;1;1","CANCER","1","6.1 PHARMACEUTICALS;6.4 SURGERY","1;1","CLINICAL","1","CLINICAL MEDICINE AND SCIENCE","1","STOMACH CANCER","1",NA,NA
"IRCCS_TUMORIBARI",2018,101,15.990099009901,2.2970297029703,0.227722772277228,0.207920792079208,0.287128712871287,1.99137931034483,1,1.16666666666667,1.16,0.584158415841584,2,63,26,5,0,0.62,0.26,0.05,0,28.89,0.946992536742116,4.56387665198238,0.287128712871287,0.97029702970297,0.448,0.362,0.308,0.303,"NICOLA SILVESTRIS;DOMÉNICO RIBATTI;DANIELE SANTINI;MARIO SCARTOZZI;PAOLO MARCHETTI;ATTILIO GUARINI;GENNARO CORMIO;DOMENICO GALETTA;SANDRO BARNI;SILKE KROL;ROSA MARIA IACOBAZZI;STEFANIA TOMMASI;SIMONA DE SUMMA;ANITA MANGIA;ANNAMARIA CATINO;GIUSEPPE APRILE;NUNZIO DENORA;GIORGIA MANGILI;FILIPPO DE BRAUD;ANGELO VACCA","10;8;8;7;7;7;7;6;6;6;5;5;5;5;5;5;5;4;4;4","DOMÉNICO RIBATTI;M. BETTIOL;NICOLA SILVESTRIS;SILKE KROL;VITTORIO DIDONNA;NUNZIO DENORA;GIUSEPPE FELICE MANGIATORDI;DOMENICO ALBERGA;CRISTIAN BORRAZZO;ENRICO PREZIOSI;ROSA MARIA IACOBAZZI;SIMONA DE SUMMA;DOMENICO GALETTA;ATTILIO GUARINI;ROBERTO TAMMA;ORAZIO NICOLOTTI;DANIELA TRISCIUZZI;GENNARO CORMIO;ANNAMARIA CATINO;ANITA MANGIA","2.55;0.89;0.61;0.6;0.59;0.52;0.51;0.51;0.5;0.5;0.5;0.47;0.47;0.45;0.43;0.42;0.42;0.41;0.4;0.39","NICOLA SILVESTRIS;DOMÉNICO RIBATTI;ATTILIO GUARINI;GENNARO CORMIO;DOMENICO GALETTA;SILKE KROL;ROSA MARIA IACOBAZZI;STEFANIA TOMMASI;SIMONA DE SUMMA;ANITA MANGIA;ANNAMARIA CATINO;GIUSEPPE FELICE MANGIATORDI;ROBERTO TAMMA;ANNA SCATTONE;DANIELE LA FORGIA;GIUSI GRAZIANO;VITTORIO DIDONNA;M. BETTIOL;FRANCESCO GIULIANI;ORONZO BRUNETTI","10;8;7;7;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4","DOMÉNICO RIBATTI;M. BETTIOL;NICOLA SILVESTRIS;SILKE KROL;VITTORIO DIDONNA;GIUSEPPE FELICE MANGIATORDI;ROSA MARIA IACOBAZZI;SIMONA DE SUMMA;DOMENICO GALETTA;ATTILIO GUARINI;ROBERTO TAMMA;GENNARO CORMIO;ANNAMARIA CATINO;ANITA MANGIA;RAFFAELE DE LUCA;GIROLAMO RANIERI;DANIELE LA FORGIA;ANNARITA FANIZZI;ALESSIO MENGA;STEFANIA TOMMASI","2.55;0.89;0.61;0.6;0.59;0.51;0.5;0.47;0.47;0.45;0.43;0.41;0.4;0.39;0.36;0.35;0.35;0.35;0.35;0.33","PAOLO MARCHETTI;STEFANIA TOMMASI;DOMÉNICO RIBATTI;CINZIA DI FRANCO;SILKE KROL;D. TURCI;DIANA GIANNARELLI;DOMENICO ALBERGA;GIUSEPPE FELICE MANGIATORDI;FRANCESCO GIOTTA;DANIELE LA FORGIA;ANTONIO RUSSO;ALAIN GELIBTER;ARMANDO LÓPEZ‐GUILLERMO;BRIGITTE HOLZER;ELEONORA MACCHIA;FABRIZIO TORRICELLI;GAETANO SCAMARCIO;GERARDO PALAZZO;KYRIAKI MANOLI","324;314;311;268;260;247;247;235;235;218;214;212;211;203;200;200;200;200;200;200","DOMÉNICO RIBATTI;STEFANIA TOMMASI;SILKE KROL;FRANCESCO GIOTTA;DANIELE LA FORGIA;ANNA SCATTONE;ANITA MANGIA;DOMENICO GALETTA;SIMONA DE SUMMA;ATTILIO GUARINI;GIUSI GRAZIANO;GENNARO CORMIO;SABINO CIAVARELLA;ALFREDO ZITO;ANTONIO MOSCHETTA;CLAUDIO TRIPODO;F. MELE;G. SIMONE;GIACOMO LOSETO;GIUSEPPINA OPINTO","311;298;260;218;214;198;194;180;157;143;129;123;119;110;110;110;110;110;110;110","NICOLA SILVESTRIS;DOMÉNICO RIBATTI;ATTILIO GUARINI;STEFANIA TOMMASI;SILKE KROL;DOMENICO GALETTA;GENNARO CORMIO;ANITA MANGIA;ANNAMARIA CATINO;ROSA MARIA IACOBAZZI;ANNA SCATTONE;DANIELE LA FORGIA;FRANCESCO GIOTTA;FRANCESCO GIULIANI;GIUSI GRAZIANO;M. BETTIOL;VITO LORUSSO;VITTORIO DIDONNA;SIMONA DE SUMMA;GIROLAMO RANIERI","9;8;7;7;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;3","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;MATERIALS SCIENCE;MATHEMATICS;ECONOMICS;ENGINEERING;PHILOSOPHY;PSYCHOLOGY;SOCIOLOGY","86;44;21;13;9;7;6;3;2;2;2;1","INTERNAL MEDICINE;ONCOLOGY;BIOCHEMISTRY;SURGERY;CANCER RESEARCH;GASTROENTEROLOGY;PATHOLOGY;GENETICS;IMMUNOLOGY;OPTICS;RADIOLOGY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;ORGANIC CHEMISTRY;NURSING;PALEONTOLOGY;PHARMACOLOGY;ARTIFICIAL INTELLIGENCE;MEDICAL PHYSICS;NUCLEAR MEDICINE","71;39;26;20;19;18;18;16;16;8;8;7;7;7;6;6;6;5;5;5","CANCER;GENE;CHEMOTHERAPY;ADVERSE EFFECT;LUNG CANCER;COHORT;IN VITRO;RETROSPECTIVE COHORT STUDY;CONFIDENCE INTERVAL;DISEASE;ANTIBODY;IMMUNE SYSTEM;MULTIVARIATE ANALYSIS;POPULATION;ANGIOGENESIS;ENZYME;INCIDENCE (GEOMETRY);PROPORTIONAL HAZARDS MODEL;QUALITY OF LIFE (HEALTHCARE);RECEPTOR;STAGE (STRATIGRAPHY)","50;15;14;10;10;8;8;8;7;7;6;6;6;6;5;5;5;5;5;5;5","BREAST CANCER;IMMUNOTHERAPY;TOLERABILITY;COLORECTAL CANCER;UNIVARIATE ANALYSIS;CLINICAL ENDPOINT;HAZARD RATIO;OVARIAN CANCER;PROGRESSION-FREE SURVIVAL;TUMOR MICROENVIRONMENT;ADENOCARCINOMA;B CELL;GENE EXPRESSION;METASTASIS;ADJUVANT THERAPY;BLOOD–BRAIN BARRIER;CHROMOSOME;COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS;CUMULATIVE INCIDENCE;CYTOTOXICITY;FOLLICULAR LYMPHOMA;GENOTYPE;GERIATRIC ONCOLOGY;GERMLINE;MALIGNANT PLEURAL EFFUSION;MONOAMINE OXIDASE;MONOCLONAL ANTIBODY;MULTICENTER STUDY;MUTATION;NEUTROPENIA;NITRIC OXIDE SYNTHASE;PHASES OF CLINICAL RESEARCH;QUALITY ASSURANCE;RITUXIMAB;SCINTILLATOR;T CELL;TRYPTASE;TUBULIN;TUMOR PROGRESSION","17;8;6;5;5;4;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","NIVOLUMAB;MAMMOGRAPHY;METASTATIC BREAST CANCER;ANTHRACYCLINE;CRIZOTINIB;GERMINAL CENTER;GERMLINE MUTATION;LYSO-;MONOCLONAL;PEMBROLIZUMAB;SINGLE-NUCLEOTIDE POLYMORPHISM;TAXANE;TRASTUZUMAB;5-HT RECEPTOR;ABCA1;ADJUVANT CHEMOTHERAPY;ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE;ANAPLASTIC LYMPHOMA KINASE;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;ANTIFOLATE;ANTIGEN-PRESENTING CELL;ANTIMITOTIC AGENT;APREPITANT;AROMATASE;BETA CELL;BOMBESIN;BRUTON'S TYROSINE KINASE;CANCER-ASSOCIATED FIBROBLASTS;CD163;CD28;CD40;CD86;CELL CYCLE CHECKPOINT;CETUXIMAB;CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING;CIRCULATING TUMOR CELL;COMPARATIVE GENOMIC HYBRIDIZATION;CRITERION VALIDITY;CTLA-4;CYCLIN-DEPENDENT KINASE 1;DASATINIB;DEBULKING;DIGITAL IMAGE;DIGLYCIDYL ETHER;DIPEPTIDYL PEPTIDASE-4;DOSE-VOLUME HISTOGRAM;ENOS;ESTROGEN RECEPTOR;EXOME SEQUENCING;FAMILIAL ADENOMATOUS POLYPOSIS;FLUORESCENCE IN SITU HYBRIDIZATION;FOLINIC ACID;GELATINASES;GENE EXPRESSION PROFILING;GENOTYPING;GERIATRIC DEPRESSION SCALE;HAPLOTYPE;HES1;HORMONE RECEPTOR;IBRUTINIB;INTERLEUKIN 33;IPILIMUMAB;IRINOTECAN;KRAS;LYMPHANGIOGENESIS;METHYLTRANSFERASE;MICROARRAY;MONOAMINE OXIDASE A;MONOAMINE OXIDASE B;MTORC1;MUCOADHESION;MYELOPROLIFERATIVE NEOPLASM;NEOADJUVANT THERAPY;NINTEDANIB;OXALIPLATIN;PANCREATIC ISLETS;PARGYLINE;POLY ADP RIBOSE POLYMERASE;RASAGILINE;REPRESSOR;REVERSE CHOLESTEROL TRANSPORT;ROS1;SOMATIC HYPERMUTATION;SPINDLE APPARATUS;STEAROYL-COA DESATURASE;SUPERPARAMAGNETISM;SYSTEMIC THERAPY;TERIFLUNOMIDE;TRABECTEDIN;TRANSLOCATOR PROTEIN","5;4;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MIDDLE AGED;;AGED;ADULT;BREAST NEOPLASMS;MALE;AGED, 80 AND OVER;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ITALY;LUNG NEOPLASMS;PROGNOSIS;RETROSPECTIVE STUDIES;ANIMALS;CARCINOMA, NON-SMALL-CELL LUNG;NEOPLASM RECURRENCE, LOCAL;YOUNG ADULT;ANTINEOPLASTIC AGENTS;BIOMARKERS, TUMOR","61;43;38;36;36;33;33;30;23;19;18;13;12;12;11;11;11;11;10;10","CANCER IMMUNOTHERAPY;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;LYMPHOID NEOPLASMS;ADVANCEMENTS IN LUNG CANCER RESEARCH;GASTRIC CANCER RESEARCH AND TREATMENT;INFLAMMATION'S ROLE IN CANCER DEVELOPMENT AND PROGRESSION;NANOPARTICLE-BASED DRUG DELIVERY SYSTEMS;ROLE OF MAST CELLS IN IMMUNOREGULATION AND DISEASE;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;HER2 SIGNALING IN BREAST CANCER TREATMENT;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;PANCREATIC CANCER RESEARCH AND TREATMENT;POLYOXOMETALATE CLUSTERS AND MATERIALS;RADIOTHERAPY PHYSICS AND TECHNOLOGY;ROLE OF FIBROBLAST ACTIVATION IN CANCER PROGRESSION;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH","6;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;1;1;1","BREAST CANCER;CANCER;TOLERABILITY;BIOMARKERS FOR IMMUNOTHERAPY;PROGRESSION-FREE SURVIVAL;CLINICAL ENDPOINT;UNIVARIATE ANALYSIS;BIOMARKER ANALYSIS;CANCER SUSCEPTIBILITY;GASTRIC CANCER;METASTATIC GASTRIC CANCER;REGIMEN;TUMOR MICROENVIRONMENT;ADJUVANT THERAPY;BREAST MRI;CANCER IMAGING;CANCER RISK;CANCER THERAPY;CANCER TREATMENT;CONJUGATE","6;6;6;5;5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2","CANCER PATIENTS;BREAST CANCER;LUNG CANCER;CELL LUNG;GASTRIC CANCER;PATIENTS TREATED;OVARIAN CANCER;BIOLOGICAL EVALUATION;ELDERLY PATIENTS;HYPERCAN STUDY;MULTICENTER RETROSPECTIVE;NON-SMALL CELL;OBSERVATIONAL STUDY;PROSPECTIVE STUDY;ADJUVANT THERAPY;ADVANCED GASTRIC;BLOOD BIOMARKERS;BREAST CARCINOMA;COLORECTAL CANCER;DENSE BREASTS;EXPANDED ACCESS;FIRST-LINE TREATMENT;FOLLICULAR LYMPHOMA;GENE EXPRESSION;GLYCOL CHITOSAN;HEMOSTATIC BIOMARKERS;HISTORICAL OVERVIEW;INVASIVE BREAST;MALE BREAST;MAST CELLS","11;8;8;5;5;5;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;CANCER PATIENTS;ADVISORY BOARD;RESEARCH FUNDING;PROGRESSION-FREE SURVIVAL;RESPONSE RATE;SURVIVAL OS;BARI ITALY;LUNG CANCER;MAST CELLS;OVARIAN CANCER;CONFIDENCE INTERVAL;ISCD MICE;MEDIAN AGE;MEDIAN PFS;MONTHS CI;ADVERSE EVENTS;CUMULATIVE INCIDENCE;ENTITY RESPONSIBLE;FATTY ACIDS;GI CANCER;HR CI;ISCDAPCMIN MICE;LEGAL ENTITY;MM PATIENTS;NOTCH PATHWAY;OLEIC ACID;VALIDATION SET;ADVISORY COMMITTEES;BACKGROUND PAIN","20;12;11;11;10;10;10;9;9;9;9;8;8;7;7;7;6;6;6;6;6;6;6;6;6;6;6;6;5;5",44,0.44,6.84,5.25,1,1.5,2,2,1,1,1,6.25,1,1,5,1,1,2,2,4,2.25,0,0,68,68,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,4,207,2.75,2,0.67,62,0,0,2,0,1,0,0,0,0,3,0,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,0,0,0,0,"United States","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY","3;2;1;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;LUNG;LUNG CANCER","2;2;2;1;1","CANCER","2","6.2 CELLULAR AND GENE THERAPIES;6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS","3;2;1","LUNG CANCER;MELANOMA;NON-HODGKIN'S LYMPHOMA","1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","3",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,"SPRINGER NATURE","3","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","6;3",NA,NA,"CANCER","1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","1",NA,NA,"CLINICAL MEDICINE AND SCIENCE","2","BREAST CANCER","3",NA,NA
"IRCCS_TUMORIBARI",2019,125,17.168,2.816,0.248,0.28,0.248,2.47887323943662,1.14814814814815,1.59090909090909,1.34782608695652,0.64,1,55,30,8,7,0.44,0.24,0.06,0.06,24.49,1.00703678647658,5.05709023941068,0.28,0.976,0.437,0.363,0.436,0.422,"DOMENICO GALETTA;NICOLA SILVESTRIS;ANNAMARIA CATINO;ANGELO DELMONTE;FRANCESCO GROSSI;RITA CHIARI;ATTILIO GUARINI;ORONZO BRUNETTI;FEDERICO CAPPUZZO;EMANUELE NAGLIERI;MARIO SCARTOZZI;SIMONA DE SUMMA;DANIELE LA FORGIA;HÉCTOR SOTO PARRÀ;MICHELE GUIDA;ROSA MARIA IACOBAZZI;ANNARITA FANIZZI;SABINA TANGARO;LORENZO FORNARO;L. LOSURDO","18;15;11;10;9;8;8;8;7;7;7;7;7;7;7;6;6;6;6;6","NICOLA SILVESTRIS;VM GARRISI;DOMENICO GALETTA;ATTILIO GUARINI;ORONZO BRUNETTI;ANITA MANGIA;DANIELE LA FORGIA;ANNAMARIA CATINO;ANTONELLA ARGENTIERO;SIMONA DE SUMMA;ANGELA CALABRESE;ANTONIO GIOVANNI SOLIMANDO;FRANCESCO GIOTTA;EMANUELA SCARPI;ANNA SCATTONE;EMANUELE NAGLIERI;ROSA MARIA IACOBAZZI;L. LOSURDO;ANNARITA FANIZZI;SABINA TANGARO","1.2;1;0.97;0.8;0.78;0.71;0.69;0.68;0.61;0.6;0.59;0.59;0.58;0.58;0.55;0.54;0.51;0.49;0.49;0.49","DOMENICO GALETTA;NICOLA SILVESTRIS;ANNAMARIA CATINO;ATTILIO GUARINI;ORONZO BRUNETTI;EMANUELE NAGLIERI;SIMONA DE SUMMA;DANIELE LA FORGIA;MICHELE GUIDA;ROSA MARIA IACOBAZZI;ANNARITA FANIZZI;L. LOSURDO;ANTONELLA ARGENTIERO;ANITA MANGIA;FRANCESCO GIOTTA;ANNA SCATTONE;MICHELE MONTRONE;CARLA MINOIA;ANTONIO GIOVANNI SOLIMANDO;GIACOMO LOSETO","18;15;11;8;8;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5","NICOLA SILVESTRIS;VM GARRISI;DOMENICO GALETTA;ATTILIO GUARINI;ORONZO BRUNETTI;ANITA MANGIA;DANIELE LA FORGIA;ANNAMARIA CATINO;ANTONELLA ARGENTIERO;SIMONA DE SUMMA;ANGELA CALABRESE;ANTONIO GIOVANNI SOLIMANDO;FRANCESCO GIOTTA;ANNA SCATTONE;EMANUELE NAGLIERI;ROSA MARIA IACOBAZZI;L. LOSURDO;ANNARITA FANIZZI;CARLA MINOIA;CONCETTA SAPONARO","1.2;1;0.97;0.8;0.78;0.71;0.69;0.68;0.61;0.6;0.59;0.59;0.58;0.55;0.54;0.51;0.49;0.49;0.47;0.41","NICOLA SILVESTRIS;DOMENICO GALETTA;ANGELO DELMONTE;FRANCESCO GROSSI;DIANA GIANNARELLI;LORENZA LANDI;RITA CHIARI;FEDERICO CAPPUZZO;MARCELLO TISEO;ROSA MARIA IACOBAZZI;LUCIO CRINÓ;HÉCTOR SOTO PARRÀ;R. FONTE;AMALIA AZZARITI;FEDERICA D’INCÀ;GABRIELE MINUTI;LETIZIA PORCELLI;DIEGO CORTINOVIS;ANTONIO CHELLA;KATIA CAGOSSI","547;523;521;443;429;426;418;407;404;336;310;308;294;287;283;283;276;275;271;267","NICOLA SILVESTRIS;DOMENICO GALETTA;ROSA MARIA IACOBAZZI;R. FONTE;AMALIA AZZARITI;LETIZIA PORCELLI;ANNARITA FANIZZI;DANIELE LA FORGIA;MICHELE GUIDA;STEFANIA TOMMASI;MARIA DIGENNARO;L. LOSURDO;RAFFAELLA MASSAFRA;VITTORIO DIDONNA;GAETANO ACHILLE;ANNAMARIA CATINO;FRANCESCO GIOTTA;VITO LORUSSO;ANTONELLA ARGENTIERO;PASQUALE TAMBORRA","522;516;336;294;287;276;223;223;210;198;181;175;175;175;159;148;148;133;131;129","DOMENICO GALETTA;NICOLA SILVESTRIS;ANNAMARIA CATINO;ATTILIO GUARINI;FRANCESCO GIOTTA;SIMONA DE SUMMA;EMANUELE NAGLIERI;STEFANIA TOMMASI;DANIELE LA FORGIA;MICHELE GUIDA;ROSA MARIA IACOBAZZI;ANITA MANGIA;ANTONELLA ARGENTIERO;ANGELA CALABRESE;MICHELE MONTRONE;ORONZO BRUNETTI;VITO LONGO;VITO LORUSSO;ANNARITA FANIZZI;FRANCESCO GIULIANI","17;14;10;8;8;7;7;7;7;7;6;6;6;5;5;5;5;5;5;5","MEDICINE;BIOLOGY;CHEMISTRY;MATHEMATICS;COMPUTER SCIENCE;PHYSICS;PHILOSOPHY;POLITICAL SCIENCE;SOCIOLOGY;MATERIALS SCIENCE","117;34;16;10;9;9;3;3;3;2","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;SURGERY;BIOCHEMISTRY;GASTROENTEROLOGY;IMMUNOLOGY;PATHOLOGY;GENETICS;RADIOLOGY;CELL BIOLOGY;PALEONTOLOGY;ARTIFICIAL INTELLIGENCE;ENVIRONMENTAL HEALTH;GYNECOLOGY;ASTROBIOLOGY;BIOTECHNOLOGY;GENERAL SURGERY;UROLOGY;BIOPHYSICS;COMPUTATIONAL BIOLOGY;COMPUTER VISION;ENDOCRINOLOGY;GEOMETRY;LAW;ORGANIC CHEMISTRY;QUANTUM MECHANICS;STATISTICS","101;68;31;24;18;17;15;14;13;10;9;9;7;6;5;4;4;4;4;3;3;3;3;3;3;3;3;3","CANCER;CHEMOTHERAPY;LUNG CANCER;GENE;COHORT;ADVERSE EFFECT;DISEASE;MULTIVARIATE ANALYSIS;PROPORTIONAL HAZARDS MODEL;CONFIDENCE INTERVAL;IMMUNE SYSTEM;MELANOMA;RANDOMIZED CONTROLLED TRIAL;CLINICAL TRIAL;PATTERN RECOGNITION (PSYCHOLOGY);IMMUNOHISTOCHEMISTRY;IN VITRO;POPULATION;PROSPECTIVE COHORT STUDY;STAGE (STRATIGRAPHY)","77;28;22;16;12;10;10;10;10;8;8;8;8;7;7;6;6;6;6;6","BREAST CANCER;IMMUNOTHERAPY;COLORECTAL CANCER;ADENOCARCINOMA;CLINICAL ENDPOINT;UNIVARIATE ANALYSIS;GENE EXPRESSION;OVARIAN CANCER;PANCREATIC CANCER;CHEMOTHERAPY REGIMEN;HAZARD RATIO;PROGRESSION-FREE SURVIVAL;TUMOR MICROENVIRONMENT;DOCETAXEL;GEMCITABINE;METASTASIS;PROGRESSIVE DISEASE;CISPLATIN;PI3K/AKT/MTOR PATHWAY;SORAFENIB","23;14;13;10;9;8;7;7;7;6;6;6;6;5;5;5;5;4;4;4","NIVOLUMAB;MAMMOGRAPHY;KRAS;BRCA MUTATION;GENE SIGNATURE;PEMBROLIZUMAB;TAMOXIFEN;TRANSCRIPTOME;TUMOR-INFILTRATING LYMPHOCYTES;ANDROGEN RECEPTOR;CD163;COLONOSCOPY;CRIZOTINIB;GEFITINIB;IPILIMUMAB;NINTEDANIB;NON-SMALL CELL LUNG CANCER (NSCLC);PANCREATIC DUCTAL ADENOCARCINOMA;PEMETREXED;ROS1;TRASTUZUMAB","8;6;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2",";HUMANS;FEMALE;MIDDLE AGED;MALE;AGED;LUNG NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BREAST NEOPLASMS;CARCINOMA, NON-SMALL-CELL LUNG;ADULT;AGED, 80 AND OVER;MELANOMA;OVARIAN NEOPLASMS;NEOPLASM RECURRENCE, LOCAL;ITALY;TREATMENT OUTCOME;BIOMARKERS, TUMOR;PROGNOSIS;RETROSPECTIVE STUDIES","63;60;48;39;38;36;33;30;30;28;26;19;17;17;15;13;13;11;11;11","CANCER IMMUNOTHERAPY;PANCREATIC CANCER RESEARCH AND TREATMENT;ADVANCEMENTS IN LUNG CANCER RESEARCH;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;LYMPHOID NEOPLASMS;PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;RENAL CELL CARCINOMA;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CHOLANGIOCARCINOMA;DEEP LEARNING IN MEDICAL IMAGE ANALYSIS;ACUTE MYELOID LEUKEMIA;BREAST PATHOLOGY AND IMAGING TECHNIQUES;CANCER OF UNKNOWN PRIMARY SITE;CANCER SURVIVORSHIP AND QUALITY OF LIFE;COLORECTAL CANCER RESEARCH AND TREATMENT;EDUCATION AND PEDAGOGY RESEARCH;GASTRIC CANCER RESEARCH AND TREATMENT;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEPATOCELLULAR CARCINOMA;HER2 SIGNALING IN BREAST CANCER TREATMENT","14;6;5;4;4;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2","CLINICAL ENDPOINT;TUMOR MICROENVIRONMENT;UNIVARIATE ANALYSIS;BIOMARKERS FOR IMMUNOTHERAPY;BREAST CANCER;CHEMOTHERAPY REGIMEN;PROGRESSION-FREE SURVIVAL;MELANOMA;METASTATIC PANCREATIC CANCER;TREATMENT GUIDELINES;BREAST CANCER DIAGNOSIS;OVARIAN CANCER;REFRACTORY (PLANETARY SCIENCE);SOFT TISSUE METASTASES;B-CELL RECEPTOR SIGNALING;BIOMARKER ANALYSIS;BRCA MUTATION;CANCER IMAGING;COMPUTER-AIDED DETECTION;COMPUTER-AIDED DIAGNOSIS","10;9;8;7;6;6;6;5;5;5;4;4;4;4;3;3;3;3;3;3","LUNG CANCER;BREAST CANCER;CELL LUNG;NON-SMALL CELL;CANCER PATIENTS;ADVANCED NON-SMALL;OVARIAN CANCER;PHASE II;CANCER NSCLC;DUCTAL ADENOCARCINOMA;III TRIAL;NSCLC PATIENTS;PANCREATIC DUCTAL;PATIENTS TREATED;PHASE III;RANDOMIZED PHASE;CANCER ANSCLC;COLORECTAL CANCER;CONTRAST-ENHANCED SPECTRAL;ITALIAN COHORT;PILOT STUDY;PROGENITOR CELLS;PROGNOSTIC ROLE;REAL WORLD;SPECTRAL MAMMOGRAPHY;ACCESS PROGRAM;ANAL CANCER;ANSCLC PATIENTS;ATALANTE- RANDOMIZED;BLOOD BIOMARKERS","16;15;13;11;9;6;6;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2","ADVISORY CONSULTANCY;SPEAKERS BUREAU;BREAST CANCER;PATIENTS TREATED;MULTIVARIATE ANALYSIS;PROGRESSION-FREE SURVIVAL;CANCER PATIENTS;RESPONSE RATE;HR CI;LUNG CANCER;SURVIVAL OS;CONSULTANCY SPEAKERS;SURVIVAL PFS;CONTENT HTTPSLINKSLWWCOMHSA;DIGITAL CONTENT;GENE EXPRESSION;SUPPLEMENTAL DIGITAL;BOEHRINGER INGELHEIM;PROGNOSTIC FACTORS;ADVERSE EVENTS;CLINICAL OUTCOME;FREE SURVIVAL;PROGNOSTIC STAGE;CELL LUNG;CLINICAL PRACTICE;CONSULTANCY ASTRAZENECA;MEDIAN AGE;MEDIAN PROGRESSION-FREE;NON-SMALL CELL;STATISTICALLY SIGNIFICANT","56;34;29;29;17;17;15;15;14;14;14;12;12;11;11;11;11;10;10;9;9;9;9;8;8;8;8;8;8;8",55,0.44,6.58,6.5,2.25,1,0,1,1.5,1,1,7,1,1,7,1,0,2,3.5,5,4,0,0,60.5,60.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,5.1,231.1,7.19,5,0.5,68,0,0,4,0,3,0,1,2,0,9,1,0,0,0,0,0,0,10,0,0,10,0,0,0,0,0,0,0,0,0,"United States","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","10;8;3;2;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;LYMPHOMA;ORPHAN DRUG;PREVENTION;LUNG;LUNG CANCER;PATIENT SAFETY;BRAIN CANCER;BRAIN DISORDERS;DIGESTIVE DISEASES;LIVER CANCER;LIVER DISEASE;NEURODEGENERATIVE;NEUROSCIENCES","9;9;7;5;4;3;3;3;2;2;2;1;1;1;1;1;1;1","CANCER;RESPIRATORY","8;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","8;3;1;1","NON-HODGKIN'S LYMPHOMA;LUNG CANCER;LIVER CANCER;NOT SITE-SPECIFIC CANCER;SKIN CANCER","3;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","7;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_TUMORIBARI",2020,163,19.1042944785276,2.58282208588957,0.269938650306748,0.190184049079755,0.312883435582822,2.71612903225806,1.375,1.40909090909091,1.54545454545455,0.736196319018405,0,77,46,5,5,0.47,0.28,0.03,0.03,24.84,0.985789836749538,6.18396226415094,0.349693251533742,1,0.466,0.4,0.415,0.4,"NICOLA SILVESTRIS;ANGELO PARADISO;DOMENICO GALETTA;MICHELE GUIDA;DANIELE SANTINI;EMANUELE NAGLIERI;PAMELA PIZZUTILO;ANNAMARIA CATINO;GIUSEPPE LUIGI BANNA;PAOLO MARCHETTI;MARCO TUCCI;DIEGO SIGNORELLI;SEBASTIANO BUTI;CORRADO FICORELLA;ALEX FRIEDLAENDER;GIUSEPPE PROCOPIO;ALESSIO CORTELLINI;ALFREDO ADDEO;UGO DE GIORGI;ALESSANDRO DE TOMA","19;17;15;13;13;11;11;11;9;9;8;8;8;8;8;8;8;8;8;8","NICOLA SILVESTRIS;ANGELO PARADISO;MICHELE GUIDA;ORONZO BRUNETTI;DOMENICO GALETTA;ANTONIO MOSCHETTA;DONATO F. ALTOMARE;ARCANGELO PICCIARIELLO;ERICA SILVESTRIS;ANTONIO GIOVANNI SOLIMANDO;ROSA MARIA IACOBAZZI;LETIZIA PORCELLI;NUNZIO DENORA;GENNARO CORMIO;EMANUELE NAGLIERI;SIMONA DE SUMMA;AMALIA AZZARITI;ANNAMARIA CATINO;ANNARITA FANIZZI;FRANCESCA ROMITO","1.8;1.78;1.07;0.85;0.81;0.75;0.71;0.71;0.69;0.65;0.63;0.63;0.62;0.61;0.6;0.59;0.56;0.56;0.56;0.52","NICOLA SILVESTRIS;ANGELO PARADISO;DOMENICO GALETTA;MICHELE GUIDA;EMANUELE NAGLIERI;PAMELA PIZZUTILO;ANNAMARIA CATINO;MARCO TUCCI;SIMONA DE SUMMA;ATTILIO GUARINI;ANTONIO GIOVANNI SOLIMANDO;ORONZO BRUNETTI;ROSA MARIA IACOBAZZI;ANNARITA FANIZZI;LETIZIA PORCELLI;DANIELE LA FORGIA;SABINO STRIPPOLI;GENNARO CORMIO;STEFANIA TOMMASI;ERICA SILVESTRIS","19;17;15;13;11;11;11;8;7;7;7;7;6;6;6;6;6;6;5;5","NICOLA SILVESTRIS;ANGELO PARADISO;MICHELE GUIDA;ORONZO BRUNETTI;DOMENICO GALETTA;ANTONIO MOSCHETTA;DONATO F. ALTOMARE;ERICA SILVESTRIS;ANTONIO GIOVANNI SOLIMANDO;ROSA MARIA IACOBAZZI;LETIZIA PORCELLI;GENNARO CORMIO;EMANUELE NAGLIERI;SIMONA DE SUMMA;AMALIA AZZARITI;ANNAMARIA CATINO;ANNARITA FANIZZI;FRANCESCA ROMITO;MARCO TUCCI;AFSHIN DERAKHSHANI","1.8;1.78;1.07;0.85;0.81;0.75;0.71;0.69;0.65;0.63;0.63;0.61;0.6;0.59;0.56;0.56;0.56;0.52;0.52;0.52","ATTILIO GUARINI;CORRADO FICORELLA;ALESSIO CORTELLINI;GIAMPIERO PORZIO;MICHÈLE CAVO;PAOLO MARCHETTI;SARA GALIMBERTI;OLGA NIGRO;AGOSTINO TAFURI;ANNA CANDONI;ANNA MARIA SCATTOLIN;FELICETTO FERRARA;LIVIO PAGANO;PATRIZIA ZAPPASODI;PELLEGRINO MUSTO;ROBERTO M. LEMOLI;MARCO FILETTI;RITA CHIARI;MARCO RUSSANO;NICOLA DI RENZO","651;599;575;562;552;545;542;539;536;536;536;536;536;536;536;536;521;520;518;518","ATTILIO GUARINI;NICOLA SILVESTRIS;DOMENICO GALETTA;PAMELA PIZZUTILO;ANNAMARIA CATINO;MARCO TUCCI;SIMONA DE SUMMA;MICHELE GUIDA;DANIELE LA FORGIA;ANTONIO GIOVANNI SOLIMANDO;ANGELO PARADISO;ANTONIO MOSCHETTA;VITO LORUSSO;CARLA MINOIA;ERICA SILVESTRIS;N. VARESANO;MIRIAM DELLINO;ANNARITA FANIZZI;RAFFAELLA MASSAFRA;GIACOMO LOSETO","651;513;485;426;422;347;218;189;185;184;180;170;164;160;159;157;149;139;139;128","NICOLA SILVESTRIS;ANGELO PARADISO;DOMENICO GALETTA;MICHELE GUIDA;ANNAMARIA CATINO;PAMELA PIZZUTILO;EMANUELE NAGLIERI;STEFANIA TOMMASI;ORONZO BRUNETTI;ANTONIO GIOVANNI SOLIMANDO;ATTILIO GUARINI;SIMONA DE SUMMA;MARCO TUCCI;DANIELE LA FORGIA;ROSA MARIA IACOBAZZI;ERICA SILVESTRIS;VITO LORUSSO;CARLA MINOIA;DONATO F. ALTOMARE;GIROLAMO RANIERI","20;16;15;12;11;11;11;9;7;7;7;7;6;6;6;5;5;5;5;5","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;COMPUTER SCIENCE;POLITICAL SCIENCE;ECONOMICS;MATERIALS SCIENCE;PSYCHOLOGY;MATHEMATICS;PHILOSOPHY;SOCIOLOGY;ART;BUSINESS;ENGINEERING;ENVIRONMENTAL SCIENCE;GEOGRAPHY;HISTORY","149;57;24;9;8;6;4;4;4;3;3;2;1;1;1;1;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CANCER RESEARCH;GENETICS;GASTROENTEROLOGY;PATHOLOGY;BIOCHEMISTRY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;PHARMACOLOGY;CELL BIOLOGY;PALEONTOLOGY;VIROLOGY;GYNECOLOGY;INTENSIVE CARE MEDICINE;RADIOLOGY;UROLOGY;ENDOCRINOLOGY;LAW;NURSING","135;79;33;32;29;28;26;24;22;17;12;11;10;10;8;8;8;8;7;6;6","CANCER;CHEMOTHERAPY;DISEASE;GENE;LUNG CANCER;POPULATION;COHORT;ADVERSE EFFECT;CLINICAL TRIAL;CONFIDENCE INTERVAL;RETROSPECTIVE COHORT STUDY;MELANOMA;OUTBREAK;PROSPECTIVE COHORT STUDY;RECEPTOR;APOPTOSIS;IMMUNE SYSTEM;MULTIVARIATE ANALYSIS;RANDOMIZED CONTROLLED TRIAL;REGIMEN;RENAL CELL CARCINOMA","99;29;21;21;16;16;14;12;12;12;12;10;8;8;8;7;7;7;7;7;7","IMMUNOTHERAPY;BREAST CANCER;COLORECTAL CANCER;INFECTIOUS DISEASE (MEDICAL SPECIALTY);HAZARD RATIO;CLINICAL ENDPOINT;METASTASIS;2019-20 CORONAVIRUS OUTBREAK;OVARIAN CANCER;PROGRESSION-FREE SURVIVAL;SUNITINIB;BEVACIZUMAB;CISPLATIN;PHASES OF CLINICAL RESEARCH;CELL CYCLE;GEMCITABINE;MICRORNA;NEUTROPENIA;PANCREATIC CANCER;PHENOTYPE;PROSTATE CANCER;SORAFENIB;UNIVARIATE ANALYSIS","23;21;18;15;12;11;7;6;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4","CORONAVIRUS DISEASE 2019 (COVID-19);PEMBROLIZUMAB;NIVOLUMAB;IPILIMUMAB;MAMMOGRAPHY;OXALIPLATIN;COLONOSCOPY;PENETRANCE;FOLINIC ACID;METASTATIC BREAST CANCER;TAMOXIFEN;TRASTUZUMAB;BONE METASTASIS;BRCA MUTATION;CAPECITABINE;ESTROGEN RECEPTOR;FERTILITY PRESERVATION;GERMINAL CENTER;IRINOTECAN;KRAS;NUCLEAR RECEPTOR;PAZOPANIB;PD-L1;PROPIDIUM IODIDE;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;TRANSCRIPTOME","15;10;8;5;5;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2",";HUMANS;FEMALE;MIDDLE AGED;ADULT;CARCINOMA, NON-SMALL-CELL LUNG;AGED;MALE;LUNG NEOPLASMS;BREAST NEOPLASMS;ITALY;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;OVARIAN NEOPLASMS;ANTIBODIES, MONOCLONAL, HUMANIZED;B7-H1 ANTIGEN;LIVER NEOPLASMS;NEOPLASMS;ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL","108;54;38;28;27;26;25;25;22;20;20;18;17;16;16;15;15;14;14;12","CANCER IMMUNOTHERAPY;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;RENAL CELL CARCINOMA;LYMPHOID NEOPLASMS;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;BREATH ANALYSIS TECHNOLOGY;CHOLANGIOCARCINOMA;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;HEPATOCELLULAR CARCINOMA;HER2 SIGNALING IN BREAST CANCER TREATMENT;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;PANCREATIC CANCER RESEARCH AND TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;CANCER STEM CELLS AND TUMOR METASTASIS;CANCER SURVIVORSHIP AND QUALITY OF LIFE;CHALLENGES IN PAIN MANAGEMENT AND TREATMENT;CLINICOPATHOLOGY OF FIBROUS TUMORS AND TREATMENT STRATEGIES;CORONAVIRUS DISEASE 2019","12;12;7;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2","CLINICAL ENDPOINT;PANDEMIC;BIOMARKERS FOR IMMUNOTHERAPY;BREAST CANCER;CANCER;IMMUNE CHECKPOINT BLOCKADE;REGIMEN;2019-20 CORONAVIRUS OUTBREAK;PROGRESSION-FREE SURVIVAL;PD-1 AND PD-L1;CANCER SURVIVORSHIP;MELANOMA;METASTATIC PANCREATIC CANCER;NEUTROPHIL-TO-LYMPHOCYTE RATIO;PENETRANCE;UNIVARIATE ANALYSIS;BREATH ANALYSIS;BREATH GAS ANALYSIS;CANCER IMMUNOTHERAPY;CANCER RISK","12;10;9;7;7;7;7;6;6;5;4;4;4;4;4;4;3;3;3;3","CANCER PATIENTS;BREAST CANCER;CHECKPOINT INHIBITORS;PHASE II;LUNG CANCER;CELL CARCINOMA;COLORECTAL CANCER;METASTATIC RENAL;PD-L EXPRESSION;CANCER TREATED;CARCINOMA TREATED;CLINICAL OUTCOMES;COVID- PANDEMIC;HEPATOCELLULAR CARCINOMA;II STUDY;METASTATIC MELANOMA;NSCLC PATIENTS;PHASE III;PILOT STUDY;ADVANCED NSCLC;CARCINOMA PATIENTS;CELL LUNG;COLON CANCER;ENDOTHELIAL CELLS;FIRST-LINE PEMBROLIZUMAB;IMMUNE CHECKPOINT;LOCALLY ADVANCED;MULTICENTER STUDY;MULTICENTRE STUDY;PANCREATIC CANCER","11;10;7;7;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","HR CI;PATIENTS TREATED;CANCER PATIENTS;SPEAKERS BUREAU;PROGRESSION-FREE SURVIVAL;ADVISORY COMMITTEES;BONE METASTASES;ENTITYS BOARD;LUNG CANCER;BREAST CANCER;SURVIVAL OS;MEDIAN FOLLOW-UP;SURVIVAL PFS;CONSULTANCY HONORARIA;RESPONSE RATE;CHECKPOINT INHIBITORS;COLORECTAL CANCER;CLINICAL PRACTICE;COVID- PANDEMIC;MEDIAN AGE;MEDIAN OS;MULTIVARIATE ANALYSIS;PRIMARY ENDPOINT;NSCLC PATIENTS;OBJECTIVE RESPONSE;PATIENTS RECEIVING;PD-L EXPRESSION;ADVERSE EVENTS;CELL LUNG;INDEPENDENT PROGNOSTIC","39;22;21;21;19;17;17;17;17;16;16;14;14;13;13;12;12;11;11;11;11;11;11;10;10;10;10;9;9;9",98,0.6,8.73,9.75,1,1,0,5.5,1,0,1,11,1,0,10,0,0,2,4.25,5,3.25,0,0,48.5,48.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,2.5,13,1.33,1,0.5,51,0,0,2,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3204 IMMUNOLOGY","2;2;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES","2;2;2;1","CANCER","2","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","2;1","BLADDER CANCER","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_TUMORIBARI",2021,220,17.4227272727273,3.57727272727273,0.318181818181818,0.309090909090909,0.395454545454545,3.51339285714286,1.70731707317073,1.74358974358974,1.93333333333333,0.731818181818182,0,74,64,18,17,0.34,0.29,0.08,0.08,13.71,0.889299848261171,6.57888040712468,0.363636363636364,0.986363636363636,0.529,0.431,0.443,0.47,"NICOLA SILVESTRIS;ANNARITA FANIZZI;RAFFAELLA MASSAFRA;DANIELE LA FORGIA;ATTILIO GUARINI;DOMENICO GALETTA;MICHELE GUIDA;ANNAMARIA CATINO;PAMELA PIZZUTILO;ANGELO PARADISO;SIMONA DE SUMMA;CARLA MINOIA;VITTORIO DIDONNA;VITO LORUSSO;SEBASTIANO BUTI;AMALIA AZZARITI;MICHELE MONTRONE;PASQUALE TAMBORRA;AGNESE LATORRE;UGO DE GIORGI","30;23;21;19;19;17;17;16;15;14;13;13;13;13;12;12;12;12;12;12","NICOLA SILVESTRIS;ANNARITA FANIZZI;RAFFAELLA MASSAFRA;DANIELE LA FORGIA;ATTILIO GUARINI;DOMENICO GALETTA;MICHELE MONTRONE;ANGELO PARADISO;MICHELE GUIDA;ORONZO BRUNETTI;ANNAMARIA CATINO;PAMELA PIZZUTILO;AMALIA AZZARITI;DOMENICO POMARICO;VITTORIO DIDONNA;SIMONA DE SUMMA;CARLA MINOIA;AFSHIN DERAKHSHANI;AGNESE LATORRE;VITO LORUSSO","2.42;2.07;1.82;1.8;1.34;1.32;1.25;1.19;1.17;1.15;1.14;1.14;1.11;1.05;1.04;1.04;1.01;0.98;0.92;0.91","NICOLA SILVESTRIS;ANNARITA FANIZZI;RAFFAELLA MASSAFRA;DANIELE LA FORGIA;ATTILIO GUARINI;DOMENICO GALETTA;MICHELE GUIDA;ANNAMARIA CATINO;PAMELA PIZZUTILO;ANGELO PARADISO;SIMONA DE SUMMA;CARLA MINOIA;VITTORIO DIDONNA;VITO LORUSSO;AMALIA AZZARITI;MICHELE MONTRONE;PASQUALE TAMBORRA;AGNESE LATORRE;FRANCESCO GIOTTA;ORONZO BRUNETTI","30;23;21;19;19;17;17;16;15;14;13;13;13;13;12;12;12;12;12;12","NICOLA SILVESTRIS;ANNARITA FANIZZI;RAFFAELLA MASSAFRA;DANIELE LA FORGIA;ATTILIO GUARINI;DOMENICO GALETTA;MICHELE MONTRONE;ANGELO PARADISO;MICHELE GUIDA;ORONZO BRUNETTI;ANNAMARIA CATINO;PAMELA PIZZUTILO;AMALIA AZZARITI;DOMENICO POMARICO;VITTORIO DIDONNA;SIMONA DE SUMMA;CARLA MINOIA;AFSHIN DERAKHSHANI;AGNESE LATORRE;VITO LORUSSO","2.42;2.07;1.82;1.8;1.34;1.32;1.25;1.19;1.17;1.15;1.14;1.14;1.11;1.05;1.04;1.04;1.01;0.98;0.92;0.91","NICOLA SILVESTRIS;ANNARITA FANIZZI;RAFFAELLA MASSAFRA;VITO LORUSSO;ALESSIO CORTELLINI;MICHELE GUIDA;DANIELE LA FORGIA;BEHZAD BARADARAN;AFSHIN DERAKHSHANI;PASQUALE TAMBORRA;SEBASTIANO BUTI;VITTORIO DIDONNA;FRANCESCO GIOTTA;CORRADO FICORELLA;ANTONIO GIOVANNI SOLIMANDO;AGNESE LATORRE;ANGELO PARADISO;VITO RACANELLI;ANDREA BOTTICELLI;MELISSA BERSANELLI","581;372;372;353;341;341;327;323;302;293;285;262;253;244;241;236;236;227;221;216","NICOLA SILVESTRIS;RAFFAELLA MASSAFRA;ANNARITA FANIZZI;MICHELE GUIDA;VITO LORUSSO;DANIELE LA FORGIA;PASQUALE TAMBORRA;VITTORIO DIDONNA;ANGELO PARADISO;FRANCESCO GIOTTA;AGNESE LATORRE;ORONZO BRUNETTI;AFSHIN DERAKHSHANI;PAMELA PIZZUTILO;ANNAMARIA CATINO;ANNALISA NARDONE;AMALIA AZZARITI;ALFREDO ZITO;SIMONA DE SUMMA;EMANUELE NAGLIERI","581;372;365;341;329;320;289;255;236;233;209;207;203;183;180;175;171;170;168;167","NICOLA SILVESTRIS;RAFFAELLA MASSAFRA;ANNARITA FANIZZI;ATTILIO GUARINI;MICHELE GUIDA;DOMENICO GALETTA;DANIELE LA FORGIA;ANNAMARIA CATINO;ANGELO PARADISO;VITO LORUSSO;PAMELA PIZZUTILO;SIMONA DE SUMMA;AMALIA AZZARITI;ORONZO BRUNETTI;CARLA MINOIA;MICHELE MONTRONE;FRANCESCO GIOTTA;EMANUELE NAGLIERI;STEFANIA TOMMASI;PASQUALE TAMBORRA","30;21;19;18;17;16;16;15;14;14;14;13;12;12;12;11;11;10;10;10","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;CHEMISTRY;ECONOMICS;MATHEMATICS;ENGINEERING;POLITICAL SCIENCE;PSYCHOLOGY;SOCIOLOGY;MATERIALS SCIENCE;BUSINESS;GEOGRAPHY;PHILOSOPHY;GEOLOGY;HISTORY","199;72;27;23;22;13;10;8;8;8;7;5;3;2;2;1;1","INTERNAL MEDICINE;ONCOLOGY;CANCER RESEARCH;PATHOLOGY;GENETICS;SURGERY;IMMUNOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;RADIOLOGY;ARTIFICIAL INTELLIGENCE;GASTROENTEROLOGY;GENERAL SURGERY;CELL BIOLOGY;FAMILY MEDICINE;OPTICS;COMPUTATIONAL BIOLOGY;MACHINE LEARNING;PALEONTOLOGY;INTENSIVE CARE MEDICINE","173;90;44;41;35;33;30;28;25;20;16;15;13;12;12;12;11;11;10;9","CANCER;GENE;DISEASE;LUNG CANCER;POPULATION;CHEMOTHERAPY;RETROSPECTIVE COHORT STUDY;ADVERSE EFFECT;COHORT;CLINICAL TRIAL;IMMUNE SYSTEM;MELANOMA;CONFIDENCE INTERVAL;INCIDENCE (GEOMETRY);MULTIVARIATE ANALYSIS;LYMPHOMA;APOPTOSIS;IN VITRO;RANDOMIZED CONTROLLED TRIAL;CELL;LYMPH NODE","116;39;30;23;22;21;20;19;19;15;15;14;11;11;11;10;9;9;9;8;8","BREAST CANCER;IMMUNOTHERAPY;COLORECTAL CANCER;INFECTIOUS DISEASE (MEDICAL SPECIALTY);METASTASIS;GENE EXPRESSION;CANCER CELL;CLINICAL ENDPOINT;PANCREATIC CANCER;PROGRESSION-FREE SURVIVAL;UNIVARIATE ANALYSIS;HAZARD RATIO;METASTATIC MELANOMA;MUTATION;ADENOCARCINOMA;GEMCITABINE;MICRORNA;DOWNREGULATION AND UPREGULATION;GENE SILENCING;GERMLINE;OVARIAN CANCER;TELEMEDICINE","32;30;21;16;12;11;9;9;8;8;8;7;7;7;6;6;6;5;5;5;5;5","CORONAVIRUS DISEASE 2019 (COVID-19);PEMBROLIZUMAB;NIVOLUMAB;SENTINEL LYMPH NODE;IPILIMUMAB;PD-L1;EPITHELIAL–MESENCHYMAL TRANSITION;ESTROGEN RECEPTOR;GERMLINE MUTATION;IMMUNE CHECKPOINT;MAMMOGRAPHY;MICROSATELLITE;MICROVESICLES;TRANSCRIPTOME;AXILLARY LYMPH NODES;BILIARY TRACT CANCER;METASTATIC BREAST CANCER;NON-SMALL CELL LUNG CANCER (NSCLC);RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;UROTHELIAL CARCINOMA","16;10;8;6;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3",";HUMANS;FEMALE;LUNG NEOPLASMS;CARCINOMA, NON-SMALL-CELL LUNG;AGED;MIDDLE AGED;BREAST NEOPLASMS;MALE;ADULT;AGED, 80 AND OVER;MELANOMA;RETROSPECTIVE STUDIES;NEOPLASMS;IMMUNE CHECKPOINT INHIBITORS;SKIN NEOPLASMS;MULTIPLE MYELOMA;PROGNOSIS;BRAIN NEOPLASMS;BIOMARKERS, TUMOR","136;81;42;32;29;28;28;26;25;21;21;21;20;18;17;16;15;15;14;11","CANCER IMMUNOTHERAPY;LYMPHOID NEOPLASMS;MOLECULAR RESEARCH ON BREAST CANCER;RADIOMICS IN MEDICAL IMAGING ANALYSIS;RENAL CELL CARCINOMA;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;PANCREATIC CANCER RESEARCH AND TREATMENT;CHOLANGIOCARCINOMA;COLORECTAL CANCER RESEARCH AND TREATMENT;CORONAVIRUS DISEASE 2019 RESEARCH;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;EXOSOME BIOLOGY AND FUNCTION IN INTERCELLULAR COMMUNICATION;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;EPIDEMIOLOGY AND MANAGEMENT OF SKIN CANCER;FERTILITY PRESERVATION IN CANCER PATIENTS;IMPACT OF COVID-19 ON MENTAL HEALTH;NANOPARTICLE-BASED DRUG DELIVERY SYSTEMS","16;7;7;7;7;6;5;5;5;4;4;4;4;4;4;4;3;3;3;3","BIOMARKERS FOR IMMUNOTHERAPY;IMMUNE CHECKPOINT BLOCKADE;CANCER IMAGING;MELANOMA;PANDEMIC;TREATMENT;TUMOR MICROENVIRONMENT;CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;UNIVARIATE ANALYSIS;BREAST CANCER;CANCER IMMUNOEDITING;BREAST CANCER DIAGNOSIS;PROGNOSTIC MARKERS;CANCER;GRADING (ENGINEERING);PD-1 AND PD-L1;BILIARY TRACT CANCER;CANCER GENOMICS;CANCER PROGNOSIS","14;14;12;12;10;10;10;9;9;9;8;7;6;6;5;5;5;4;4;4","BREAST CANCER;CANCER PATIENTS;LUNG CANCER;CELL CARCINOMA;COLORECTAL CANCER;IMMUNE CHECKPOINT;CHECKPOINT INHIBITORS;FONDAZIONE ITALIANA;ITALIANA LINFOMI;LYMPH NODE;ADVANCED LUNG;PATIENTS TREATED;CELL LUNG;CHECKPOINT INHIBITOR;LOCALLY ADVANCED;LYMPHOMA SURVIVORS;MACHINE LEARNING;METASTATIC MELANOMA;MULTIPLE MYELOMA;PANCREATIC CANCER;RETROSPECTIVE STUDY;TRACT CANCER;BILIARY TRACT;CLASSICAL HODGKIN;CLINICALLY NEGATIVE;COHORT STUDY;COLON CANCER;CUTANEOUS SQUAMOUS;GENE EXPRESSION;HODGKIN LYMPHOMA","26;16;14;9;9;9;7;7;7;7;6;6;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4","BREAST CANCER;ADVISORY COMMITTEES;ENTITYS BOARD;PATIENTS TREATED;LUNG CANCER;CANCER PATIENTS;HR CI;MONTHS CI;ADVERSE EVENTS;MEDIAN AGE;CLINICAL PRACTICE;GENE EXPRESSION;SPEAKERS BUREAU;SURVIVAL OS;CHECKPOINT INHIBITORS;CONSULTANCY HONORARIA;AF PROPHYLAXIS;CLINICAL TRIALS;IMMUNE CHECKPOINT;SURVIVAL PFS;CANCER CELLS;CELL LINES;CLINICAL OUTCOMES;MACHINE LEARNING;NSCLC PATIENTS;RESPONSE RATE;MEDIAN OS;PATIENTS RECEIVING;PROGRESSION-FREE SURVIVAL;CELL CYCLE","39;33;33;25;24;23;23;23;19;18;17;17;17;16;15;15;13;13;13;13;12;12;12;12;12;12;11;11;11;10",119,0.54,4.9,6.5,1,1,0,8.25,1.75,1,1,7,1,0,6,0,0,1,3,4,3,0,0,29,29,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,5.25,476.14,3.76,8,1,133.62,0,0,3,0,5,0,0,0,0,8,0,0,0,0,0,0,0,8,0,0,8,0,0,0,0,0,0,0,0,0,"United States","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY","8;7;3;2;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;BREAST CANCER;HEMATOLOGY;LUNG;LYMPHOMA;GENETICS;LUNG CANCER;PATIENT SAFETY","8;8;7;3;2;2;2;2;1;1;1","CANCER","6","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","7;3;1","BREAST CANCER;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;BLADDER CANCER;MELANOMA","2;2;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","7",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,"FRONTIERS","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","2;1;1","CANCER;CLINICAL RESEARCH;KIDNEY DISEASE","1;1;1",NA,NA,"6.4 SURGERY","1","CLINICAL","1","CLINICAL MEDICINE AND SCIENCE","1","KIDNEY CANCER","1",NA,NA
"IRCCS_TUMORIBARI",2022,198,18.8282828282828,2.88383838383838,0.267676767676768,0.227272727272727,0.378787878787879,2.89847715736041,1.60606060606061,2.04545454545455,1.59574468085106,0.843434343434343,1,78,46,9,11,0.39,0.23,0.05,0.06,8.86,0.992923327314655,5.92246294184721,0.343434343434343,0.98989898989899,0.557,0.413,0.343,0.407,"ALESSANDRO RIZZO;GERARDO CAZZATO;GENNARO CORMIO;ATTILIO GUARINI;ANNARITA FANIZZI;RAFFAELLA MASSAFRA;VERA LOIZZI;DOMENICO GALETTA;DANIELE SANTINI;GIUSEPPE PROCOPIO;MARIA COLOMBA COMES;FRANCESCA AREZZO;GIOVANNI BRANDI;UGO DE GIORGI;NICOLA SILVESTRIS;SEBASTIANO BUTI;MICHELE GUIDA;SAMANTHA BOVE;FRANCESCO GIOTTA;ALFREDO ZITO","22;17;17;16;15;15;14;14;12;11;10;10;10;10;10;9;9;9;9;9","ALESSANDRO RIZZO;GIOVANNI BRANDI;ANGELA DALIA RICCI;DOMENICO GALETTA;GERARDO CAZZATO;GENNARO CORMIO;GENNARO PALMIOTTI;ANNARITA FANIZZI;RAFFAELLA MASSAFRA;ATTILIO GUARINI;VERA LOIZZI;FRANCESCA AREZZO;ANTONIO CUSMAI;MICHELE MONTRONE;GENNARO GADALETA‐CALDAROLA;FRANCESCO GIOTTA;MARIA COLOMBA COMES;SIMONA DE SUMMA;ANNAMARIA CATINO;ERICA SILVESTRIS","5.64;2.68;1.56;1.49;1.44;1.35;1.33;1.23;1.23;1.21;1.16;0.97;0.9;0.86;0.83;0.79;0.7;0.69;0.65;0.64","ALESSANDRO RIZZO;GENNARO CORMIO;ATTILIO GUARINI;ANNARITA FANIZZI;RAFFAELLA MASSAFRA;VERA LOIZZI;DOMENICO GALETTA;MARIA COLOMBA COMES;FRANCESCA AREZZO;NICOLA SILVESTRIS;MICHELE GUIDA;SAMANTHA BOVE;FRANCESCO GIOTTA;ALFREDO ZITO;ANTONIO CUSMAI;DANIELE LA FORGIA;MICHELE MONTRONE;GIAN MARIA ZACCARIA;CRESCENZA PASCIOLLA;GENNARO PALMIOTTI","22;17;16;15;15;14;14;10;10;10;9;9;9;9;8;8;8;8;8;8","ALESSANDRO RIZZO;DOMENICO GALETTA;GENNARO CORMIO;GENNARO PALMIOTTI;ANNARITA FANIZZI;RAFFAELLA MASSAFRA;ATTILIO GUARINI;VERA LOIZZI;FRANCESCA AREZZO;ANTONIO CUSMAI;MICHELE MONTRONE;FRANCESCO GIOTTA;MARIA COLOMBA COMES;SIMONA DE SUMMA;ANNAMARIA CATINO;ERICA SILVESTRIS;SAMANTHA BOVE;AGNESE MARIA FIORETTI;ANGELO PARADISO;STEFANO OLIVA","5.64;1.49;1.35;1.33;1.23;1.23;1.21;1.16;0.97;0.9;0.86;0.79;0.7;0.69;0.65;0.64;0.63;0.63;0.62;0.61","MICHELE GUIDA;MARCO TUCCI;PAOLA QUEIROLO;ALESSANDRO RIZZO;DIANA GIANNARELLI;LIANG WU;GIACOMO VOLPE;CHUANYU LIU;JIANGSHAN XU;LONGQI LIU;MENGNAN CHENG;VANNA CHIARION‐SILENI;MIGUEL A. ESTEBAN;YIWEI LAI;YONG HOU;YUE YUAN;PAOLO A. ASCIERTO;LEI HAN;XUN XU;EVARISTO MAIELLO","274;228;228;192;186;181;171;161;161;161;161;156;155;155;155;155;151;150;150;149","MICHELE GUIDA;ALESSANDRO RIZZO;GIACOMO VOLPE;SABINO STRIPPOLI;ANNARITA FANIZZI;RAFFAELLA MASSAFRA;SIMONA DE SUMMA;IVANA DE RISI;ANTONIO CUSMAI;DANIELE LA FORGIA;AMALIA AZZARITI;ANGELO PARADISO;SIMONA SERRATÌ;ALFREDO ZITO;NICOLA SILVESTRIS;LETIZIA PORCELLI;R. FONTE;ROSA MARIA IACOBAZZI;MARCO TUCCI;GENNARO PALMIOTTI","274;192;171;136;134;134;132;126;125;119;118;118;115;110;110;101;101;91;88;87","ALESSANDRO RIZZO;ANNARITA FANIZZI;RAFFAELLA MASSAFRA;ATTILIO GUARINI;DOMENICO GALETTA;GENNARO CORMIO;ALFREDO ZITO;VITO LORUSSO;MARIA COLOMBA COMES;FRANCESCO GIOTTA;SAMANTHA BOVE;CARLA MINOIA;MICHELE GUIDA;ANTONIO CUSMAI;GENNARO PALMIOTTI;GIAN MARIA ZACCARIA;MICHELE MONTRONE;DANIELE LA FORGIA;NICOLA SILVESTRIS;CRESCENZA PASCIOLLA","22;15;15;15;14;13;11;11;10;9;9;9;9;8;8;8;8;8;8;8","MEDICINE;BIOLOGY;COMPUTER SCIENCE;CHEMISTRY;PHYSICS;ECONOMICS;POLITICAL SCIENCE;BUSINESS;PSYCHOLOGY;MATHEMATICS;SOCIOLOGY;ENGINEERING;PHILOSOPHY;ART;ENVIRONMENTAL SCIENCE;MATERIALS SCIENCE","180;72;22;12;9;6;6;5;5;3;3;2;2;1;1;1","INTERNAL MEDICINE;ONCOLOGY;IMMUNOLOGY;SURGERY;GENETICS;CANCER RESEARCH;PATHOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;PALEONTOLOGY;CELL BIOLOGY;INTENSIVE CARE MEDICINE;RADIOLOGY;GYNECOLOGY;BIOINFORMATICS;ARTIFICIAL INTELLIGENCE;FAMILY MEDICINE;UROLOGY;VIROLOGY","163;99;34;32;30;27;27;25;21;20;19;12;12;12;11;10;9;9;8;8","CANCER;GENE;CHEMOTHERAPY;DISEASE;CLINICAL TRIAL;LYMPHOMA;POPULATION;LUNG CANCER;RETROSPECTIVE COHORT STUDY;ADVERSE EFFECT;COHORT;IMMUNE SYSTEM;RANDOMIZED CONTROLLED TRIAL;STAGE (STRATIGRAPHY);CONFIDENCE INTERVAL;MALIGNANCY;RADIATION THERAPY;RENAL CELL CARCINOMA;MELANOMA;BIOPSY;LEUKEMIA;VACCINATION","95;35;34;25;22;20;19;17;16;14;14;14;14;12;11;9;9;9;8;7;7;7","IMMUNOTHERAPY;BREAST CANCER;GENE EXPRESSION;PROGRESSION-FREE SURVIVAL;CLINICAL ENDPOINT;COLORECTAL CANCER;INFECTIOUS DISEASE (MEDICAL SPECIALTY);NEUTROPENIA;OVARIAN CANCER;HAZARD RATIO;MALIGNANT PLEURAL EFFUSION;NEUTROPHIL TO LYMPHOCYTE RATIO;BLADDER CANCER;CISPLATIN;DIFFUSE LARGE B-CELL LYMPHOMA;FOLLICULAR LYMPHOMA;GEMCITABINE;PHASES OF CLINICAL RESEARCH;PROGRESSIVE DISEASE;RITUXIMAB","28;25;15;13;12;10;10;7;7;6;6;6;5;5;5;5;5;5;5;5","NIVOLUMAB;CORONAVIRUS DISEASE 2019 (COVID-19);TRANSCRIPTOME;IMMUNE CHECKPOINT;PEMBROLIZUMAB;CRIZOTINIB;DNA METHYLATION;IPILIMUMAB;METASTATIC BREAST CANCER;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;UROTHELIAL CARCINOMA;BILIARY TRACT CANCER;CANCER IMMUNOTHERAPY;FEBRILE NEUTROPENIA;KRAS;LONG NON-CODING RNA;NEOADJUVANT THERAPY;PEMETREXED;RIVAROXABAN;SENTINEL LYMPH NODE","13;10;8;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3",";HUMANS;FEMALE;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;MELANOMA;RETROSPECTIVE STUDIES;COVID-19;LUNG NEOPLASMS;MALE;CARCINOMA, NON-SMALL-CELL LUNG;OVARIAN NEOPLASMS;SKIN NEOPLASMS;IMMUNOTHERAPY;LYMPHOMA, LARGE B-CELL, DIFFUSE;TREATMENT OUTCOME;BILIARY TRACT NEOPLASMS;BREAST NEOPLASMS;COLORECTAL NEOPLASMS;IMMUNE CHECKPOINT INHIBITORS;PROTEIN KINASE INHIBITORS","119;75;24;22;22;21;14;13;13;11;11;11;10;10;10;9;9;9;9;9","CANCER IMMUNOTHERAPY;LYMPHOID NEOPLASMS;ADVANCEMENTS IN LUNG CANCER RESEARCH;CHOLANGIOCARCINOMA;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;RENAL CELL CARCINOMA;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;COMPREHENSIVE INTEGRATION OF SINGLE-CELL TRANSCRIPTOMIC DATA;DEEP LEARNING IN MEDICAL IMAGE ANALYSIS;INFLAMMATION'S ROLE IN CANCER DEVELOPMENT AND PROGRESSION;RADIOMICS IN MEDICAL IMAGING ANALYSIS;ACUTE MYELOID LEUKEMIA;CORONAVIRUS DISEASE 2019 RESEARCH;EXOSOME BIOLOGY AND FUNCTION IN INTERCELLULAR COMMUNICATION;FERTILITY PRESERVATION IN CANCER PATIENTS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GYNECOLOGIC ONCOLOGY;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;MOLECULAR RESEARCH ON BREAST CANCER","13;13;10;7;7;6;6;5;4;4;4;4;3;3;3;3;3;3;3;3","CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;BIOMARKERS FOR IMMUNOTHERAPY;CANCER IMAGING;TREATMENT;IMMUNE CHECKPOINT BLOCKADE;MANTLE CELL LYMPHOMA;MEDICAL IMAGE ANALYSIS;NEOADJUVANT THERAPY;BREAST CANCER;TUMOR MICROENVIRONMENT;BILIARY TRACT CANCER;CANCER IMMUNOEDITING;CANCER IMMUNOTHERAPY;FOLLICULAR LYMPHOMA;IMMUNE CHECKPOINT;PANDEMIC;REGIMEN;TARGETED THERAPY;BREAST CANCER DIAGNOSIS","13;13;10;9;9;7;7;7;7;6;6;5;5;5;5;5;5;5;5;4","BREAST CANCER;CELL CARCINOMA;RENAL CELL;CHECKPOINT INHIBITORS;METASTATIC RENAL;IMMUNE CHECKPOINT;LUNG CANCER;PHASE II;CELL LUNG;CANCER PATIENTS;FONDAZIONE ITALIANA;ITALIANA LINFOMI;LOCALLY ADVANCED;MACHINE LEARNING;ADVANCED UROTHELIAL;BILIARY TRACT;CELL LYMPHOMA;CLINICAL OUTCOME;COLORECTAL CANCER;HEPATOCELLULAR CARCINOMA;OBSERVATIONAL STUDY;PATIENTS TREATED;RANDOMIZED PHASE;TRACT CANCER;UROTHELIAL CARCINOMA;ACUTE LYMPHOBLASTIC;B-CELL LYMPHOMA;CANCER TREATED;CERVICAL CANCER;COHORT STUDY","15;10;9;8;8;7;7;7;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3","CANCER PATIENTS;BREAST CANCER;MONTHS CI;CLINICAL PRACTICE;PROGRESSION-FREE SURVIVAL;LUNG CANCER;MEDIAN AGE;PATIENTS TREATED;STATISTICALLY SIGNIFICANT;SURVIVAL OS;MEDIAN FOLLOW-UP;STAGE III;SURVIVAL PFS;VIEW LARGEDOWNLOAD;ADVERSE EVENTS;MONTHS NA;CELL CARCINOMA;CELL LUNG;CHECKPOINT INHIBITORS;IMMUNE CHECKPOINT;RESPONSE RATE;RETROSPECTIVE STUDY;MEDIAN OS;CLINICAL TRIALS;DISEASE PROGRESSION;LOCALLY ADVANCED;LYMPH NODE;MACHINE LEARNING;NON-SMALL CELL;TARGETED THERAPY","28;25;25;24;20;18;18;17;17;17;16;16;16;16;15;14;13;13;13;13;13;13;12;11;11;11;11;11;11;11",104,0.53,8.39,9,1,2,0,2,1,1,1,11,1,0,8,0,1,1,4,6,3.5,0,0,19,19,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,5.43,463.71,3.66,6,0.86,98,0,0,2,0,4,0,1,0,0,7,0,0,0,0,0,0,0,7,0,0,7,0,0,0,0,0,0,0,0,0,"United States;Belgium","4;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","7;6;5","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;BREAST CANCER;LUNG;LUNG CANCER;PATIENT SAFETY;UROLOGIC DISEASES","7;6;5;1;1;1;1;1","CANCER","5","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","6;1","MELANOMA;BLADDER CANCER;BREAST CANCER;LUNG CANCER","2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","3;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_TUMORIBARI",2023,195,21.9282051282051,2.93333333333333,0.205128205128205,0.164102564102564,0.292307692307692,2.86,1.33333333333333,1.6,1.35714285714286,0.784615384615385,0,77,43,12,15,0.39,0.22,0.06,0.08,3.86,0.881008366911334,5.6236012207528,0.42051282051282,0.98974358974359,0.522,0.477,0.562,0.461,"GENNARO CORMIO;ALESSANDRO RIZZO;ATTILIO GUARINI;RAFFAELLA MASSAFRA;VERA LOIZZI;MICHELE GUIDA;ANNARITA FANIZZI;FRANCESCA AREZZO;SEBASTIANO BUTI;DOMENICO GALETTA;ERICA SILVESTRIS;UGO DE GIORGI;FRANCESCO GIOTTA;DIANA GIANNARELLI;MATTEO SANTONI;DANIELE LA FORGIA;CRESCENZA PASCIOLLA;CARLA MINOIA;PAOLO ANDREA ZUCALI;SAMANTHA BOVE","23;20;18;17;16;16;15;15;14;13;12;12;12;12;11;11;11;10;10;10","GENNARO CORMIO;ALESSANDRO RIZZO;RAFFAELLA MASSAFRA;VERA LOIZZI;MICHELE MONGELLI;FRANCESCA AREZZO;ATTILIO GUARINI;ANNARITA FANIZZI;ERICA SILVESTRIS;FRANCESCO GIOTTA;DANIELE LA FORGIA;MICHELE GUIDA;ANILA KARDHASHI;SAMANTHA BOVE;GERARDO CAZZATO;CARLA MINOIA;DOMENICO GALETTA;MARIA COLOMBA COMES;GUIDO GINI;GIUSEPPE DE PALMA","2.16;1.72;1.32;1.3;1.15;1.14;1.11;1.08;1.02;0.82;0.82;0.79;0.73;0.69;0.65;0.64;0.63;0.62;0.57;0.55","GENNARO CORMIO;ALESSANDRO RIZZO;ATTILIO GUARINI;RAFFAELLA MASSAFRA;VERA LOIZZI;MICHELE GUIDA;ANNARITA FANIZZI;FRANCESCA AREZZO;DOMENICO GALETTA;ERICA SILVESTRIS;FRANCESCO GIOTTA;DANIELE LA FORGIA;CRESCENZA PASCIOLLA;CARLA MINOIA;SAMANTHA BOVE;ANNAMARIA CATINO;MARIA COLOMBA COMES;ANILA KARDHASHI;GIACOMO LOSETO;GERARDO CAZZATO","23;20;18;17;16;16;15;15;13;12;12;11;11;10;10;10;9;9;9;7","GENNARO CORMIO;ALESSANDRO RIZZO;RAFFAELLA MASSAFRA;VERA LOIZZI;FRANCESCA AREZZO;ATTILIO GUARINI;ANNARITA FANIZZI;ERICA SILVESTRIS;FRANCESCO GIOTTA;DANIELE LA FORGIA;MICHELE GUIDA;ANILA KARDHASHI;SAMANTHA BOVE;GERARDO CAZZATO;CARLA MINOIA;DOMENICO GALETTA;MARIA COLOMBA COMES;GIUSEPPE DE PALMA;ANNAMARIA CATINO;CRESCENZA PASCIOLLA","2.16;1.72;1.32;1.3;1.14;1.11;1.08;1.02;0.82;0.82;0.79;0.73;0.69;0.65;0.64;0.63;0.62;0.55;0.53;0.5","ALESSANDRO RIZZO;MATTEO SANTONI;RAFFAELLA MASSAFRA;FRANCESCO MASSARI;VERONICA MOLLICA;VALENTINA TATEO;ANDREA MARCHETTI;ELISA TASSINARI;MATTEO ROSELLINI;UGO DE GIORGI;SEBASTIANO BUTI;PAOLO ANDREA ZUCALI;MIMMA RIZZO;NICOLA BATTELLI;GIUSEPPE FORNARINI;CAMILLO PORTA;GIANDOMENICO ROVIELLO;ORAZIO CAFFO;ROBERTO IACOVELLI;GIUSEPPE PROCOPIO","218;203;201;194;193;122;113;113;113;113;99;90;88;88;84;82;77;77;77;76","ALESSANDRO RIZZO;RAFFAELLA MASSAFRA;ANNARITA FANIZZI;DOMENICO GALETTA;MICHELE GUIDA;FRANCESCO GIOTTA;ANNAMARIA CATINO;SAMANTHA BOVE;DANIELE LA FORGIA;MARIA COLOMBA COMES;MARIA DIGENNARO;ATTILIO GUARINI;SABINO STRIPPOLI;GENNARO CORMIO;AMALIA AZZARITI;VITO LORUSSO;ANNALISA NARDONE;STEFANIA TOMMASI;SIMONA DE SUMMA;FRANCESCO ALFREDO ZITO","218;201;75;68;65;51;50;49;48;47;47;43;43;40;39;39;36;35;34;33","GENNARO CORMIO;ALESSANDRO RIZZO;ATTILIO GUARINI;RAFFAELLA MASSAFRA;MICHELE GUIDA;VERA LOIZZI;ANNARITA FANIZZI;DOMENICO GALETTA;ERICA SILVESTRIS;CRESCENZA PASCIOLLA;DANIELE LA FORGIA;FRANCESCO GIOTTA;CARLA MINOIA;ANNAMARIA CATINO;SAMANTHA BOVE;ANILA KARDHASHI;GIACOMO LOSETO;MARIA COLOMBA COMES;GIUSEPPE DE PALMA;PAMELA PIZZUTILO","22;21;18;18;16;15;14;13;13;11;11;11;10;10;10;9;9;8;7;6","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;CHEMISTRY;MATHEMATICS;POLITICAL SCIENCE;ENGINEERING;PHILOSOPHY;SOCIOLOGY;BUSINESS;GEOLOGY;PSYCHOLOGY;ECONOMICS;HISTORY;MATERIALS SCIENCE","182;62;22;15;10;7;5;4;4;4;2;2;2;1;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CANCER RESEARCH;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;ENVIRONMENTAL HEALTH;PATHOLOGY;GYNECOLOGY;BIOCHEMISTRY;PALEONTOLOGY;RADIOLOGY;ARTIFICIAL INTELLIGENCE;MACHINE LEARNING;CELL BIOLOGY;OPTICS;UROLOGY;ENDOCRINOLOGY;NURSING","154;109;50;38;30;28;25;24;22;21;19;15;13;11;11;9;9;9;8;8","CANCER;CHEMOTHERAPY;GENE;LYMPHOMA;POPULATION;ADVERSE EFFECT;RETROSPECTIVE COHORT STUDY;LUNG CANCER;COHORT;MELANOMA;CONFIDENCE INTERVAL;IMMUNE SYSTEM;RANDOMIZED CONTROLLED TRIAL;CLINICAL TRIAL;LEUKEMIA;REGIMEN;RENAL CELL CARCINOMA;DISCONTINUATION;INCIDENCE (GEOMETRY);OVERALL SURVIVAL;STAGE (STRATIGRAPHY)","99;43;27;26;24;19;17;16;15;15;14;12;12;11;10;10;10;9;9;8;8","BREAST CANCER;IMMUNOTHERAPY;RITUXIMAB;CLINICAL ENDPOINT;COLORECTAL CANCER;HAZARD RATIO;OVARIAN CANCER;TOLERABILITY;PROGRESSION-FREE SURVIVAL;FERTILITY;GENE EXPRESSION;NEUTROPENIA;METASTATIC MELANOMA;CHRONIC LYMPHOCYTIC LEUKEMIA;CISPLATIN;CYCLOPHOSPHAMIDE;PHENOTYPE;TARGETED THERAPY;UNIVARIATE ANALYSIS;BEVACIZUMAB;CERVICAL CANCER;PANCREATIC CANCER;PROGRESSIVE DISEASE;TUMOR MICROENVIRONMENT","31;26;15;14;11;10;10;9;8;7;7;7;6;5;5;5;5;5;5;4;4;4;4;4","NIVOLUMAB;BENDAMUSTINE;FERTILITY PRESERVATION;IPILIMUMAB;KRAS;PEMBROLIZUMAB;MAMMOGRAPHY;METASTATIC BREAST CANCER;BRCA MUTATION;BRENTUXIMAB VEDOTIN;CHEMOIMMUNOTHERAPY;CORONAVIRUS DISEASE 2019 (COVID-19);IBRUTINIB;MICROSATELLITE;TAMOXIFEN;VINCRISTINE;ALTERNATIVE SPLICING;ANTHRACYCLINE;BLINATUMOMAB;CARBOPLATIN;CHLORAMBUCIL;CHROMOPHOBE CELL;DUCTAL CARCINOMA;ELTROMBOPAG;ERLOTINIB;FEBRILE NEUTROPENIA;INTERNATIONAL PROGNOSTIC INDEX;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;IRINOTECAN;MASTECTOMY;METHYLTRANSFERASE;NEOADJUVANT THERAPY;PEMETREXED;PERIPHERAL T-CELL LYMPHOMA;POSACONAZOLE;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;SEROUS CARCINOMA;TRANSCRIPTOME;TRASTUZUMAB;TRIPLE-NEGATIVE BREAST CANCER;UROTHELIAL CARCINOMA","11;5;5;5;5;5;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",";HUMANS;FEMALE;RETROSPECTIVE STUDIES;BREAST NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;NEOPLASM RECURRENCE, LOCAL;MELANOMA;CARCINOMA, RENAL CELL;LUNG NEOPLASMS;CARCINOMA, NON-SMALL-CELL LUNG;KIDNEY NEOPLASMS;COVID-19;LEUKEMIA, MYELOID, ACUTE;BRAIN NEOPLASMS;CARCINOMA, PANCREATIC DUCTAL;NEOPLASMS;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;PROTEIN KINASE INHIBITORS;ADULT","116;74;22;22;20;16;14;13;12;12;11;11;8;8;7;7;7;7;7;6","LYMPHOID NEOPLASMS;RENAL CELL CARCINOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;CANCER IMMUNOTHERAPY;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;ACUTE MYELOID LEUKEMIA;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;MOLECULAR RESEARCH ON BREAST CANCER;FERTILITY PRESERVATION IN CANCER PATIENTS;RADIOMICS IN MEDICAL IMAGING ANALYSIS;CHOLANGIOCARCINOMA;DEEP LEARNING IN MEDICAL IMAGE ANALYSIS;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;HUMAN PAPILLOMAVIRUS AND CERVICAL CANCER EPIDEMIOLOGY;MANAGEMENT OF BRAIN METASTASES IN CANCER PATIENTS;UTERINE CONDITIONS AND TREATMENTS;BREAST CANCER SCREENING TECHNOLOGY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT","19;10;7;7;7;6;6;5;5;5;4;4;3;3;3;3;3;3;2;2","CLINICAL ENDPOINT;MANTLE CELL LYMPHOMA;REGIMEN;DISCONTINUATION;PROGRESSION-FREE SURVIVAL;TOLERABILITY;BIOMARKERS FOR IMMUNOTHERAPY;BREAST CANCER;CANCER IMAGING;IMMUNE CHECKPOINT BLOCKADE;MELANOMA;BREAST CANCER DIAGNOSIS;HEMATOLOGY;RENAL CELL CARCINOMA;BENDAMUSTINE;CONCOMITANT;REFRACTORY (PLANETARY SCIENCE);TARGETED THERAPY;TREATMENT;TUMOR MICROENVIRONMENT","14;11;10;9;9;9;8;8;7;7;7;6;6;6;5;5;5;5;5;5","BREAST CANCER;CELL CARCINOMA;CANCER PATIENTS;RENAL CELL;FONDAZIONE ITALIANA;ITALIANA LINFOMI;LUNG CANCER;RETROSPECTIVE STUDY;MACHINE LEARNING;PHASE II;RETROSPECTIVE ANALYSIS;II STUDY;ACUTE MYELOID;BRAIN METASTASES;METASTATIC RENAL;MYELOID LEUKEMIA;OBSERVATIONAL STUDY;OVARIAN CANCER;PATIENTS PTS;PRIMARY MEDIASTINAL;BIOMARKERS EVALUATION;BRAF V-MUTATED;CHECKPOINT INHIBITORS;COLORECTAL CANCER;LINFOMI FIL;LYMPHOMA PATIENTS;MELANOMA SECOMBIT;METASTATIC BRAF;METASTATIC BREAST;MULTICENTER RETROSPECTIVE","17;14;13;12;9;9;9;8;7;7;7;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4","MONTHS CI;ADVISORY ROLE;BREAST CANCER;CANCER PATIENTS;SURVIVAL OS;SURVIVAL PFS;PROGRESSION-FREE SURVIVAL;PATIENTS TREATED;MEDIAN AGE;LUNG CANCER;CLINICAL PRACTICE;MEDIAN FOLLOW-UP;PATIENTS RECEIVING;STATISTICALLY SIGNIFICANT;MEDIAN PFS;PATIENTS RECEIVED;ADVERSE EVENTS;EDUCATIONAL GRANTS;MONTHS NA;OVARIAN CANCER;SIGNIFICANT DIFFERENCES;MEDIAN OS;NSCLC PATIENTS;STABLE IMPROVED;WORSENED STABLE;RESEARCH FUNDING;RESPONSE RATE;SIGNIFICANT DIFFERENCE;DISEASE PROGRESSION;LIQUID BIOPSY","36;32;32;29;28;28;26;25;24;23;22;22;21;21;18;17;16;16;16;16;16;15;15;15;15;14;14;14;13;13",83,0.43,5.82,8,1,1.25,0,2,0,1,1,8.5,1,0,8,0,0,1,4.25,5,4,0,0,9,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,5.75,926,2.07,3,0.75,131,0,0,1,0,3,0,0,0,0,4,0,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,0,0,0,0,"United States;Japan","3;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES","4;4;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER","4;3;2","CANCER","4","6.1 PHARMACEUTICALS","4","MELANOMA","3","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","3",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_TUMORIBARI",2024,127,22.9527559055118,2.90551181102362,0.228346456692913,0.228346456692913,0.346456692913386,2.41176470588235,1.52631578947368,1.61111111111111,1.51724137931034,0.62992125984252,1,52,28,8,8,0.41,0.22,0.06,0.06,1.02,1.0710653924258,4.76963906581741,0.354330708661417,0.992125984251969,0.512,0.442,0.453,0.432,"RAFFAELLA MASSAFRA;ANNARITA FANIZZI;GENNARO CORMIO;MICHELE GUIDA;SANDRO PIGNATA;ELSA VITALE;ALESSANDRO RIZZO;EMANUELE NAGLIERI;MARIA COLOMBA COMES;SEBASTIANO BUTI;DOMENICO GALETTA;UGO DE GIORGI;SAMANTHA BOVE;VERA LOIZZI;ROBERTO LUPO;LUANA CONTE;DIANA GIANNARELLI;STEFANIA TOMMASI;IVAN RUBBI;PAOLO A. ASCIERTO","18;13;13;11;11;10;9;9;8;8;8;8;8;7;7;7;7;6;6;6","RAFFAELLA MASSAFRA;ELSA VITALE;GENNARO CORMIO;ALESSANDRO RIZZO;AGNESE MARIA FIORETTI;ANNARITA FANIZZI;VERA LOIZZI;SANDRO PIGNATA;ROBERTO LUPO;LUANA CONTE;MARIA COLOMBA COMES;SAMANTHA BOVE;ERICA SILVESTRIS;IVAN RUBBI;GIORGIO DE NUNZIO;MICHELE GUIDA;DOMENICO GALETTA;STEFANIA TOMMASI;ALESSIA LEZZI;NICOLA SILVESTRIS","1.43;1.4;1.39;1.28;1;0.94;0.79;0.73;0.66;0.66;0.59;0.59;0.56;0.55;0.55;0.54;0.53;0.51;0.45;0.44","RAFFAELLA MASSAFRA;ANNARITA FANIZZI;GENNARO CORMIO;MICHELE GUIDA;ELSA VITALE;ALESSANDRO RIZZO;EMANUELE NAGLIERI;MARIA COLOMBA COMES;DOMENICO GALETTA;SAMANTHA BOVE;VERA LOIZZI;STEFANIA TOMMASI;FRANCESCO ALFREDO ZITO;MICHELE MONTRONE;NICOLA SILVESTRIS;ORONZO BRUNETTI;MARCO TUCCI;ERICA SILVESTRIS;SABINO STRIPPOLI;FRANCESCO GIOTTA","18;13;13;11;10;9;9;8;8;8;7;6;6;6;6;6;5;5;5;5","RAFFAELLA MASSAFRA;ELSA VITALE;GENNARO CORMIO;ALESSANDRO RIZZO;AGNESE MARIA FIORETTI;ANNARITA FANIZZI;VERA LOIZZI;MARIA COLOMBA COMES;SAMANTHA BOVE;ERICA SILVESTRIS;MICHELE GUIDA;DOMENICO GALETTA;STEFANIA TOMMASI;NICOLA SILVESTRIS;ANNAMARIA CATINO;FRANCESCO ALFREDO ZITO;EMANUELE NAGLIERI;MICHELE MONTRONE;SABINO STRIPPOLI;ORONZO BRUNETTI","1.43;1.4;1.39;1.28;1;0.94;0.79;0.59;0.59;0.56;0.54;0.53;0.51;0.44;0.44;0.43;0.4;0.37;0.37;0.35","MICHELE GUIDA;DIANA GIANNARELLI;MARIO MANDALÁ;MICHELE DEL VECCHIO;ANA ARANCE;FRANCESCO SPAGNOLO;MARCO TUCCI;MARIA GRAZIA VITALE;MASSIMO GUIDOBONI;PAOLA QUEIROLO;PAOLO A. ASCIERTO;PIER FRANCESCO FERRUCCI;PIOTR RUTKOWSKI;VANNA CHIARION‐SILENI;ALESSANDRO RIZZO;VIRGINIA FERRARESI;ALESSANDRO MARCO MINISINI;ANTONIO COSSU;ANTONIO M. GRIMALDI;CLAUDIA PICCININI","38;35;35;35;29;29;29;29;29;29;29;29;29;29;27;25;23;23;23;23","MICHELE GUIDA;ALESSANDRO RIZZO;RAFFAELLA MASSAFRA;DANIELE LA FORGIA;ELSA VITALE;ANNARITA FANIZZI;EMANUELE NAGLIERI;ANNALISA NARDONE;MICHELE MONTRONE;VITO LONGO;DOMENICO GALETTA;GIACOMO VOLPE;MARIA COLOMBA COMES;ORONZO BRUNETTI;SAMANTHA BOVE;ANNAMARIA CATINO;ANTONELLA PERRONE;ELISABETTA MONTAGNA;FEDERICO FADDA;FRANCESCO PESOLA","38;27;20;15;14;12;9;7;7;7;6;5;5;5;5;4;4;4;4;4","RAFFAELLA MASSAFRA;ANNARITA FANIZZI;GENNARO CORMIO;MICHELE GUIDA;ELSA VITALE;ALESSANDRO RIZZO;EMANUELE NAGLIERI;MARIA COLOMBA COMES;SAMANTHA BOVE;DOMENICO GALETTA;ORONZO BRUNETTI;MICHELE MONTRONE;FRANCESCO ALFREDO ZITO;STEFANIA TOMMASI;VERA LOIZZI;ANNAMARIA CATINO;ERICA SILVESTRIS;FRANCESCO GIOTTA;SABINO STRIPPOLI;CONCETTA SAPONARO","18;13;13;11;10;9;9;8;8;8;6;6;6;6;6;5;5;5;5;4","MEDICINE;BIOLOGY;COMPUTER SCIENCE;CHEMISTRY;ECONOMICS;POLITICAL SCIENCE;PSYCHOLOGY;PHYSICS;PHILOSOPHY;MATHEMATICS;SOCIOLOGY;ENGINEERING","117;42;13;7;6;6;6;5;4;3;3;2","INTERNAL MEDICINE;ONCOLOGY;GENETICS;CANCER RESEARCH;SURGERY;PATHOLOGY;GYNECOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;FAMILY MEDICINE;RADIOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;ARTIFICIAL INTELLIGENCE;NURSING;OBSTETRICS;BIOINFORMATICS;LAW;ECOLOGY;GENERAL SURGERY;MACHINE LEARNING;PALEONTOLOGY;PHARMACOLOGY","105;68;26;25;20;17;13;11;11;10;10;9;9;8;7;7;6;6;5;5;5;5;5","CANCER;CHEMOTHERAPY;RETROSPECTIVE COHORT STUDY;GENE;CLINICAL TRIAL;RANDOMIZED CONTROLLED TRIAL;COHORT;LUNG CANCER;ADVERSE EFFECT;DISEASE;MELANOMA;POPULATION;PREGNANCY;OBSERVATIONAL STUDY;PROPORTIONAL HAZARDS MODEL;BIOMARKER;CONFIDENCE INTERVAL;RENAL CELL CARCINOMA;SIGNAL TRANSDUCTION;BASAL CELL;CARCINOMA;HEALTH CARE;HORMONE;LYMPHOMA;MULTIVARIATE ANALYSIS;QUALITY OF LIFE (HEALTHCARE);RADIATION THERAPY;RECEPTOR","76;21;18;14;12;10;9;9;8;8;8;8;7;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4","IMMUNOTHERAPY;BREAST CANCER;COLORECTAL CANCER;OVARIAN CANCER;METASTATIC MELANOMA;PROGRESSION-FREE SURVIVAL;BLADDER CANCER;CLINICAL ENDPOINT;ENDOMETRIAL CANCER;FERTILITY;METASTASIS;CISPLATIN;GENE EXPRESSION;HAZARD RATIO;INFERTILITY;MAPK/ERK PATHWAY;MULTICENTER STUDY;MUTATION;PACLITAXEL;PI3K/AKT/MTOR PATHWAY","21;20;9;7;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3","NIVOLUMAB;PEMBROLIZUMAB;IPILIMUMAB;FERTILITY PRESERVATION;MAMMOGRAPHY;BRCA MUTATION;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;TRIPLE-NEGATIVE BREAST CANCER;UROTHELIAL CARCINOMA;BILIARY TRACT CANCER;BREAST SELF-EXAMINATION;CORONAVIRUS DISEASE 2019 (COVID-19);CRIZOTINIB;KRAS;OXALIPLATIN;PEMETREXED;PTEN;TRANSCRIPTOME;VEMURAFENIB;ANAPLASTIC LYMPHOMA KINASE;ANTHRACYCLINE;ANTIBODY-DRUG CONJUGATE;BRAIN METASTASIS;BREAST RECONSTRUCTION;CARBOPLATIN;CD28;CD40;CHROMATIN REMODELING;CIRCULATING TUMOR CELL;CLASSICAL HODGKIN LYMPHOMA;COLONOSCOPY;CYSTECTOMY;DARATUMUMAB;ERLOTINIB;FIBROBLAST GROWTH FACTOR RECEPTOR;FIBROBLAST GROWTH FACTOR RECEPTOR 2;FRAMESHIFT MUTATION;GASTRIC BYPASS;GENE EXPRESSION PROFILING;GENE SIGNATURE;GENOTYPING;GERMLINE MUTATION;HEPATITIS E VIRUS;HORMONE RECEPTOR;HORMONE THERAPY;HPV INFECTION;HUMAN BREAST;IBRUTINIB;IMMUNE CHECKPOINT;INTERNATIONAL PROGNOSTIC INDEX;IRINOTECAN;KAPOSI'S SARCOMA;LEYDIG CELL;LONG NON-CODING RNA;LYMPHOVASCULAR INVASION;MASTECTOMY;MEK INHIBITOR;MERKEL CELL POLYOMAVIRUS;METASTATIC BREAST CANCER;MICRONUCLEUS;MONOCLONAL;MORBID OBESITY;MYELOPROLIFERATIVE NEOPLASM;NEOADJUVANT THERAPY;NON-CODING RNA;OESTROGEN RECEPTOR;OVARIAN RESERVE;PDGFRA;PERIPHERAL T-CELL LYMPHOMA;PLEURAL DISEASE;POLY ADP RIBOSE POLYMERASE;POMALIDOMIDE;PROTEIN PHOSPHATASE 2;RENAL STEM CELL;ROS1;SENTINEL LYMPH NODE;SENTINEL NODE;SMALL HAIRPIN RNA;SYSTEMIC THERAPY;TRAMETINIB;UROTHELIAL CANCER;VINCRISTINE;WATCHFUL WAITING","8;7;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MIDDLE AGED;AGED;MALE;ADULT;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;IMMUNOTHERAPY;ITALY;BREAST NEOPLASMS;IMMUNE CHECKPOINT INHIBITORS;LUNG NEOPLASMS;MELANOMA;ANTIBODIES, MONOCLONAL, HUMANIZED;MUTATION;PROSPECTIVE STUDIES;TREATMENT OUTCOME","74;52;32;27;25;24;22;15;11;9;9;8;7;7;6;6;5;5;5;5","CANCER IMMUNOTHERAPY;GENOMIC STUDIES AND TREATMENT OF OVARIAN CARCINOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;LYMPHOID NEOPLASMS;CHOLANGIOCARCINOMA;RADIOMICS IN MEDICAL IMAGING ANALYSIS;RENAL CELL CARCINOMA;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;FERTILITY PRESERVATION IN CANCER PATIENTS;GLOBAL CANCER INCIDENCE AND MORTALITY PATTERNS;MAMMALIAN MAP KINASE SIGNALING PATHWAYS;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA;ESOPHAGEAL INTERVENTION TECHNIQUES;GASTRIC CANCER RESEARCH AND TREATMENT;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GYNECOLOGIC ONCOLOGY;HER2 SIGNALING IN BREAST CANCER TREATMENT;IMPACT OF OBESITY ON CANCER RISK AND PROGNOSIS","7;7;6;5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2","BREAST CANCER;BIOMARKERS FOR IMMUNOTHERAPY;BIOMARKER ANALYSIS;PROGRESSION-FREE SURVIVAL;CANCER IMAGING;CLINICAL ENDPOINT;IMMUNE CHECKPOINT BLOCKADE;PREDICTIVE MODELING;TREATMENT GUIDELINES;TUMOR MODELS;BILIARY TRACT CANCER;BRAIN METASTASES;BRCA MUTATION;BREAST CANCER SCREENING;CANCER IMMUNOEDITING;CHEMOTHERAPY;CROSS-SECTIONAL STUDY;FERTILITY PRESERVATION;MANTLE CELL LYMPHOMA;MEDICAL IMAGE ANALYSIS","8;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","BREAST CANCER;LUNG CANCER;CELL CARCINOMA;MEET-URO STUDY;OBSERVATIONAL STUDY;CANCER PATIENTS;COLORECTAL CANCER;ITALIAN SOCIETY;MACHINE LEARNING;PHASE III;RENAL CELL;BILIARY TRACT;BRAIN METASTASES;CELL LUNG;CHECKPOINT INHIBITORS;CROSS-SECTIONAL STUDY;FERTILITY PRESERVATION;FIRST-LINE PEMBROLIZUMAB;ITALIAN ASSOCIATION;ITALIAN ONCOLOGY;MELANOMA PATIENTS;METASTATIC RENAL;MULTICENTER STUDY;NON-SMALL CELL;ONCOLOGY NURSES;PATIENTS TREATED;RETROSPECTIVE OBSERVATIONAL;SQUAMOUS CELL;TRACT CANCER;UROTHELIAL CARCINOMA","12;8;7;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","BREAST CANCER;CLINICAL PRACTICE;CANCER PATIENTS;LUNG CANCER;PATIENTS TREATED;MONTHS CI;CLINICAL TRIALS;MRCC PATIENTS;NSCLC PATIENTS;MEDIAN FOLLOW-UP;PROGRESSION-FREE SURVIVAL;RISK FACTORS;SIGNIFICANT DIFFERENCES;SURVIVAL OS;ADVERSE EVENTS;BRAF VE;CANCER NSCLC;RESPONSE RATE;SODIUM LEVELS;BRAIN METASTASES;CELL CARCINOMA;CHECKPOINT INHIBITORS;EXERCISE DISCUSSION;GASTRIC TISSUE;MEDIAN AGE;PAIN MANAGEMENT;PHYSICAL ACTIVITY;PROGNOSTIC FACTORS;SURVIVAL PFS;CHINESE WOMEN","33;14;12;12;12;11;10;10;10;9;9;9;9;9;8;8;8;8;8;7;7;7;7;7;7;7;7;7;7;6",3,0.02,18.65,30,0,0,0,0,0,0,0,32,0,0,30,0,0,2,8.5,19,5.5,0,0,8.5,8.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,4.5,371,1.38,0,0,44.5,0,0,0,0,1,0,0,1,0,2,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,"Switzerland","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","1;1;1;1;1;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;LYMPHOMA;RARE DISEASES;BEHAVIORAL AND SOCIAL SCIENCE;DEPRESSION;MENTAL HEALTH;PREVENTION;REHABILITATION","2;2;2;2;2;2;1;1;1;1;1","CANCER;GENERIC HEALTH RELEVANCE","1;1","6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.1 INDIVIDUAL CARE NEEDS","1;1;1","NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER","2;1","5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
